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Abdominal aortic aneurysms (AAAs) comprise an important public health 
issue, which could be reduced by primary prevention. Identifying AAA risk factors 
is critical for developing effective preventive strategies. Previous epidemiologic 
studies have suggested that some risk factors for atherosclerotic cardiovascular 
disease are also associated with increased risk of incident AAAs, including 
advanced age, male gender, white race, greater height, smoking, hypertension, 
dyslipidemia, and some biomarkers related to inflammation and hemostasis. 
Some observational studies showed an inverse relationship between diabetes 
and AAA; while others did not show an association. The inverse relationship 
between diabetes and AAA is considered counterintuitive in the context of 
diabetes being a risk factor for various cardiovascular diseases.  To better 
understand the etiology of AAA, further investigation on the relation between 
atherosclerosis and AAA is warranted. Also, the relation between diabetes and 
AAA needs to be studied further.   
With the exception of screening studies where AAAs were defined 
commonly as a maximum infrarenal aortic diameter (IAD) ≥ 3 cm, in most 
existing epidemiologic studies, AAAs were obtained through medical records and 
death certificates. This approach ascertains clinical AAAs that were either 
symptomatic or at least clinically detected. However, large screening studies 
have suggested that most AAAs are asymptomatic, even though aortic size often 
expands rapidly and many asymptomatic AAAs may eventually become 
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symptomatic. Furthermore, an increased IAD between 2.3 and 3 cm has been 
associated with higher risk of future AAA and other cardiovascular events. Thus, 
examining the determinants of elevated IADs (i.e. IAD ≥ 2.2) among individuals 
without clinical or asymptomatic AAAs is potentially important to the prevention of 
AAAs.  
Manuscript 1 examined the associations of carotid atherosclerosis and 
stiffness with later AAAs in ARIC. We used carotid intima-media thickness (1987-
1992) and atherosclerotic plaque (1987-1989) as indices of carotid 
atherosclerosis, and used carotid Beta Index (1990-1992) to represent carotid 
distensibility. We identified 542 incident, clinical AAAs during follow-up through 
2011 using hospital discharge codes, Medicare outpatient diagnoses, or death 
certificates during 22.5 years of follow-up. After multivariable adjustment, the 
presence of carotid atherosclerotic plaque at baseline was associated with 1.31 
(95% CI: 1.10 - 1.57; P: 0.003) times higher risk of clinical AAA. Greater carotid 
intima-media thickness and Beta Index were also associated with clinical AAA 
with a dose-response across quartiles (P trend for both: 0.006; hazard ratios [95% 
CI] for the highest vs. lowest quartiles: 1.55 [1.13 - 2.11] and 1.68 [1.16 - 2.43], 
respectively). The results suggest that indices of greater carotid atherosclerosis 
and lower carotid distensibility are markers of increased AAA risk. 
Manuscript 2 explored risk factors for an elevated IAD (IAD ≥ 2.2 cm) in 
the absence of AAA in 5620 ARIC participants who attended an abdominal 
ultrasound screening in 2011-2013. We assessed a variety of risk factors and 
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created derived variables to capture their long-term cumulative effects (over 
1987-2013). In the model with adjustment for AAA risk factors, men (vs. women) 
had 2.50 (95% CI: 1.90, 3.28) times higher odds of having an elevated IAD, and 
participants with long-term diabetes (vs. non-diabetics) had 0.52 (0.35, 0.77) 
times lower odds. Height, waist circumference and smoking pack-years were 
positively associated with elevated IADs [ORs (95% CI) for the highest vs. lowest 
quintiles of each risk factor: 1.93 (1.36, 2.75), 1.67 (1.28, 2.19) and 1.62 (1.26, 
2.08), respectively]. Other factors were not associated with elevated IAD. In 
summary, male sex, smoking, greater height, larger waist circumference and not 
having diabetes were associated with elevated IAD among persons without an 
AAA. The findings highlight the potential for primary prevention of AAA through 
control of these factors. 
Manuscript 3 represents a meta-analysis of prospective cohort studies and 
case-control studies to examine further the relation between diabetes and AAAs. 
We searched for English literature from online database search (MEDLINE 
(1966-), EMBASE and Web of Science) plus a manual examination of references 
in selected articles as of Feb 2018, and included a total of 12 cohorts with 11,410 
AAAs in 2,665,121 adult participants and 4 case-control studies with 1,065 AAAs 
and 12,074 controls who met pre-determined eligibility criteria in the meta-
analyses. A DerSimonian and Laird random effects model pooled association 
estimates and their 95% confidence intervals from studies. Diabetes was 
inversely associated with the risk of AAA (pooled relative risk: 0.56; 95% 
vi 
 
confidence interval: 0.50 - 0.63). Results were similar in the subgroup analyses 
by sex (male/female), setting (population/clinical), and study design (cohort/case-
control). In summary, in contrast with diabetes being a risk factor for most 
cardiovascular diseases, diabetes appears to be strongly and inversely 
associated with the risk of AAA.   
In summary, my dissertation studies filled a gap of literature and further 
assessed AAA etiology by completing the three manuscripts. The three studies 
have potential to improve understanding of the etiology and early prevention of 
AAAs at the population level. Findings from my dissertation studies may offer a 
strategy to clinically identify high-risk individuals. 
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Chapter 1. Introduction and Literature Review  
1.1 Abdominal aortic aneurysm (AAA) is an important public health issue 
An abdominal aortic aneurysm (AAA) is a weakening in the wall of the 
abdominal aorta. The large amount of blood that flows through puts pressure on 
the weak spot, resulting in the formation of an AAA. A large proportion of AAAs 
are asymptomatic until the development of rupture. AAA rupture is acute and life-
threatening.  
AAA is a prevalent and highly-fatal disease. In the United States and 
European countries, it is estimated that AAAs affect 1% to 2% of the general 
population aged 50 years and above.1-11 The prevalence of AAA varies by region 
worldwide. In general, prevalence (among ≥ 25 years) is higher in developed 
than developing countries.12 A pooled analysis showed that in 2010 Australasia 
had the highest prevalence (approximately 0.31%), while the Central Asia had 
the lowest prevalence (approximately 0.11%).12 Each year, approximately 
200,000 American adults are diagnosed with AAA; of those, 7.5% may have 
AAAs large enough to be considered high risk for rupture.13 A rupture, which is 
often fatal and may occur without symptoms, is the primary cause of AAA 
mortality. In the United States, acute AAA rupture causes approximately 17,000 
deaths each year.14 Although mortality upon rupture has decreased from 1970s 
to 2010s, at most 5% to 30% of persons with a ruptured AAA survived, indicating 
that AAA fatality remains high.15-17 Since smoking is a well-known strong 
predictor of AAA, change in AAA mortality may be due to change in cigarette 
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smoking.18 Global trends in age-standardized AAA mortality from 1994 to 2010 
across 19 countries show substantial heterogeneity.19 For example, the age-
standardized rate of AAA mortality increased in Hungary and Romania while it 
decreased in the U.S. and United Kingdom for both males and females.19 
Therefore, AAA constitutes an important public health issue both in the U.S. and 
globally.  
1.2 Asymptomatic AAAs and elevated aortic diameters represent highly 
risky status 
Considering the fast expansion rate of AAA (the estimated mean growth 
rate: 0.13 to 0.57 cm per year), an asymptomatic AAA will have a high likelihood 
of becoming large within a few years and potentially rupture.20-23 Over the last 30 
year period before 2000, AAA incidence has substantially increased in the US 
and in the European countries; concurrently AAA mortality has slightly declined 
but still remains at a high level.18,24-26 Considering the large proportion of people 
with AAAs that are asymptomatic until the development of acute and life-
threatening rupture, examining risk factors for asymptomatic AAAs in the normal 
range is a public health priority for AAA prevention. 
Although there is no consensus for defining AAA,16,27 most studies defined  
an AAA as an infrarenal aortic diameter (IAD) of 3.0 cm and larger.16,28-37 
However, the threshold of IAD for defining an abdominal aortic aneurysm is 
somewhat arbitrary. The 3 cm cutpoint was chosen because it is more than two 
standard deviations (2.0 - 2.1 cm) above the average maximum IAD in the 
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general population,38 but abdominal aortic diameters vary somewhat by age, sex, 
and body size.39,40 Autopsy studies have shown that patients with IAD < 3 cm still 
have ruptures.41,42 Some organizations have advocated the use of other 
definitions. For example, the Society for Vascular Surgery and the International 
Society for Cardiovascular Surgery recommended that AAA be defined as an IAD 
50% greater than the population means reported in the literature.43 Therefore, 
investigation of IADs under 3 cm, particularly IADs 2.2 - 3 cm, might still be of 
potential value to identify people at high risk of AAA or other disease.   
Several prospective cohort studies have examined the risk of future AAA 
and other cardiovascular events for those people with IAD under 3 cm. Freiberg 
et al reported an IAD 2 - 3 cm vs. an IAD < 2 cm had 1.14 (95% CI: 1.02, 1.27) 
times risk of future cardiovascular events, with adjustment for age, race, renal 
insufficiency, smoking status, pack-years of smoking, height, weight, 
hypertension, diabetes, and LDL and HDL cholesterol, subclinical and clinical 
cardiovascular disease status.36 Furthermore, data from the Tromso study in 
Europe and an Australian cohort showed that compared to an IAD 2.1 - 2.3 cm, 
IADs 2.4 - 2.6 cm and 2.7 - 2.9 cm were associated with 2.4 and 4.2 times risk of 
future AAA, 1.2 and 1.3 times of all-cause mortality, 1.2 and 1.8 times of 
cardiovascular disease mortality.44-46 The results also showed that people with 
IAD < 2.0 cm did not have lower risk of future AAA and cardiovascular events 
than people with IAD 2.1 - 2.3 cm.   
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In summary, an elevated IAD, or an IAD above 2.1 - 2.3 cm, appears 
associated, albeit not linearly, with increased risk of AAA, CVD mortality, or all-
cause mortality. Therefore, an elevated IAD under 3 cm (particularly 2.3 – 3.0 cm) 
may indicate a pre-AAA stage, carrying increased risk for AAA and 
cardiovascular events. 
1.3 Determinants of AAA  
Given the high prevalence of AAA in the elderly and high fatality of AAA 
rupture, primary prevention of AAA deserves high priority for public health. The 
investigation with the aims of examining the determinants of AAA occurrence is 
needed and has potential of improving strategies for primary prevention. 
Summary of cardiovascular risk factors in relation to symptomatic AAA from 
prospective cohort studies is shown in Table 1.1. 
1.3.1 AAA shares several determinants with atherosclerosis 
Prospective cohort studies have suggested that smoking, hypertension, 
dyslipidemias, advanced age, male gender, and novel atherosclerosis risk factors 
including increased levels of D-dimer, fibrinogen, C-reactive protein, N-terminal 
pro-brain natriuretic peptide, and troponin T, are associated with higher risk of 
AAA.1,47-52 These factors are also traditional risk factors for atherosclerosis 
disease. Interestingly, diabetes which is another established risk factor for 
atherosclerosis, has been associated with lower risk of AAA.53 
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It is unclear whether atherosclerosis itself is a risk factor for AAA. The 
most recently released guideline by the U.S. Preventive Service Task Force 
stated that atherosclerosis was a risk factor for AAA; however, literature reviews 
included in this guideline and supporting this conclusion were from a cross-
sectional survey.16,54 To date, data on this topic from population-based cohort 
studies is still sparse. Data from the Tromso study has examined the relation 
between subclinical markers of atherosclerosis and AAA, by relating baseline 
carotid plaques and plaque growth with change in abdominal aortic diameter over 
6 years.55 That study reported that a one-standard-deviation increase in carotid 
plaque area was associated with 0.12 mm growth in IADs. However, that study 
had a limited number of AAA cases (N = 130).55 More studies are needed to 
further examine this issue.  
1.3.2 Negative association between diabetes and AAA 
The relation between diabetes and AAA has been examined in cross-
sectional studies, case-control studies and prospective cohort studies. 
A meta-analysis of 14 cross-sectional studies examined the possible 
relation between diabetes and prevalent AAA.56 This meta-analysis did not find a 
significant association between diabetes and prevalent AAA.56 Since the 2004 
meta-analysis only included cross-sectional studies, it was subject to potential 
limitations such as influence of reverse causality.  
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Recent large case-control studies and prospective cohort studies have 
reported inconsistent associations between diabetes and AAA in various 
populations; some studies showed an inverse relationship,48,52,57-61 while others 
did not show an association.38,49,62-68 (Tables 1.2 and 1.3) A meta-analysis in 
2015 which pooled data from case-control and prospective cohort studies 
reported a negative association between diabetes and AAA.69  However, that 
meta-analysis only included small number of studies (two case-control studies 
and six cohort studies), could not assess the effects of potential confounders 
(three cohorts without adjustment for age, sex, race, and smoking), and could not 
study the subgroups (e.g., population-based/ clinical-based groups) due to 
limited number of included studies.  
Genetic epidemiologic studies may provide additional information on the 
possible relationship between diabetes and AAAs. A Mendelian Randomization 
study conducted in Dutch descents did not show an association between AAA 
and the instrumental variable which was defined based on genotypes of 65 
single-nucleotide polymorphisms associated with type-2 diabetes.70 That 
evidence suggested that type-2 diabetes was not associated with AAA.70 Another 
Mendelian randomization study reported that genetic variants that lead to 
inhibition of Interleukin-1 are associated with AAAs but not with diabetes.71 In 
contrast, randomized controlled trials showed that anakinra, an interleukin-1 
receptor antoganist, decreased HbA1c levels.72-74 Dyslipidemia is a hypothesized 
risk factor for diabetes. A genome-wide association study showed that rs1466535, 
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located within intron 1 of low-density-lipoprotein receptor-related protein 1, is 
significantly associated with AAAs.76 However, Mendelian randomization study 
results should be interpreted with caution because of the possible limitations 
related to the assumptions of Mendelian randomization analysis such as potential 
pleiotropic effect, weak instruments, etc.75 Therefore, evidence from genetic 
studies did not consistently support inverse relationship between diabetes and 
AAAs.  
Therefore, the relationship between diabetes and AAA has been 
inconsistent across published studies. Additional well-designed studies with large 
sample sizes are needed to examine the association between diabetes and AAA 
and the associations by subgroups.  
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1.3.3 Determinants of asymptomatic AAA and aortic size 
Little is known about the determinants of asymptomatic AAAs, though risk 
factors for symptomatic AAAs have been studied.1,47-52 Prospective cohort 
studies have suggested that male sex, white race, greater height, smoking and 
dyslipidemia are risk factors for asymptomatic AAA detected by ultrasound 
exam.47,50,52 Most of these variables are also risk factors for atherosclerosis, but 
no study has examined the relation between atherosclerosis and asymptomatic 
AAAs.  
Determinants of an elevated IAD among non-AAAs are not established. A 
few cross-sectional studies conducted in clinical settings have examined this 
issue, and they reported that greater height and measures of adiposity, male sex, 
and smoking were risk factors.77-80 Those risk factors have also been reported in 
a few population-based cross-sectional studies.55,81,82 The relation between 
cholesterol and elevated IAD has only been examined in a sex-specific, age-
adjusted univariate analysis.81 Advanced age was associated with elevated IADs 
in previous studies conducted in clinic settings77,78 or in middle-age 
populations.55,82 Other population-based studies showed that the median IAD 
remained stable after 55 years of age;46,83-85 however, they did not exclude AAAs. 
Thus, the age-IAD relation is unclear, particularly in elderly populations which are 
at higher AAA risk than middle ages. Some studies have reported being free of 
diabetes is a risk factor,55,78 but newly-diagnosed diabetes was not related to 
elevated IAD in one study.77 It is unclear whether duration of diabetes matters in 
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the diabetes-IAD relationship. To our knowledge, most previous population-
based studies of IADs also included AAAs that were likely symptomatic; and 
most studies did not conduct a separate analysis of elevated IAD among 
participants without AAA.55,81 Some studies reported association estimates that 
were not adjusted for some essential confounders such as lipids and smoking.82 
Therefore, more well-designed, population-based studies conducted among 
patients free of AAA are warranted.  
Major determinants for atherosclerotic CVD, clinical AAA occurrence, 
ultrasound-detected AAA occurrence, and elevated IAD among non-AAAs are 
summarized in Table 1.4. 
1.4 AAA pathophysiology 
It is well-known that AAAs are characterized by destruction of aortic walls, 
but a complex pathophysiology is involved in the process (Figure 1.1). Several 
pathways have been identified to be involved in the formation of an AAA: 
upregulation of metal matrix metalloproteinases (MMPs) and other proteinases, 
activation of chronic aortic wall inflammation; and infiltration of mononuclear 
phagocytes and antigen-driven T cells.86,87 MMPs and other proteinases are very 
important in the formation of an AAA, and other risk factors likely act through 
MMPs and proteinases pathways.86,87 It is worth noting that a number of proteins 
relevant to the arterial wall and pro-inflammatory cytokines appear to be 
involved.88-90 Smoking may stimulate some endogenous products such as 
oxidized lipoproteins, localized tissue hypoxia, cytokines, chemokines, and 
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elevated local expression of angiotension, all of which have been linked to 
pathways of inflammation and immune system.91 Moreover, AAA can be formed 
after Marfan’s syndrome and some infectious diseases such as Chlamydia 
pneumoniae infection and syphilis.92 The underlying mechanisms are unclear.  
Atherosclerosis is widespread throughout the vasculature while AAA 
occurs only in some specific locations. Although atherosclerosis initially occurs in 
the intima, it promotes the dilation or shrinkage of the tunica media and adventitia, 
which in turn produces collagen and elastin fragments and promotes vascular 
remodeling via a disturbance in the synthesis and degradation of matrix 
proteins.93,94 Regarding the potential pathway from atherosclerosis to AAA, 
angiotensin-2, endothelin-1, and oxidative stress, which are involved in the 
development of atherosclerotic diseases, have been associated with increased 
risk of AAA.95-97 Data from early animal studies showed that the expansion of 
atherosclerotic plaques which include matrix fibers may simultaneously dilate and 
weaken aortic walls that support mural tension and then lead to aneurysmal 
enlargement.98 That evidence indicates that aneurysms often form after 
prolonged exposure to atherogenic conditions. In addition, atherosclerotic lipid 
plaques may be associated with later expansive remodeling of the vessel and 
arterial dilation.99  
Proteolysis and matrix destruction, including accelerated collagen turnover 
and elastin depletion, are mechanisms involved in the pathophysiology of AAA, 
which result in progressive dysfunction of aortic elastin and collagen in the walls, 
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increasing the risk of AAA.100,101 Diabetes is characterized by increased matrix 
volume which thickens the basement membrane and in turn may reduce the risk 
of AAAs.102 Diabetes has been associated with an increase in connective tissue 
and a decrease in aortic wall stress, while AAA formation is associated with 
increased aortic wall stress.103,104 On the other hand, the manifestations of AAA 
and diabetes have some physiological features in common. For example, both 
increase arterial stiffness,104,105 and stimulate transforming growth factor - β1 
expression which is a secreted protein that performs cell proliferation and 
apoptosis.106,107 In summary, although paradoxical differences in pathophysiology 
between AAAs and diabetes have been suggested, literature in general suggest 
that diabetes may increase matrix volume which thickens the basement 
membrane and avoids progressive dysfunction of aortic elastin and collagen in 
the walls.102 
Genetic variants may contribute to the formation of AAA. Family history is 
a known risk factor for development of an AAA. It is estimated that approximately 
15% of patients with an AAA have a positive family history. Genetic linkage 
analysis of families with AAAs has identified two loci on chromosomes 19q13 and 
4q31 that correlate with a susceptibility to the formation of AAA when sex and 
family history are taken into account.108 Although candidate genes in these two 
regions may be linked to the formation of AAA, to our knowledge, no single 
genetic polymorphism in that area has been identified as a determinant of AAA. 
Nonetheless, a meta-analysis of 13 studies including 1,258 cases and 1,406 
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controls showed that MMP-3 rs3025058, a common single nucleotide 
polymorphism (SNP) within the MMP-3 promoter region, is associated with 
higher risk for AAAs.109 An exome sequencing for AAA confirmed 34 protein-
altering somatic mutations in 25 genes which may contribute to the development 
of AAA.110 Moreover, genetic variants may be involved in many other process 






Table 1.1 Summary of cardiovascular risk factors in relation to symptomatic AAA from prospective cohort 
studies 
Groups Individual factors  Association  Ref 
    
Cohort studies  







Lifestyle  Cigarette smoking  +++ 47-50,64,111 





Metabolic risk factors Hypertension + 47-50,63,64,111 
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Total cholesterol  
Low-density lipoprotein cholesterol 






Circulating biomarkers  White blood cell (WBC) 
Fibrinogen 
C-reactive protein (CRP) 










    
Cross-sectional studies or case-control studies  
Lipid lowering 
medication 
Statin use - 5,112 
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Subclinical indices by 
ultrasound 
Carotid intima-media thickness (cIMT) 




Family history Family history of AAA ++ 16 
Circulating biomarkers matrix metalloproteinase (MMP)-3 
MMP-9 
N-terminal propeptide of Type Ill procollagen (PIIINP) 













Table 1.2 Characteristics of included studies examining the association between diabetes and AAA 






DM definition AAA 
ascertainment 
AAA definition 
Baumgartner 2008 clinical cohort 1 68236 1752 DM treatment record clinical records Not provided 
Blanchard 2000 clinical case-control N/A 200 98 FG ≥7 mmol/L or self-
reported DM 
diagnosis or DM 
treatment 
ultrasound scan Any definite 
focal widening 
classified as 
AAA, 92% ≥3 
cm 
Franks 1996 clinical case-control N/A 288 44 self-reported DM 
diagnosis 
clinical records Not provided 
Iribarren 2007 population cohort 13 104813 605 self-reported DM 
diagnosis 
clinical records ICD-9:441.3, 
441.4 
Jahangir 2015 population cohort 4.9 18782 281 self-reported DM 
diagnosis 
clinical records ICD-9:441.3, 
441.4 




Ohrlander 2012 population cohort 13 246957 3335 DM treatment record clinical records ICD-10: I71.3, 
I71.4 
Robin 2003 population cohort 30 19274 418 self-reported DM 
diagnosis 
clinical records ICD-9: 441.3, 
441.4, ICD-10: 
71.3, 71.4 
Shah 2015 population cohort 5.5 1921260 3051 DM treatment record clinical records Not provided 
Smelser 2014 clinical case-control N/A 11411 888 type-2 DM related 







Max IAD ≥3 cm 
Tang 2016 population Cohort 22.5 15703 588 FG ≥7 mmol/L or Non-


























Mean max IAD 
by the two 
methods ≥3 cm 
Wong 2007 population cohort 4 39352 376 self-reported DM 
diagnosis 
clinical records Not provided 





Max IAD ≥3 cm 










Table 1.2 Characteristics of included studies examining the association between diabetes and AAA (cont’) 
Author Year Relative Risk (95% 
confidence interval) 
Covariates 
Baumgartner 2008 0.59 (0.53, 0.66) age, sex, race, smoking, HTN, and dyslipidemia 
Blanchard 2000 0.32 (0.12, 0.87) age, sex, smoking, and family history 
Franks 1996 0.33 (0.04, 2.67) age and sex matched 
Iribarren 2007 0.62 (0.37. 1.05) age, sex, race, education, height, weight, smoking, alcohol, white blood cell 
counts, chronic kidney disease, HTN, CVD, and hormone use. 
Jahangir 2015 0.75 (0.54, 1.05) sex, race, education, BMI, smoking, CVD, and HTN 
Lederle 2008 0.29 (0.13, 0.66) age, sex, race, height, weight, smoking, alcohol, CVD, HTN, COPD, hormone 
use, and lipid meds 
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Ohrlander 2012 0.40 (0.21, 0.76) age, income, HTN, CVD and COPD 
Robin 2003 0.80 (0.43, 1.51) N/A 
Shah 2015 0.46 (0.35, 0.60) age, sex, deprivation, BMI, smoking, lipids and lipid meds, BP and BP meds 
Smelser 2014 0.43 (0.29, 0.64) age and sex matched 
Tang 2016 0.52 (0.36, 0.75) age, sex, race, height, smoking, alcohol, lipids, HTN and PAD 
Tornwall 2001 0.43 (0.16, 1.15) age, education, BMI, smoking, physical activity, BP, lipids, and trial group 
Wanhainen 2005 0.75 (0.11, 5.12) N/A 
Wong 2007 0.55 (0.26, 1.17) age, smoking, BMI, physical activity, HTN and dyslipidemia, 
Stackelberg 2017 0.52 (0.25, 1.09) education, smoking, BMI, WC, diet, physical activity, alcohol intake, HTN, 
CVD, and dyslipidemias 
Wang 2017 0.58 (0.51, 0.66) age, race, trial assignment, BMI, smoking status, alcohol use, physical 




AAA, abdominal aortic aneurysm; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; COPD, 
chronic obstructive pulmonary disease; DM, diabetes; FG, fasting glucose; IAD, infrarenal aortic diameter; HTN, 



















Baumgartner 68.6 (10.1) 63.0% 67.2% N/A 14.8% 81.8% 44.0% 
With established 
CVD, or with ≥3 
CVD risk factors 
Blanchard 69.0 51.0% 100.0% N/A 26.9% 38.4% 14.5% Not indicated 
Franks 70.4 (10.5) 83.0% 100.0% 172 100.0% 20.7% 6.3% Not indicated 
Iribarren 43.9 (14.1) 44.8% 82.0% 167 37.3% 36.5% 3.2% Not indicated 
Jahangir 64.4 (5.6) 63.9% 40.0% 168 21.2% 71.3% 30.0% Not indicated 
Lederle 63.2 (7.2) 0.0% 82.5% 162 6.9% 38.9% 5.9% Not indicated 
Ohrlander 71.4 43.4% 100% N/A N/A N/A 2.4% Not indicated 
Robin 50.5 (6.6) 54.9% 94.9% 169 38.0% 59.1% 3.4% Not indicated 
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Shah 46.9 (14) 49.4% 90.0% N/A 20.5% N/A 1.8% b Not indicated 
Smelser N/A 42.2% 100.0% N/A N/A N/A N/A b Not indicated 
Tang 54.2 (5.8) 44.8% 72.9% 169 26.1% 35.0% 11.9% Not indicated 
Tornwall 57 (53-61) a 100.0% 100.0% N/A 100.0% N/A 4.0% a Not indicated 
Wanhainen N/A 83.0% 100.0% N/A 12.0% 43.2% 11.4% Not indicated 
Wong 53.3 100.0% N/A N/A 9.6% 19.3% 2.0% Not indicated 
Stackelberg 55.3 (4.2) 100% 100% N/A 22.3% 17.9% 4.6% Not indicated 
Wang 65.5 (8.3) 100% 90.50% N/A 3.8% 45.9% 7.6% Not indicated  
CVD, cardiovascular disease; HTN, hypertension. 
a Median value (Interquartile range). 




Table 1.4 Summary of determinants for atherosclerotic CVD, abdominal aortic aneurysm (AAA) occurrence and 







Elevated IAD among 
non-AAAs 
Age ++ + ? + 
White race (vs. 
black) 
- + + - 
Male sex + +++ ++ ++ 
Height  - + + + 
Obesity  + + + + 
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Smoking  ++ +++ ++ ? 
Diabetes + - ? ? 
Hypertension  ++ + ? ? 
Dyslipidemia  + + + ? 
+, possible risk factor;  
-, possible protective factor;  













Destruction of aortic walls
AAA formation
Smoking 
Nordon IM. Nat Rev Cardiol 2011
Golledge J. Circulation. 2008
Oxidized lipoproteins
Localized tissue hypoxia, 
cytokines, chemokines, 
Angiotensin expression 
Vascular aging, Collagen 
and elastin fragments 



















Chapter 2. Detailed Methods  
2.1 The ARIC Study: Design and Population 
The ARIC study was designed to investigate risk factors for 
atherosclerosis and its clinical sequelae.115 The ARIC investigators created a 
cohort comprising 15,792 biracial men and women aged 45 - 64 from four 
communities (Washington County, MD; Forsyth County, NC; Jackson, MS; and 
suburban Minneapolis, MN) in 1987-89. The ARIC conducted follow-up 
examinations in 1990-92 (Visit 2), 1993-95 (Visit 3), 1996-98 (Visit 4), 2011-13 
(Visit 5), and 2016-17 (Visit 6). The seventh visit is ongoing. ARIC administered a 
telephone interview annually or semiannually through 2014 to ask about any 
interim hospitalizations or deaths and these records were sought to identify 
cardiovascular events including AAAs. To identify additional hospitalizations or 
deaths, the ARIC study also conducted surveillance of local hospital discharge 
lists for cohort members. For each hospitalization identified through 2014, all 
International Classification of Disease (ICD)-9-CM discharge codes were 
recorded. Additionally, ARIC linked participant identifiers with Medicare data from 
the Centers for Medicare and Medicaid Services (CMS) for 1991-2011, to find 
any missing hospital or outpatient events for those over 65 years.   
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2.2 Data Collection in ARIC 
2.2.1 Clinical AAA ascertainment  
Although participants were not queried about AAA history at the baseline 
examination (ARIC Visit 1) in 1987-89, they were asked extensively about prior 
arterial surgery. Clinical AAAs were identified by searching hospitalization, death 
records, and Medicare data. ARIC obtained any interim hospitalizations and 
identified deaths by conducting annual telephone calls with participants. ARIC 
also identified additional hospitalizations or deaths by conducting surveillance of 
local hospitals. Participants’ identifiers were linked to Medicare data from the 
Centers for Medicare and Medicaid Services (CMS) for 1991-2011, which was 
used to find additional hospital or outpatient events for those over 65 years. 
Clinical AAAs were defined as participants who had a hospital discharge 
diagnosis from any of the above sources, or two Medicare outpatient claims that 
occurred at least one week apart with ICD-9-CM codes of 441.3 (ruptured AAA) 
or 441.4 (AAA without mention of rupture), or procedure codes of 38.44 (AAA 
resection and replacement) or 39.71 (AAA endovascular repair), or a listed cause 
of death coded as ICD-9 code 441.3 or 441.4 or ICD-10 code I71.3 (ruptured 
AAA) or I71.4 (AAA without mention of rupture).52 AAA based on procedure 
codes were required to be verified by diagnosis codes. Both symptomatic and 
asymptomatic AAAs were medically documented. Thoracic, thoracoabdominal, or 
unspecified aortic aneurysms were not deemed as clinical AAA events but 
treated as non-events in this study (Tables 2.1 - 2.2). 
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2.2.2 Asymptomatic AAA and abdominal aortic size by ultrasound  
In the fifth ARIC examination (2011-13), a screening abdominal ultrasound 
was performed among 5,913 participants (59% of the 10,036 surviving ARIC 
participants through August 2013) to measure abdominal aortic diameters to 
identify additional asymptomatic AAAs in the surviving ARIC cohort.  
Both a radiologist and an ultrasound technician specializing in vascular 
imaging centrally trained experienced cardiac ultrasonographers from each ARIC 
field center in the technique of abdominal aortic scanning. Certified site 
sonographers followed standard protocols and obtained images with a Philips 
iE33 high resolution duplex scanner using a Philips C5-1 transducer and read all 
images in the field centers. Certified sonographers measured the following points 
of the aorta directly across the largest anterior posterior (AP) (front to back) or 
transverse (side to side) diameter to the outer edge of the wall on the opposite 
side:  at the proximal aorta just below the superior mesenteric artery, the 
proximal infrarenal aorta 2 cm below the renal arteries, the distal infrarenal aorta 
1 cm above the bifurcation, and the point of maximal infrarenal aortic diameter 
(IAD). A longitudinal view of the infrarenal aorta was also recorded to 
demonstrate whether the aneurysm begins above, at, or below the renal arteries. 
A maximum IAD was used to represent the size of AAAs and to define 
asymptomatic AAA. An asymptomatic AAA was defined by a maximum IAD ≥ 3 
cm, as commonly used in the literature.16,28-36,82 To ensure the completeness of 
identification of asymptomatic AAAs, experienced physicians specializing in 
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vascular imaging over-read any image that the sonographers recorded had > 2.8 
cm IAD or any possible vascular or non-vascular pathology, plus a 5% of the 
remaining cohort.  
Ultrasonography is accepted as the standard method of screening imaging 
for AAA due to several advantages. Ultrasonography is a low-cost and 
noninvasive method, and does not involve radiation exposure. It has a high 
sensitivity (≥ 94%) and specificity (≥ 98%).116-121 Although a computed 
tomography scan is also highly sensitive and specific in detecting AAAs, it is not 
recommended for first-line screening and therefore not useful in an 
epidemiological study, because of high cost and radiation exposure.16,116,122 
2.2.3 Carotid artery ultrasound measures 
At Visits 1 to 4, ARIC measured cIMT bilaterally in the extracranial carotid 
arteries, namely in the common carotid artery (1 cm proximal to the dilatation of 
the carotid bulb), the carotid bifurcation (1 cm proximal to the flow divider), and 
the internal carotid artery (1 cm distal to the flow divider). The mean cIMT was 
produced by combining the averages of cIMT measures at the six carotid sites. A 
previous study has reported that between-reader reliability coefficients ranged 
from 0.78 to 0.93 and coefficients of variation ranged from 13.1% to 18.3% in 
ARIC Visit 1.123 The presence of atherosclerotic plaque at any of the 6 segments 
was recorded by ARIC ultrasound readers as wall thickness in excess of 1.5 mm 
or the presence of lumen encroachment or irregular intimal surface and/or image 
characteristics indicative of structural heterogeneity of the arterial wall.  
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In the carotid ultrasound examination at Visit 2, the diastolic arterial 
diameter and the arterial diameter change, which represents change in arterial 
diameter between systole and diastole from the left carotid artery during cardiac 
cycles, were measured. Change in arterial diameter is an index of arterial 
stiffness. Concurrent brachial blood pressure was measured every 5 minutes 
with an automated oscillometric device (1846SX Dinamap), and the mean of the 
two blood pressure measures before the completion of ultrasound examination 
was used in calculating arterial stiffness indices. Pulse pressure was defined as 
the difference between systolic and diastolic blood pressure. Based on these 
ultrasound and blood pressure measures, several indices of stress-strain ratio 
were generated to represent carotid artery distensibility, including Peterson’s 
elastic modulus, Young’s elastic modulus, and beta index. Specifically, 
Peterson’s elastic modulus was calculated as (pulse pressure * diastolic arterial 
diameter)/ arterial diameter change; Young’s elastic modulus was calculated as 
[Petersons’ elastic modulus * diastolic arterial diameter / 2 * cIMT]; and beta 
index was calculated as log (systolic blood pressure / diastolic blood pressure) / 
(arterial diameter change / diastolic arterial diameter). More details on the 
measurement of these indices have been reported in previous studies.124,125  
2.2.4 Demographic and lifestyle variables 
In home interview and clinical examination at Visits 1 to 5, standardized 
questionnaires were used to obtain demographic information, educational status, 
lifestyle factors, medication use, and history of disease. Smoking status and 
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history were assessed by self-report. Smoking status was categorized as never, 
former (more than 100 cigarettes in the past), or current at each Visit.126 Smoking 
pack-years were calculated among the current and former smoker groups, based 
on the number of cigarettes per day and duration of smoking. Alcohol 
consumption was self-reported at all Visits. Usual alcohol consumption (in grams 
per week) was calculated based on the frequency of consumption of wine, beer 
and liquor, assuming that 4 oz of wine contains 10.8 g, 12 oz of beer contains 
13.2 g, and 1.5 oz of liquor contains 15.1 g of ethanol. Physical activity was 
assessed by interview using a questionnaire developed by Baecke in Visits 1 and 
3.127,128 The questionnaire included 16 items about usual exertion, and three 
indexes ranging from 1 (low) to 5 (high) were derived for physical activity at work, 
during leisure time, and in sports. Leisure time physical activity showed no 
relation with carotid atherosclerosis, so associations are shown for the work and 
sport indexes only.  
2.2.5 Diabetes, serum glucose, and hemoglobin A1c 
In ARIC, participants were asked to fast for 12 hours before each 
examination. Blood specimens were collected into vacuum tubes, then 
centrifuged at 3000g for 10 minutes at 4°C, and then stored at -70°C until 
analysis within a few weeks. In Visits 1 and 2, serum glucose was assessed by 
the hexokinase method. In Visits 3, 4 and 5 serum or plasma glucose (Visit 3 
only included plasma glucose) was measured using glucose-6-phosphate 
dehydrogenase method. Reliability coefficient for serum glucose was 0.84 in 
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participants examined several times,129 and quality control data for the other 
exams was similar. Prevalent diabetes mellitus was defined as a fasting glucose > 
126 mg/dL, a nonfasting glucose > 200 mg/dL, and/or a history of or treatment for 
diabetes.  
Hemoglobin A1c was measured on 4918 participants in 2003-2004 using 
the Tosoh 2.2 Plus HPLC instrument (Tosoh Bioscience, South San Francisco, 
CA, USA), and on the remaining 9151 participants using the Tosoh G7 HPLC 
instrument in 2007-2008.130 In a validation study, the coefficients of variation 
were 1.8% (N = 89) in 2003-2004 and 1.4% (N = 259) in 2007-2008.131 The 
correlation between measurements at the two time points was high (r = 0.99).  
2.2.6 Lipids  
Plasma lipids were measured in each ARIC Visit. Plasma total cholesterol 
and triglycerides were measured by enzymatic methods, and LDL cholesterol 
was calculated using Friedewald methods (plasma triglyceride levels ≤ 400 
mg/dL).132,133 If plasma triglycerides levels were > 400 mg/dL, LDL cholesterol 
was not calculated. HDL cholesterol was measured after dextran-magnesium 
precipitation.134 The lipid laboratory participated in the Centers for Disease 
Control Standardization Program throughout the study. As demonstrated in an 
intra-individual variability study, reliability coefficients (r) were ≥ 0.85 for LDL-C, 
HDL-C, and triglycerides in ARIC Visit 1.135 Quality control data for lipids 
measured in other visits are similar.  
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2.2.7 Blood pressure and hypertension 
In clinic examinations, after a 5-minute rest period, repeated blood 
pressures were obtained in seated participants by certified technicians using 
random zero sphygmomanometers. At Visits 1, 2, and 3, systolic and diastolic 
fifth phase blood pressures were measured three times in the right arm of seated 
participants. The mean of the last two measurements was used in analysis. At 
Visits 4 and 5, seated blood pressure was measured twice, and then averaged.  
Prevalent hypertension was defined as systolic pressure ≥ 140 mm Hg or 
diastolic pressure ≥ 90 mm Hg or use of antihypertensive medications.  
2.2.8 Anthropometric measurements 
At each ARIC Visit, weight was measured in standard scrub attire without 
shoes using a scale that was zeroed daily and calibrated quarterly. Height was 
measured to the nearest centimeter in Visits 1, 3, 4 and 5. Body mass index 
(kg/m2) was computed from height and weight. Waist circumference was 
measured at umbilicus level.  
2.2.9 Circulating biomarkers 
At Visit 1, white blood cells (WBC) were counted with Coulter counters in 
each study community. Fibrinogen was measured by the thrombin-time titration 
method with reagents and calibration materials (Fibriquik) obtained from General 
Diagnostics (Organon-Technika Co) at Visit 1.136 At Visit 3, ARIC measured D-
dimer concentrations via an immunoturbidimetric assay (Liatest D-DI, 
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Diagnostica Stago, Parsippany, NJ) on the Evolution analyzer (Diagnostica 
Stago, Parsippany, NJ). At Visit 4, ARIC measured cardiac troponin T using 
Cobas e411 analyzer (the Elecsys Troponin T immunoassay, Roche Diagnostics, 
Indianapolis, IN), N-terminal pro-brain natriuretic peptide (proBNP) using Cobas 
e411 analyzer (the Elecys proBNP II immunoassay, Roche Diagnostics, 
Indianapolis, IN), and high-sensitivity C-reactive protein (CRP) by the 
immunoturbidimetric CRP-Latex (II) high-sensitivity assay using a Hitachi 911 
analyzer (Roche Diagnostics, Denka Seiken, Tokyo, Japan). Although intra-
individual reliability coefficients were not available for these biomarkers in the 
ARIC, the reliability coefficient for blinded replicate measurements on split 
specimens was 0.99 for CRP, 0.99 for proBNP, 0.98 for Tropinin T, 0.92 for D 





Table 2.1 The 9th and 10th revision of the International Statistical Classification of Diseases (ICD) for aorta 
aneurysm 





































Dissection of aorta 
441.00:  
Dissection of unspecified site 
of aorta 
441.5:  
Aortic aneurysm of 




Dissection of aorta, 
thoracoabdominal 
rupture Aortic aneurysm of 
unspecified site w/o mention 
of rupture 




Resection of vessel 
with replacement, 
aorta, abdominal  
39.71:  
Endovascular 
implantation of graft in 





 39.52:  
Other repair of aneurysm;  
38.64:  
Other excision of vessels, 
aorta, abdominal 









































Dissection of unspecified site 
of aorta  
I71.8:  
Aortic aneurysm of 
unspecified site, ruptured 
I71.9:  
Aortic aneurysm of 

















Table 2.2 Definition of Definite and Probable Abdominal Aortic Aneurysm 
 Definite AAA 
(Specific AAA coding) 
Probable AAA (uncertain AAA status) 
(Non-specific sites of AA coding, and  
1. Not specific AAA coding;  
2. Not thoracic AA coding; 




(441.3 + 441.4) (441.0 + 441.00 + 441.5 + 441.9) 
- (441.3 + 441.4) 
- (441.01 + 441.1 + 441.2) 
- (441.6 + 441.7 + 441.03) 
 Repairs  
 
(38.44 + 39.71) (39.52 + 38.64) 







(I71.3 + I71.4 + 441.3 + 441.4) (I71.0 + I71.00 + I71.8 + I71.9 + 441 + 441.0 + 441.5 + 441.9) 
- (I71.3 + I71.4 + 441.3 + 441.4) 
- (I71.01 + I71.1 + I71.2) 
- (I71.03 + I71.5 + I71.6) 
Total Cases+ Repairs+ Deaths (There might be some overlaps among them) 
 
If a person had a thoracic or thoracoabdominal AA diagnosis code and a definite repair code of AAA, we categorized that 




Chapter 3. Manuscript 1: Association of Subclinical Carotid 
Atherosclerosis and Stiffness with Abdominal Aortic Aneurysm: the 
Atherosclerosis Risk in Communities (ARIC) Study 
3.1 Introduction 
Abdominal aortic aneurysms (AAA) affect about 1% to 2% of the general 
population aged ≥ 50 years in the US.50,138 According to the most recent 
estimates, AAA rupture causes about 2,446 deaths annually in the US.139 Thus, 
AAA is an important public health concern. 
There is a debate about whether atherosclerosis is a cause of AAA.1 
Prospective cohort studies have suggested that traditional risk factors for 
atherosclerotic disease, including smoking, hypertension, dyslipidemia, advanced 
age, male gender, and some inflammatory and hemostasis biomarkers, are 
associated with a higher risk of AAA.1,47-52 In addition, angiotensin-2,  endothelin-
1, and measures of oxidative stress, which are involved in the development of 
atherosclerotic diseases, are associated positively with the risk of AAA.95-97 In 
contrast, some risk factors for atherosclerosis, such as type 2 diabetes, may 
decrease the risk of AAA.53 Pathologically, atherosclerosis is widespread 
throughout the vasculature,140 while aortic aneurysms occur only in specific 
locations of the body such as the abdominal aorta. Moreover, atherosclerosis 
primarily forms in the intima while AAA primarily affects the media and 
adventitia.140 The most recently released guideline by the US Preventive Service 
Task Force stated that atherosclerosis was a risk factor for AAA;16 however, 
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literature reviews included in this guideline to support the statement were based 
on cross-sectional data for abdominal diameter among patients free of AAA.16,82  
Current knowledge gaps regarding the determinants of AAA are due to 
limited evidence. Epidemiologic data on atherosclerosis and AAA are sparse; 
only one population-based study, to date, has examined the relation between 
subclinical markers of atherosclerosis and maximal abdominal aortic diameter.55 
Data on the relation between arterial stiffness and AAA are also limited.141,142 To 
better understand the possible relationship of generalized measures of 
atherosclerosis and arterial stiffness with AAA occurrence, we analyzed data 
collected from a large population-based cohort study with over 20 years of follow-
up. We hypothesized that greater baseline carotid intima-media thickness (cIMT) 
and carotid plaque, and reduced carotid artery distensibility are associated with 
higher incidence of AAA. 
3.2 Methods 
3.2.1 The ARIC Study  
The ARIC study was designed to investigate risk factors for 
atherosclerosis and its clinical sequelae.115 The ARIC investigators recruited a 
population-based cohort comprising 15,792 men and women aged 45 - 64 from 
four communities (Washington County, MD; Forsyth County, NC; Jackson, MS; 
and suburban Minneapolis, MN) in 1987-89 (Visit 1). ARIC conducted follow-up 
examinations in 1990-92 (Visit 2), 1993-95 (Visit 3), 1996-98 (Visit 4), and 2011-
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13 (Visit 5). ARIC administered a telephone interview annually or semiannually to 
ask about any interim hospitalizations or deaths and these records were sought 
to identify cardiovascular events including AAAs. To identify additional 
hospitalizations or deaths, ARIC also conducted surveillance of local hospital 
discharge lists for cohort members. For each hospitalization identified, all 
International Classification of Disease (ICD)-9-CM discharge and procedure 
codes were recorded, and for deaths, the ICD-9 or ICD-10 codes for the 
underlying cause were recorded. Additionally, ARIC linked participant identifiers 
with Medicare data from the Centers for Medicare and Medicaid Services (CMS), 
since 1991, to find any missing hospital or outpatient events for participants over 
65 years.   
3.2.2 Ascertainment of AAA 
Participants reporting prior AAA surgery or aortic angioplasty at baseline 
were excluded from all analyses. Clinical AAAs were ascertained since the 
baseline examination through 2011, defined as either a hospital discharge 
diagnosis from any sources or two Medicare outpatient claims that occurred at 
least one week apart, with ICD-9-CM codes of 441.3 (ruptured AAA) or 441.4 
(AAA without mention of rupture), or procedure codes of 38.44 (AAA resection 
and replacement) or 39.71 (AAA endovascular repair), or a listed cause of death 
coded as ICD-9 441.3 or 441.4, or ICD-10 code I71.3 (ruptured AAA) or I71.4 
(AAA without mention of rupture).52 Both symptomatic and asymptomatic AAAs 
that were medically documented were included.  Thoracic, thoracoabdominal, or 
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aortic aneurysms at unspecified locations were not deemed to be AAA events in 
this study.  
In the fifth ARIC examination in 2011-13, an abdominal ultrasound was 
performed among 5,911 participants (excluding those with clinical AAA), 
comprising 59% of the 10,036 surviving ARIC participants through August 2013. 
Details on the abdominal ultrasound exam in ARIC can be found elsewhere.52 In 
short, certified cardiac ultrasonographers obtained images with a Philips iE33 
high resolution duplex scanner using a Philips C5-1 transducer. Transverse 
images of anterior-posterior and transverse diameters were recorded at the 
proximal aorta just below the superior mesenteric artery, the proximal infrarenal 
aorta 2 cm below the renal arteries, the distal infrarenal aorta 1 cm above the 
bifurcation, and the point of maximal infrarenal aortic diameter. A longitudinal 
view of the infrarenal aorta was also recorded. Infrarenal abdominal aortic 
maximum diameter ≥ 3 cm was used to define asymptomatic AAA.16,28-36,82 To 
ensure the completeness of identification of asymptomatic AAAs, experienced 
physicians specializing in vascular imaging over-read any image that the 
sonographers judged had > 2.8 cm infrarenal diameter or probable pathology, 
plus a 5% random sample of the normal images.  
3.2.3 Risk factor assessment 
At Visits 1 and 2, ARIC measured cIMT bilaterally in the extracranial 
carotid arteries, namely in the common carotid artery (1 cm proximal to the 
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dilatation of the carotid bulb), the carotid bifurcation (1 cm proximal to the flow 
divider), and the internal carotid artery (1 cm distal to the flow divider). In each 1-
cm section, there were up to 11 measurements (along the far wall) at 1-mm 
intervals.143 For each Visit, the mean cIMT was calculated by averaging all 
measures (far wall) from the six carotid sites (Figure 3.1). A previous study 
reported that in ARIC between-reader reliability coefficients for cIMT ranged from 
0.78 to 0.93 and coefficients of variation ranged from 13.1% to 18.3%.123 ARIC 
ultrasound readers recorded the presence of atherosclerotic plaque at any of the 
6 segments, defined as wall thickness more than 1.5 mm or the presence of 
lumen encroachment, irregular intimal surface, and/or image characteristics 
indicative of structural heterogeneity of the arterial wall. 
In the carotid ultrasound examination at Visit 2, the carotid arterial systolic 
and diastolic arterial diameters were measured with an ultrasonic echo-tracking 
radiofrequency device (Autrec 4881-AWT, Winston-Salem, NC).125 A diameter 
change was calculated to represent change in arterial diameter between systole 
and diastole from the left common carotid artery during cardiac cycles. 
Concurrently, two brachial blood pressures were measured with an automated 
oscillometric device (1846SX Dinamap, Critikon, Inc., Tampa, FL), and the mean 
of the two blood pressure measures was used in calculating arterial stiffness 
indices. Based on the ultrasound and blood pressure measures, Beta Index was 
generated as a stress-strain ratio representing carotid artery distensibility125. Beta 
Index was calculated as log (systolic blood pressure / diastolic blood pressure) / 
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(arterial diameter change / diastolic arterial diameter). A higher Beta Index 
indicates less carotid distensibility. Beta Index has been used as an index of 
carotid stiffness in ARIC,125 and is highly correlated with other indices of carotid 
artery distensibility measured at ARIC Visit 2 (Tables 3.1 and 3.2).  
In home interview and clinical examinations at Visits 1 and 2, standardized 
questionnaires were used to obtain information on demographics, lifestyle risk 
factors including smoking history, medication use, and medical history. Smoking 
status was categorized as never, former (more than 100 cigarettes in the past), 
or current smoker at each Visit.126 Smoking pack-years were calculated among 
the current and former smoker groups, based on the number of cigarettes per 
day and duration of smoking. Height was measured without shoes to the nearest 
centimeter at Visit 1. Weight was measured in a scrub suit to the nearest pound 
using a beam balance scale at Visits 1 and 2. Body mass index (BMI) was 
calculated by dividing weight (in kilograms) from the corresponding Visit by 
height (in meters) squared from Visit 1. At both Visits, systolic and diastolic fifth 
phase blood pressures were measured three times after a 5-minute rest in the 
right arm of seated participants by certified technicians using random zero 
sphygmomanometers. The mean of the last two measurements was used in 
analysis. Prevalent hypertension was defined as systolic blood pressure ≥ 140 
mmHg or diastolic blood pressure ≥ 90 mmHg or use of antihypertensive 
medications. Blood specimens were collected into vacuum tubes, centrifuged at 
3000g for 10 minutes at 4°C, and then stored at - 70°C until analysis within a few 
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weeks. Serum glucose was assessed by the hexokinase method.144 Prevalent 
diabetes mellitus was defined as a fasting glucose ≥ 126 mg/dL, a nonfasting 
glucose ≥ 200 mg/dL, and/or a history of or treatment for diabetes. Plasma total 
cholesterol was measured by enzymatic methods.132 HDL cholesterol was 
measured after dextran-magnesium precipitation134. At Visit 1, white blood cells 
were counted with Coulter counters,51 and fibrinogen was measured by the 
thrombin-time titration method with reagents and calibration materials (Fibriquik) 
obtained from General Diagnostics (Organon-Technika Co).136  
3.2.4 Statistical analyses 
 SAS (Version 9.4, SAS Institute Inc., Cary, NC, USA) was used in all 
analyses. We included ARIC participants who had carotid ultrasound measures 
at ARIC Study Visits 1 or 2 (N = 15,671), all of whom were then followed for 
clinical AAA status. For the analysis of cIMT and plaque, we excluded 55 
participants who were in race groups other than white or black or blacks in 
Minneapolis or Washington County, 11 who had prior AAA surgery, and 30 with 
uncertain AAA status during follow-up. We further excluded 1,002 participants 
without measurement of cIMT, leaving a final sample size of 14,573. For the 
analysis of Beta Index which was measured at Visit 2 only, we excluded from 
14,348 participants of baseline population 91 who were in race groups other than 
white or black or blacks in Minneapolis or Washington County, 22 who had AAA 
surgery or AAA prior to Visit 2, 24 with uncertain AAA status during follow-up, 
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and 3,921 without carotid Beta Index, leaving a final sample of 10,290 
participants.   
Carotid plaque (yes/no) measured at Visit 1 and Beta Index measured at 
Visit 2 were analyzed. For cIMT analyses, if the measurement was available only 
at Visit 1, or if a participant had an AAA between Visits 1 and 2, then the Visit 1 
measure of cIMT was used. Otherwise, the average cIMT value of both Visits 1 
and 2 (three years apart) was used in the analysis to reduce random error in the 
measurement. In both situations, ARIC Visit 1 was baseline for the analysis of 
cIMT. Both cIMT and Beta Index were categorized into quartiles in the analysis. 
The associations of measures of carotid atherosclerosis and stiffness with 
AAA were examined separately for clinical and ultrasound-detected AAAs. First, 
restricted a cubic spline was used to examine the shape of associations between 
continuous exposure variables (cIMT and Beta Index) and risk of AAA (clinical 
AAA only due to the relatively small sample size of the ultrasound AAA analysis). 
Unlike regression-based models, the spline method does not assume the shape 
of association but can fit complex distribution and linear regression.145 The shape 
of association is dependent on polynomials.146,147 Cubic spline, which is most 
widely used, includes a linear, a quadratic, and a cubic term to the category-
specific models to allow for a slope within category and to avoid a ‘sudden jump’ 
between categories. Also, if symmetric cutpoints are chosen, which almost 
always occurs, the shape is related to the number of cutpoints rather than the 
location of cutpoints.146 Since the number of cutpoints determines the degree of 
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smoothing, the more knots, the less smoothing. Typically, a small number of 
knots (between 3 and 8) are used. In this analysis, we started to use three 
cutpoints within cubic splines. We also used the restricted form of cubic spline, 
which excludes those in the upper 1% and the lower 1% of continuous exposure 
variables so as to provide conservative estimates for the tail regions and thus 
reduce the influence of outliers.145 If a linear relationship was found from 
restricted cubic spline, we used a linear model. If a non-linear relationship was 
observed, we considered non-linear techniques such as square or log 
transformations. In a special case where a threshold pattern of association was 
observed, we considered re-categorizing the data or analyzing it separately by 
the threshold. 
For the clinical AAA analysis, we plotted Kaplan-Meier curves to depict the 
unadjusted association of cIMT and Beta Index with clinical AAA risk. We used 
Poisson regression models to generate crude incident rates of AAA, and 
presented rates by category of exposure measures.  
We used Cox regression models to calculate hazard ratios (95% 
confidence intervals) of incident clinical AAA according to presence/absence of 
carotid plaque or across quartiles of cIMT and Beta Index. Follow-up time was 
calculated from Visit 1 for carotid plaque analysis and cIMT analysis while from 
Visit 2 for carotid distensibility analysis. A trend test across quartiles was 
calculated using the ordinal number for quartiles as a continuous variable in the 
Cox models. The assumption of proportional hazard was examined by testing the 
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interaction for exposure variable by time. Schoenfeld residuals were checked for 
testing the proportional hazard assumption.   
For analysis of ultrasound-detected AAA, we performed weighted general 
estimating equation regression. Given that 40% of the cohort were either lost to 
follow-up or died prior to the ultrasound exam at Visit 5, attrition yielded 
differential participation in the Visit 5 exam based on exposure status and AAA 
occurrence. To reduce the potential selection bias in the ultrasound AAA analysis, 
we used inverse probability of attrition weighting (IPAW) to account for attrition. 
As previously described,148 the weights were calculated based on the product of 
the probability of being alive at Visit 5 and the probability of having an abdominal 
ultrasound conditional on being alive given a variety of covariates measured at 
baseline and during follow-up. Regression coefficients to calculate odds ratios 
and their 95% CIs were obtained from IPAW general estimating equation models. 
The basic models to test our hypotheses were adjusted for age, sex, race, and 
ARIC field center. The additional models (i.e., fully adjusted models) were further 
adjusted for baseline height, smoking status, pack-years of smoking, total 
cholesterol, high-density lipoprotein cholesterol, lipid medications, systolic blood 
pressure, use of antihypertensive medications, and diabetes. In addition, 
interactions by sex or race in the association of cIMT, plaque, and Beta Index 
with AAA were explored. 




1. Given that there was no ultrasound examination available to identify 
prevalent AAAs at baseline, to address the possibility of reverse causality, we 
performed a secondary analysis by excluding AAAs ascertained during the first 
10 years of follow-up.  
2. Since Medicare outpatient claims have unknown validity in the 
diagnosis of AAA, we also performed a sensitivity analysis by excluding 
outpatient AAAs which were not verified by hospitalization records, death records, 
or the ultrasound exam.  
3. Additional sensitivity analyses included further adjustment for Visit 1 
fibrinogen or white blood cell count, which were novel cardiovascular biomarkers 
related to homeostasis and both have been associated with AAA in ARIC (also 
known to related to atherosclerosis).51  
4. Adiposity and diastolic blood pressure appears to be associated with 
AAA although it is not a well-established AAA risk factor.52,149 However, it is worth 
to evaluate the potential impact of these variables. We performed sensitivity 
analyses by further adjusting for body mass index, waist circumference, and 
diastolic blood pressure in turn in the fully adjusted models for the clinical AAA 
analysis  
5. In the previous study conducted in ARIC, alcohol or triglycerides was 
not significantly associated with clinical AAA (P > 0.50 for both in fully adjusted 
model), and triglycerides and alcohol were associated with ultrasound AAA at 
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borderline significance (P = 0.07 for triglycerides and P = 0.20 for alcohol).52 
Therefore, we did not include them for the adjustments in the analyses of clinical 
AAAs in the primary analysis but conduct a sensitivity analysis by further 
adjusting for alcohol consumption and triglycerides in the fully adjusted models of 
the clinical AAA analysis 
6. We conducted the following analyses to account for competing risks of 
atherosclerotic cardiovascular disease and death: a) excluded prevalent coronary 
heart disease, stroke, and myocardial infarction at baseline; b) used a cause-
specific Cox regression model where each participant was classified as either an 
AAA event, censored, or a cardiovascular disease event, whichever occurred 
first;150-153 the time to the first event, either an AAA or another cardiovascular 
event, was considered the failure time. If an AAA event occurred on the same 
day as the day of other CVD events, which may rarely happen, the AAA event 
was coded as occurring first. In the competing risks models, the time to the first 
event, either an AAA or another CVD event, was considered the failure time. The 
competing incidence rate was calculated as the product of the hazard and the 
event-free survival time, both of which were obtained from the cause-specific 
models. Thus, hazard ratios for competing AAA compared with other CVD event 
for each comparison was estimated; c) repeated analysis b) using death instead 
of cardiovascular event.152,153  
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7. Finally, we included cIMT and Beta Index simultaneously in the fully-
adjusted models to evaluate the independence of these two indices in their 
associations with AAA.   
3.3 Results  
3.3.1 Baseline description 
At Visit 1 in 1987 - 89, the mean age of this ARIC sample (N = 14,573) at 
risk of AAA was 54.2 years (SD 5.8); 45% were male and 73% were white. 
Approximately 34.2% of participants had carotid plaque. As shown in Table 3.3, 
on average, participants in the higher quartiles of cIMT were older, more often 
male, non-white, current/former smokers, hypertensive, diabetic, had carotid 
plaque, had lower levels of high-density lipoprotein cholesterol, and had higher 
levels of weight, body mass index, total cholesterol, systolic/diastolic blood 
pressure, fibrinogen, white blood cell count, and Beta Index (all P for trend < 
0.0001). The pattern of risk factor associations with Beta Index at Visit 2 was 
similar to that for cIMT with the exception that white blood cell count was not 
associated with Beta Index and smoking was inversely associated with Beta 
Index (Table 3.4). 
3.3.2 Carotid atherosclerosis in relation to AAA  
During a median of 22.5 years of follow-up through 2011, 542 clinical 
AAAs were ascertained. A linear relationship between cIMT and risk of incident 
clinical AAA was indicated by cubic spline analyses (Figure 3.2). Distributions of 
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Schoefeld residuals of cIMT and carotid plaque over time appeared to be roughly 
random (Figures 3.3 and 3.4). In addition, the interaction term of cIMT or plaque 
by time was not significant in the Cox model including time interaction terms 
(Table 3.5). Both evidence suggested that proportional hazard assumption is not 
violated.  
Similar to the pattern observed on Kaplan-Meier curves (Figure 3.5), 
participants in the highest quartile of cIMT (> 0.82 mm) had 2.71-fold increased 
risk of incident clinical AAA [95% CI: 2.01, 3.67], compared to the lowest quartile, 
after adjustment for age, sex, race, and ARIC field center (P for trend < 0.0001) 
in Cox proportional hazard regression analysis (Table 3.6). With further 
adjustment for other risk factors (Model 2), a linear relationship remained (P for 
trend: 0.006; hazard ratio [95% CI] for the highest vs. lowest quartiles of cIMT: 
1.55 [1.13, 2.11]). Participants who had a carotid plaque had 1.31 (95% CI: 1.10, 
1.57; P: 0.003) times higher risk of incident clinical AAA than those without a 
plaque in the fully adjusted model (Table 3.7).  
Of 5,459 participants who attended the ultrasound exam in 2011-13, 69 
asymptomatic AAAs were detected. In the basic model adjusting for age, sex, 
and race, cIMT was positively, albeit not significantly, associated with 
asymptomatic AAAs (P for trend: 0.44; odds ratio [95% CI] for the highest vs 
lowest quartile of cIMT: 1.61 [0.47, 5.45]) (Table 3.8). Presence of carotid plaque 
was associated with 2.62 (95% CI: 1.01, 6.83; P: 0.04) times higher risk of 
asymptomatic AAAs than those without a plaque in the basic model (Table 3.9). 
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The association between carotid plaque and ultrasound-measured AAA was 
slightly attenuated in the fully adjusted model (odds ratio: 2.17; 95% CI: 0.71, 
6.42; P: 0.18).  
3.3.3 Carotid artery distensibility in relation to AAA 
A linear relation between Beta Index and risk of incident clinical AAA was 
indicated by restricted cubic spline (Figure 3.6). Distributions of Schoefeld 
residuals of Beta Index over time appeared to be random (Figure 3.7). In 
addition, the interaction term of Beta Index by time was not significant (Table 3.5). 
Both evidence suggested that proportional hazard assumption is met.  
Consistent with the pattern shown on the Kaplan-Meier curves (Figure 
3.8), there was a positive association between Beta Index quartiles and clinical 
AAA in the fully adjusted model (P for trend 0.006); participants in the highest 
quartile of the Beta Index (> 13.05), indicating less carotid distensibility, had 1.68 
(95% CI: 1.16, 2.43) times higher risk of incident clinical AAA compared to those 
in the lowest quartile (Table 3.10).  
The association of Beta Index with asymptomatic AAAs was also positive, 
albeit not statistically significant, in the basic model (P for trend 0.22; odds ratio 
[95% CI] for the highest vs. lowest quartiles of Beta Index: 1.44 [0.32, 6.59]) 
(Table 3.11). 
The above associations for all of the three carotid measures did not differ 
significantly by sex or race (All P values > 0.05; Table 3.12).  
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3.3.4 Sensitivity analyses 
The associations of AAA with cIMT, carotid plaque, and Beta Index were 
similar in our sensitivity analysis after excluding AAAs occurring in the first 10 
years of follow-up. For example, in the fully adjusted model, the hazard ratio of 
incident clinical AAA for carotid plaque presence vs. absence was 1.38 (95% CI: 
1.13, 1.68, P: 0.002); the hazard ratio (95% CI) of incident clinical AAAs for the 
highest vs. lowest quartile of cIMT was 1.47 (1.05, 2.05) and P for trend was 0.03; 
the hazard ratio (95% CI) of incident clinical AAAs for the highest vs. lowest 
quartile of Beta Index was 1.49 [1.01, 2.20], and P for trend was 0.04. Results 
remained consistent after removing 101 Medicare outpatient AAAs who were not 
verified by hospitalization/death records or ultrasound exam (Tables 3.13 - 3.15); 
additionally adjusting for white blood cell count, fibrinogen, waist circumference, 
body mass index, diastolic blood pressure, triglycerides, or alcohol intake did not 
materially change the associations of any of the three carotid measures with AAA 
risk (Tables 3.16 - 3.23) In the competing risk analyses, consistent results were 
observed after accounting for the competing risk of cardiovascular events or 
death; the associations became slightly stronger after excluding prevalent 
cardiovascular disease at baseline (Tables 3.24 - 3.32). Furthermore, in the fully 
adjusted model, the associations of cIMT and Beta Index with AAA risk remained 




This population-based prospective study showed that carotid 
atherosclerosis as represented by greater cIMT or presence of plaque and 
carotid stiffness as represented by reduced carotid artery distensibility were 
associated with higher risk of clinically detected, incident AAA. Associations were 
in the same direction for ultrasound-detected AAAs though most of these 
associations were not statistically significant, likely due to the low number of 
asymptomatic AAAs detected from the Visit 5 exam. Our findings indicate that 
persons with carotid atherosclerosis or ‘stiff’ carotid arteries are at a higher risk 
for AAA than those without these conditions. This information might be useful in 
consideration of a prediction model to identify high risk individuals for AAA 
screening. 
Although an atherosclerosis-AAA association has not been directly 
documented in previous epidemiological studies, a dose-response relationship 
between atherosclerosis as reflected by carotid total plaque area and maximal 
abdominal aortic diameter was reported in a cross-sectional survey including 
Norwegians aged 55 to 74 years with and without AAA.113 A follow-up study of 
2019 persons in that sample showed that one-standard-deviation increase in 
carotid plaque area was associated with 0.12 mm concurrent growth in average 
infrarenal aortic diameter over 6 - 7 years (including 130 AAAs).55 In contrast, our 
study prospectively examined the association between baseline carotid 
ultrasound and a large number of incident AAAs ascertained over two decades. 
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Our findings suggest that subclinical carotid atherosclerosis is a risk marker for 
clinical AAA. Although any biological link is indirect, because we assessed 
atherosclerosis in the carotids, not the abdominal aorta, it is well known that 
atherosclerosis is typically widespread throughout the vasculature.140 Therefore, 
the association observed in our study likely reflects a relation between general 
atherosclerosis and AAA occurrence. 
With regard to our findings that AAA is more likely to occur in the presence 
of subclinical atherosclerosis, data from animal studies have shown that aortic 
aneurysms often form after prolonged exposure to atherogenic conditions 
reflected by aortic atherosclerotic plaque.98 Atherosclerotic plaques in the aortic 
wall include matrix fibers, and the expansion of plaques may simultaneously 
dilate and weaken aortic walls that support mural tension, potentially leading to 
aneurysmal enlargement.98 Studies have demonstrated that atherosclerosis, 
although initially occurring in the intima, promotes the dilation or shrinkage of the 
tunica media and adventitia; this in turn aggravates luminal obstruction and 
promotes vascular remodeling via a disturbance in the synthesis and degradation 
of matrix proteins.93,94 In addition, atherosclerotic plaques may be associated 
with later arterial dilation.99 On the other hand, atherosclerosis clearly is not 
necessary for AAA formation. AAA can form with toxic exposure to smoking, or 
for instance, with hypertension, Marfan’s syndrome, Chlamydia pneumoniae 
infection, or syphilis.92 Thus, a link between atherosclerosis and AAA is largely 
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supported by physiological data but further pathological and epidemiological 
evidence is warranted to establish a causal relationship.  
On the other hand, it may be that both atherosclerosis and AAA are the 
result of common risk factors or a common genetic predisposition (pleiotropy), 
and there is no direct pathophysiological connection of atherosclerosis with AAA.  
We adjusted for many AAA risk factors, but residual confounding may be present 
from measurement error in those risk factors or from failure to adjust for 
unrecognized or unmeasured AAA risk factors. 
Concerning arterial stiffness and AAA, in vivo studies have shown a 
greater stiffness of dilated or aneurysmal aortic walls in AAAs.154,155 As the 
pathogenesis of AAA is related to an alteration in systemic connective tissue 
metabolism, change in wall stiffness may occur in the rest of the vascular system, 
such as the carotid arteries, of AAA patients.156 So far, only a small cross-
sectional, hospital-based study reported that patients with AAA had a higher 
carotid artery Beta Index than did those without AAA.141 In addition, carotid 
stiffness has been positively associated with abdominal aortic diameters both in 
AAAs and non-AAAs.157,158 To our knowledge, our study is the first investigation 
showing that greater carotid stiffness is prospectively associated with higher risk 
of AAA in the general population. Findings from our study as well as the previous 
studies suggest that carotid stiffness index is a risk marker of AAA.  
The inverse association between smoking (collected in 1990 - 92 at Visit 2) 
and Beta Index, suggesting that smoking is associated with more distensible 
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carotid arteries, was unexpected. A possible explanation is that some 
participants who had a more severe cardiovascular risk factor profile at Visit 1 
may have stopped smoking around the Visit 2 exam. For example, we noticed 
that participants with prevalent hypertension smoked less compared to those 
without hypertension in ARIC Visit 2 (ever smoker 57% vs. 60%; P for difference 
< 0.001); a similar pattern was also observed for prevalent diabetes (ever smoker 
56% vs. 59%; P for difference < 0.001). Future research is warranted to clarify 
this issue.   
The strengths of our study include the prospective design, high quality 
measurements of exposures and outcomes, and a large sample size with a large 
number of incident AAAs. Nonetheless, the following limitations should be 
acknowledged when interpreting our results. First, misclassification may have 
occurred. Misclassification in the carotid ultrasound measures would likely have 
been non-differential with respect to AAA status given the prospective design of 
our study. Misclassification in the AAA outcomes would also likely have been 
non-differential, since staff who ascertained AAAs in ARIC were blinded to the 
exposure status. Non-differential misclassifications most likely would have diluted 
the estimates of association between AAA and exposures. Second, as noted 
above and as in other observational studies, residual confounding cannot be 
eliminated. Third, the clinical AAAs were ascertained based on ICD codes, and 
thus included both symptomatic and medically documented, asymptomatic AAAs. 
Fourth, since there was no baseline ultrasound exam for AAA, we cannot verify 
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that atherosclerosis and carotid stiffness always preceded incident AAA. 
However, participants who had AAAs through ARIC Visit 5 were likely free of 
AAA when they were aged 45-64 years at baseline considering the low 
prevalence of AAAs in that age group (about 1.8% in men and 0.2% in women).23 
Our sensitivity analysis excluding clinical AAAs ascertained within 10 years of 
baseline showed similar results to our main analysis. Moreover, analysis of 
ultrasound-detected AAA has the following additional limitations. Since 
ultrasound was measured only once in 2011-13, it is impossible to determine 
time of incidence for ultrasound-measured AAAs. In addition, the analysis of 
ultrasound-detected AAAs, restricted to the surviving subsample of ARIC 
population, may be biased by attrition if the attrition was differential with regard to 
subclinical atherosclerosis markers and AAA outcome; however, we observed 
that the associations for ultrasound-detected AAA were in the same direction as 
those for clinical AAAs after accounting for attrition using the IPAW methods. The 
non-significant associations for ultrasound-detected AAAs may result from 
insufficient power due to their limited number. 
In conclusion, this large, population-based cohort study, with more than 20 
years of follow-up, showed that carotid atherosclerosis and stiffness were 
associated positively with future risk of AAA, independent of traditional risk 
factors for atherosclerosis and AAA. The association likely reflects the underlying 
link between general atherosclerosis, arterial stiffness, and AAA or the impact of 
risk factors common to AAA and these conditions. 
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3.5 Tables  
Table 3.1 Distribution of indices of carotid artery distensibility 




Carotid arterial strain 10337 0.053 0.018 0.001 0.153 
Young’s elastic modulus 10055 752 364 108 3026 
Arterial diameter change 10338 399 128 10 1130 
Peterson’s elastic modulus 10324 1102 605 81 9088 






















Pearson r 1 -0.62 0.92 -0.64 -0.73 
P value 
 
<.0001 <.0001 <.0001 <.0001 
N 10337 10053 10336 10322 10288 
Young’s elastic 
modulus 
Pearson r -0.62 1 -0.53 0.74 0.78 
P value <.0001 
 
<.0001 <.0001 <.0001 
N 10053 10055 10054 10041 10013 
Arterial diameter 
change 
Pearson r 0.92 -0.53 1 -0.57 -0.67 
P value <.0001 <.0001 
 
<.0001 <.0001 
N 10336 10054 10338 10323 10289 
Peterson’s elastic Pearson r -0.64 0.74 -0.57 1 0.95 
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modulus P value <.0001 <.0001 <.0001 
 
<.0001 
N 10322 10041 10323 10324 10290 
Beta Index 
Pearson r -0.73 0.78 -0.67 0.95 1 
P value <.0001 <.0001 <.0001 <.0001 
 





Table 3.3 Baseline characteristics by quartiles of carotid intima-media thickness (cIMT), ARIC, 1987 - 89   
Characteristics a 
cIMT quartile 
P for trend 1 
N = 3643 
2 
N = 3643 
3 
N = 3644 
4 
N = 3643 
cIMT median, mm 0.59 0.67 0.76 0.93  
cIMT range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
Carotid plaque, %  431 (11.8) 746 (20.5) 1279 (35.1) 2532 (69.5) <0.0001 
Age, years  51.6 (5.2) 53.4 (5.5) 54.8 (5.6) 57.0 (5.3) <0.0001 
Male, %  965 (26.5) 1395 (38.3) 1864 (51.2) 2297 (63.1) <0.0001 
White, %  2878 (79.0) 2642 (72.5) 2612 (71.7) 2705 (74.3) <0.0001 
Height, cm 166.3 (8.7) 167.8 (9.2) 169.5 (9.4) 170.5 (9.2) <0.0001 
Weight, kg 72.5 (15.5) 77.7 (15.8) 80.9 (16.5) 81.4 (16.2)  <0.0001 
Body mass index, kg/m2 26.2 (5.0) 27.5 (5.1) 28.1 (5.2) 28.0 (4.9) <0.0001 
Smoking status     <0.0001 
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Current smoker, % 833 (22.9) 881 (24.2) 930 (25.6) 1185 (32.5)  
Former smoker, % 970 (26.7) 1090 (30.0) 1221 (33.5) 1415 (38.9)  
Never smoker, % 1837 (50.4) 1669 (45.8) 1490 (40.9) 1042 (28.6)  
Pack-years among smokers  21.6 (17.6) 24.6 (19.9) 28.8 (22.7) 34.9 (24.3) <0.0001 
Total cholesterol, mg/dL 205.5 (40.2) 213.3 (40.7) 217.1 (41.3) 222.2 (42.7) <0.0001 
High-density lipoprotein cholesterol, mg/dL 56.8 (17.7) 53.3 (17.9) 49.9 (16.1) 47.2 (15.4) <0.0001 
Lipid lowering medication, % 73 (2.0) 87 (2.4) 105 (2.9) 150 (4.2) <0.0001 
Systolic blood pressure, mmHg 114.7 (16.7) 119.2 (17.1) 122.7 (18.0) 127.6 (20.5) <0.0001 
Hypertensive medication use, % 751 (20.6) 1018 (28.0) 1160 (31.8) 1411 (38.8) <0.0001 
Diabetes, % 190 (5.3) 345 (9.6) 440 (12.2) 650 (18.0) <0.0001 
Fibrinogen, mg/dL 292.9 (58.4) 298.8 (63.4) 302.5 (64.4) 316.3 (71.1) <0.0001 
White blood cell count, 1000 cells/mm3 5.9 (1.9) 6.0 (1.9) 6.1 (1.9) 6.5 (2.1) <0.0001 
Beta Index b 10.0 (3.7) 10.8 (4.1) 11.5 (4.6) 12.7 (5.6) <0.0001 
a Mean (SD) for continuous variables or N (%) for categorical variables; 
b Beta index was measured in 1990 - 92.  
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Table 3.4 Baseline characteristics by quartiles of Beta Index, ARIC, 1990 - 92   
Characteristics a 
Beta Index levels 
P for trend Quartile 1 
N = 2572 
Quartile 2 
N = 2573 
Quartile 3 
N = 2573 
Quartile 4 
N = 2572 
Beta Index median, mm b 6.93 9.20 11.48 15.91  
Beta Index range, mm 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
Age, year  54.0 (4.9) 56.0 (5.5) 57.5 (5.6) 59.5 (5.3) <0.0001 
Male, % 1200 (46.7) 1170 (45.5) 1093 (42.5) 1048 (40.8) <0.0001 
White, % 2018 (78.5) 1906 (74.1) 1927 (74.9) 1861 (72.4) <0.0001 
Height, cm 169.6 (9.2) 169.0 (9.3) 168.2 (9.3) 167.4 (9.2) <0.0001 
Weight, kg 75.1 (14.4) 77.6 (15.8) 78.8 (16.0) 80.2 (16.4)  <0.0001 
Body mass index, kg/m2 26.0 (4.1) 27.1 (4.6) 27.8 (5.0) 28.6 (5.3) <0.0001 
Smoking status     <0.0001 
Current smoker, % 748 (29.1) 564 (21.9) 487 (18.9) 428 (16.6)  
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Former smoker, % 898 (34.9) 981 (38.1) 972 (37.8) 1007 (39.2)  
Never smoker, %  925 (36.0) 1028 (40.0) 1112 (43.3) 1135 (44.2)  
Smoking among smokers, pack-year 52.3 (47.5) 46.6 (44.4) 45.2 (45.1) 42.3 (42.1) <0.0001 
Total cholesterol, mg/dL 204.2 (37.3) 207.4 (37.6) 210.7 (39.0) 214.4 (41.4) <0.0001 
High-density lipoprotein cholesterol, mg/dL 51.1 (16.7) 50.5 (17.0) 50.2 (16.9) 48.9 (16.6) <0.0001 
Lipid lowering medication, % 128 (5.0) 150 (5.8) 149 (5.8) 190 (7.4) 0.0006 
Systolic blood pressure, mmHg 114.0 (15.0) 118.6 (16.6) 122.3 (17.8) 127.7 (20.2) <0.0001 
Antihypertensive medication, %  515 (20.0) 716 (27.8) 828 (32.2) 1041 (40.5) <0.0001 
Type-2 Diabetes, % 184 (7.2) 258 (10.1) 337 (13.2) 542 (21.2) <0.0001 
Carotid intima-media thickness, mm c 0.70 (0.15) 0.73 (0.18) 0.74 (0.18) 0.79 (0.21)  
Fibrinogen, mg/dL d 290.1 (60.5) 295.6 (62.6) 301.7 (60.1) 306.2 (63.2) <0.0001 
White blood cell count, 1000 cells/mm3 d 6.0 (1.9) 6.0 (2.1) 6.0 (1.9) 6.0 (2.2) 0.46 
a Mean (standard deviation) for continuous variables or N (%) for categorical variables; 
b Higher level of the Beta Index indicates less carotid artery distensibility; 
c Carotid intima-media thickness, measured in ARIC Visit 2, 1990 - 92; 
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Table 3.5 Estimates of Cox model with time-dependent variables for linearity test 
Interaction term by follow up time Parameter Standard error Chi-square P 
Carotid intima-media thickness * time -0.1667 0.23406 0.5072 0.48 
Plaque * time 0.03911 0.14195 0.0759 0.78 
Beta Index * time -0.0128 0.01656 0.6001 0.44 
a For Carotid intima-media thickness or plaque as the exposure variable, the models also were adjusted for age, sex, race, 
ARIC center, height, smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of 
lipid medications, systolic blood pressure, use of antihypertensive medications, diabetes and their time-interaction terms 
at ARIC Visit 1; 
b For Beta Index as the exposure variable, the models were also adjusted for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 





Table 3.6 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT), ARIC, 1987 - 2011 
cIMT Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
      Quartile range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
N at risk 3643 3644 3644 3644  
No. events 59 95 139 249  
Incidence rate a  0.76 (0.59, 0.98) 1.26 (1.03, 1.55) 1.92 (1.63, 2.27) 3.90 (3.45, 4.42)  
HR (95% CI)      
Model 1 b 1 1.32 (0.96, 1.84) 1.62 (1.18, 2.21) 2.71 (2.01, 3.67) <0.0001 
Model 2 c 1 1.11 (0.80, 1.54) 1.15 (0.84, 1.59) 1.55 (1.13, 2.11) 0.006 
CI, confidence interval; HR, hazard ratio; 
a Crude incidence rate per 1000 person-years; 
b Model 1: Adjusted for age, sex, race, and ARIC center; 
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c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, high-
density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.7 Risk of clinical abdominal aortic aneurysm in relation to presence vs. absence of carotid plaque, ARIC, 
1987 - 2011 
Plaque (y/n)  Absence Presence  P value 
    N at risk 9596 4989  
No. events 259 283  
Incidence rate a  1.31 (1.16, 1.48) 3.11 (2.77, 3.49)  
HR (95% CI)    
Model 1 b 1 1.82 (1.53, 2.17) <0.0001 
Model 2 c 1 1.31 (1.10, 1.57) 0.003 
a Crude incidence rate per 1000 person-years; 
b Model 1: Adjusted for age, sex, race, and ARIC center; 
c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive medications, 
and diabetes at ARIC Visit 1. 
75 
 
Table 3.8 Risk of asymptomatic abdominal aortic aneurysm diagnosed by ultrasound exam in 2011 - 13 in relation 
to quartiles of carotid intima-media thickness in 1987 - 92, ARIC. 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       cIMT Quartile range, 
mm 
0.41 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 1.65  
 N at risk 1883 1508 1273 795  
 No. events 16 12 20 21  
 OR (95% CI) a 1 0.79 (0.26, 2.39) 1.83 (0.59, 5.65) 1.61 (0.47, 5.45) 0.44 
CI, confidence interval; cIMT, carotid intima-media thickness; OR, odds ratio 





Table 3.9 Risk of asymptomatic abdominal aortic aneurysm diagnosed by ultrasound exam in 2011-2013 in 
relation to presence vs. absence of carotid plaque in 1987 - 89, ARIC 
  Absence Presence  P value 
     Plaque (y/n) N at risk 4077 1363  
 N event (%) 37 (0.9) 32 (2.3)  
 OR (95% CI) a 1 2.62 (1.01, 6.83) 0.04 
CI, confidence interval; OR, odds ratio; 








Table 3.10 Risk of clinical abdominal aortic aneurysm in relation to quartiles of Beta Index of the carotid artery, 
ARIC, 1990 - 2011 
Beta Index a Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
      Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
N at risk 2572 2573 2573 2572  
No. events 50 89 102 111  
Incidence rate b  1.05 (0.79, 1.38) 1.91 (1.55, 2.35) 2.25 (1.85, 2.73) 2.55 (2.12, 3.07)  
HR (95% CI)      
Model 1 c 1 1.58 (1.11, 2.24) 1.68 (1.19, 2.38) 1.72 (1.21, 2.44) 0.003 
Model 2 d 1 1.61 (1.12, 2.31) 1.62 (1.12, 2.33) 1.68 (1.16, 2.43) 0.006 
CI, confidence interval; HR, hazard ratio; 
a Higher level of the Beta Index indicates less carotid artery distensibility; 
b Crude incidence rate per 1000 person-years; 
c Model 1: Adjusted for age, sex, race, and ARIC center; 
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d Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive medications, 





Table 3.11 Risk of asymptomatic abdominal aortic aneurysm diagnosed by ultrasound exam in 2011 - 13 in 
relation to quartiles of Beta stiffness index in 1990 - 92, ARIC. 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       Beta index a Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 – 40.37  
 N at risk 1336 1173 1035 807  
 No. events 12 15 16 15  
 OR (95% CI) b 1 1.14 (0.36, 3.64) 0.96 (0.22, 4.24) 1.44 (0.32, 6.59) 0.22 
CI, confidence interval; OR, odds ratio 
a Higher level of the Beta Index indicates less carotid artery distensibility; 




Table 3.12 P values for interactions by race and sex in the association of carotid intima-media thinkness (cIMT), 
plaque and Beta Index with clinical abdominal aortic aneurysm.  
Interaction term P values for interaction 
 cIMT Plaque Beta-Index 
By sex 0.69 0.07 0.60 
By race 0.60 0.17 0.79 
All models included an interaction term by sex or by race, with adjustment for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 




Table 3.13 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) after excluding outpatients only ascertained by Medicare database, ARIC, 1987 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       cIMT Quartile range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
 N at risk 3643 3643 3644 3643  
 No. events 49 76 108 208  
 Incidence rate, 1000 
person-years a,b  
0.59 (0.45, 0.78) 0.95 (0.76, 1.19) 1.41 (1.17, 1.71) 3.12 (2.73, 3.58)  
 Model 1 HR  
(95% CI) b 
1 1.27 (0.88, 1.82) 1.49 (1.06, 2.11) 2.67 (1.91, 3.71) <0.0001 
 Model 2 HR 
(95% CI) c 
1 1.04 (0.72, 1.50) 1.02 (0.71, 1.45) 1.44 (1.02, 2.02) 0.04 
CI, confidence interval; HR, hazard ratio 
a Incidence rate per 1000 person-years. 
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b Model 1: Adjusted for age, sex, race, and ARIC center 
c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 





Table 3.14 Risk of clinical abdominal aortic aneurysm in relation to presence vs. absence of carotid plaque after 
excluding outpatients only ascertained by Medicare database, ARIC, 1987 - 2011 
  Absence Presence  P value 
     Plaque (y/n) N at risk 9595 4988  
 No. events 211 230  
 Incidence rate, 1000 
person-years a  
1.00 (0.88, 1.15) 2.41 (2.11, 2.74)  
 Model 1 HR a 1 1.80 (1.49, 2.18) <0.0001 
 Model 2 HR b 1 1.27 (1.04, 1.55) 0.02 
a Model 1: Adjusted for age, sex, race, and ARIC center 
b Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.15 Risk of clinical abdominal aortic aneurysm in relation to quartiles of Beta stiffness index of the carotid 
artery after excluding outpatients only ascertained by Medicare database, ARIC, 1990 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       Beta 
Index a 
Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
N at risk 2572 2573 2573 2572  
 No. events 39 71 83 88  
 Incidence rate, 1000 
person-years b,c  
0.82 (0.60, 
1.12) 
1.52 (1.21, 1.92) 1.83 (1.48, 2.27) 2.02 (1.64, 2.49)  
 Model 1 HR  
(95% CI) c 
1 1.61 (1.09, 2.39) 1.76 (1.19, 2.60) 1.76 (1.18, 2.60) 0.005 
 Model 2 HR  
(95% CI) d 
1 1.67 (1.11, 2.52) 1.73 (1.15, 2.62) 1.73 (1.14, 2.64) 0.01 
CI, confidence interval; HR, hazard ratio 
a Higher level of the Beta Index indicates less carotid artery distensibility; 
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b Incidence rate per 1000 person-years. 
c Model 1: Adjusted for age, sex, race, and ARIC center 
d Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.16 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 




 Hazard ratio (95%CI) a,b P for 
trend  Q1 Q2 Q3 Q4 














       
















a For cIMT as the exposure variable, the models also were adjusted for age, sex, race, ARIC center, height, smoking 
status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic 
blood pressure, use of antihypertensive medications, and diabetes at ARIC Visit 1; 
b For Beta Index as the exposure variable, the models were also adjusted for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 







Table 3.17 Risk of clinical abdominal aortic aneurysm in relation to presence of carotid atherosclerotic plaque 
before and after further adjustment for waist circumference, ARIC, 1987 - 2011   
Exposure   Hazard ratio (95% CI) a P for difference 
 Absence  Presence  
Plaque Not adjusted for WC 1 1.31 (1.10, 1.57) 0.003 
 
Adjusted for WC 1 1.30 (1.09, 1.56) 0.004 
a The models were also adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total 
cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive 






Table 3.18 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) and quartiles of Beta Index before and after further adjustment for diastolic blood pressure, ARIC, 1987 - 
2011   
Exposure 
variable 
 Hazard ratio (95%CI) a,b P for 
trend 
 Q1 Q2 Q3 Q4 
















       
Beta Index Not adjusted for 1 1.61 1.62 1.68 0.006 
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DBP (1.12, 2.31) (1.12, 2.33) (1.16, 2.43) 







a For cIMT as the exposure variable, the models also were adjusted for age, sex, race, ARIC center, height, smoking 
status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic 
blood pressure, use of antihypertensive medications, and diabetes at ARIC Visit 1; 
b For Beta Index as the exposure variable, the models were also adjusted for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 




Table 3.19 Risk of clinical abdominal aortic aneurysm in relation to presence of carotid atherosclerotic plaque 
before and after further adjustment for diastolic blood pressure, ARIC, 1987 - 2011   
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Exposure   Hazard ratio (95% CI) a P for difference 
 Absence  Presence  
Plaque Not adjusted for DBP 1 1.31 (1.10, 1.57) 0.003 
 
Adjusted for DBP 1 1.34 (1.12, 1.60) 0.002 
a The models were also adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total 
cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive 
medications, and diabetes at ARIC Visit 1. 
 
 
         
Table 3.20 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 





 Hazard ratio (95%CI) a,b P for 
trend 
 Q1 Q2 Q3 Q4 

















       









Adjusted for BMI 1 1.63 1.64 1.72 0.005 
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(1.14, 2.35) (1.14, 2.37) (1.18, 2.50) 
a For cIMT as the exposure variable, the models also were adjusted for age, sex, race, ARIC center, height, smoking 
status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic 
blood pressure, use of antihypertensive medications, and diabetes at ARIC Visit 1; 
b For Beta Index as the exposure variable, the models were also adjusted for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 







Table 3.21 Risk of clinical abdominal aortic aneurysm in relation to presence of carotid atherosclerotic plaque 
before and after further adjustment for body mass index, ARIC, 1987 - 2011   
Exposure   Hazard ratio (95% CI) a P for difference 
 Absence  Presence  
Plaque Not adjusted for BMI 
 
1 1.31 (1.10, 1.57) 0.003 
Adjusted for BMI 1 1.31 (1.09, 1.56) 0.004 
a The models were also adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total 
cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive 






Table 3.22 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) and quartiles of Beta Index before and after further adjustment for alcohol and triglycerides (TG), ARIC, 
1987 - 2011   
Exposure 
variable 
 Hazard ratio (95%CI) a,b P for 
trend 
 Q1 Q2 Q3 Q4 
cIMT Not adjusted for 

















       
Beta Index Not adjusted for 1 1.61 1.62 1.68 0.006 
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alcohol and TG (1.12, 2.31) (1.12, 2.33) (1.16, 2.43) 
Adjusted for 








a For cIMT as the exposure variable, the models also were adjusted for age, sex, race, ARIC center, height, smoking 
status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic 
blood pressure, use of antihypertensive medications, and diabetes at ARIC Visit 1; 
b For Beta Index as the exposure variable, the models were also adjusted for age, sex, race, ARIC center, height, 
smoking status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, 






Table 3.23 Risk of clinical abdominal aortic aneurysm in relation to presence of carotid atherosclerotic plaque 
before and after further adjustment for alcohol and triglycerides (TG), ARIC, 1987 - 2011   
Exposure   Hazard ratio (95% CI) a P for difference 
 Absence  Presence  
Plaque Not adjusted for alcohol and TG 
 
1 1.31 (1.10, 1.57) 0.003 
Adjusted for alcohol and TG 1 1.33 (1.11, 1.59) 0.002 
a The models were also adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total 
cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic blood pressure, use of antihypertensive 





Table 3.24 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) after adjustment for competing risk of cardiovascular event, ARIC, 1987 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       cIMT Quartile range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
 N at risk 3643 3644 3644 3644  
 No. events 59 95 139 249  
 Incidence rate, 1000 
person-years a,b  
0.76 (0.59, 0.98) 1.26 (1.03, 1.55) 1.92 (1.63, 2.27) 3.90 (3.45, 4.42)  
 Model 1 HR  
(95% CI) b 
1 1.31 (0.95, 1.82) 1.58 (1.15, 2.17) 2.44 (1.79, 3.33) <0.0001 
 Model 2 HR 
(95% CI) c 
1 1.13 (0.81, 1.57) 1.20 (0.87, 1.65) 1.50 (1.09, 2.05) 0.01 
CI, confidence interval; HR, hazard ratio 
a Incidence rate per 1000 person-years. 
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b Model 1: Adjusted for age, sex, race, and ARIC center 
c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 





Table 3.25 Risk of clinical abdominal aortic aneurysm in relation to presence vs. absence of carotid plaque after 
adjustment for competing risk of cardiovascular event, ARIC, 1987 - 2011 
  Absence Presence  P value 
     Plaque (y/n) N at risk 9596 4989  
 No. events 259 283  
 
Incidence rate, 1000 
person-years a  
1.31 (1.16, 1.48) 3.11 (2.77, 3.49) 
 
 Model 1 HR a 1 1.67 (1.40, 2.00) <0.0001 
 Model 2 HR b 1 1.21 (1.01, 1.46) 0.04 
a Model 1: Adjusted for age, sex, race, and ARIC center 
b Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.26 Risk of clinical abdominal aortic aneurysm in relation to quartiles of Beta stiffness index of the carotid 
artery after adjustment for competing risk of cardiovascular event, ARIC, 1990 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       Beta 
Indexa 
Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
N at risk 2572 2573 2573 2572  
 No. events 50 89 102 111  
 Incidence rate, 1000 
person-years b,c  
1.05 (0.79, 1.38) 1.91 (1.55, 2.35) 2.25 (1.85, 2.73) 2.55 (2.12, 3.07)  
 Model 1 HR  
(95% CI) c 
1 1.57 (1.11, 2.23) 1.67 (1.19, 2.38) 1.63 (1.15, 2.31) 0.006 
 Model 2 HR  
(95% CI) d 
1 1.63 (1.13, 2.34) 1.62 (1.12, 2.34) 1.61 (1.12, 2.33) 0.01 
CI, confidence interval; HR, hazard ratio 
a Higher level of the Beta Index indicates less carotid artery distensibility; 
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b Incidence rate per 1000 person-years. 
c Model 1: Adjusted for age, sex, race, and ARIC center. 
d Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.27 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) after adjustment for competing risk of death, ARIC, 1987 - 2011  
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       cIMT Quartile range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
 N at risk 3643 3644 3644 3644  
 No. events 59 95 139 249  
 Incidence rate, 1000 
person-years a,b  
0.76 (0.59, 0.98) 1.26 (1.03, 1.55) 1.92 (1.63, 2.27) 3.90 (3.45, 4.42)  
 Model 1 HR  
(95% CI) b 
1 1.30 (0.94, 1.81) 1.57 (1.14, 2.15) 2.30 (1.68, 3.13) <0.0001 
 Model 2 HR 
(95% CI) c 
1 1.12 (0.81, 1.56) 1.19 (0.87, 1.64) 1.42 (1.04, 1.95) 0.03 
CI, confidence interval; HR, hazard ratio 
a Incidence rate per 1000 person-years. 
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b Model 1: Adjusted for age, sex, race, and ARIC center 
c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 





Table 3.28 Risk of clinical abdominal aortic aneurysm in relation to presence vs. absence of carotid plaque after 
adjustment for competing risk of death, ARIC, 1987 - 2011 
  Absence Presence  P value 
     Plaque (y/n) N at risk 9596 4989  
 No. events 259 283  
 
Incidence rate, 1000 
person-years a  
1.31 (1.16, 1.48) 3.11 (2.77, 3.49) 
 
 Model 1 HR a 1 1.59 (1.33, 1.89) <0.0001 
 Model 2 HR b 1 1.17 (0.97, 1.42) 0.09 
a Model 1: Adjusted for age, sex, race, and ARIC center. 
b Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.29 Risk of clinical abdominal aortic aneurysm in relation to quartiles of Beta stiffness index of the carotid 
artery after adjustment for competing risk of death, ARIC, 1990 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       Beta 
Index a 
Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
N at risk 2572 2573 2573 2572  
 No. events 50 89 102 111  
 Incidence rate, 
1000 person-years 
b,c  
1.05 (0.79, 1.38) 1.91 (1.55, 2.35) 2.25 (1.85, 2.73) 2.55 (2.12, 3.07)  
 Model 1 HR  
(95% CI) c 
1 1.61 (1.13, 2.28) 1.69 (1.19, 2.39) 1.67 (1.17, 2.36) 0.004 
 Model 2 HR  
(95% CI) d 
1 1.66 (1.15, 2.38) 1.64 (1.13, 2.38) 1.64 (1.14, 2.37) 0.008 
CI, confidence interval; HR, hazard ratio 
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a Higher level of the Beta Index indicates less carotid artery distensibility. 
b Incidence rate per 1000 person-years. 
c Model 1: Adjusted for age, sex, race, and ARIC center. 
d Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.30 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) after excluding prevalent CVD events, ARIC, 1987 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       cIMT Quartile range, mm 0.37 - 0.63 0.64 - 0.71 0.72 - 0.82 0.83 - 2.26  
 N at risk 3538 3479 3428 3197  
 No. events 50 85 122 204  
 Incidence rate, 1000 
person-years a,b  
0.66 (0.50, 0.87) 1.17 (0.95, 1.45) 1.77 (1.48, 2.11) 3.54 (3.08, 4.06)  
 Model 1 HR  
(95% CI) b 
1 1.42 (1.00, 2.01) 1.73 (1.23, 2.42) 2.85 (2.05, 3.95) <0.0001 
 Model 2 HR 
(95% CI) c 
1 1.18 (0.83, 1.68) 1.24 (0.88, 1.75) 1.63 (1.16, 2.28) 0.004 
CI, confidence interval; HR, hazard ratio 
a Incidence rate per 1000 person-years. 
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b Model 1: Adjusted for age, sex, race, and ARIC center 
c Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 





Table 3.31 Risk of clinical abdominal aortic aneurysm in relation to presence vs. absence of carotid plaque after 
excluding prevalent CVD events, ARIC, 1987 - 2011 
  Absence Presence  P value 
     Plaque (y/n) N at risk 9134 4508  
 No. events 226 235  
 
Incidence rate, 1000 
person-years a  
1.19 (1.04, 1.35) 2.79 (2.45, 3.17) 
 
 Model 1 HR a 1 1.82 (1.51, 2.19) <0.0001 
 Model 2 HR b 1 1.31 (1.08, 1.59) 0.006 
a Model 1: Adjusted for age, sex, race, and ARIC center. 
b Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.32 Risk of clinical abdominal aortic aneurysm in relation to quartiles of Beta stiffness index of the carotid 
artery after excluding prevalent CVD events, ARIC, 1990 - 2011 
  Quartile 1 Quartile 2 Quartile 3 Quartile 4 P for trend 
       Beta 
index a 
Quartile Range 2.83 - 8.17 8.18 - 10.28 10.29 - 13.05 13.06 - 44.49  
N at risk 2459 2447 2398 2353  
 No. events 40 79 84 95  
 Incidence rate, 
1000 person-years 
b,c  
0.87 (0.64, 1.19) 1.77 (1.42, 2.20) 1.96 (1.58, 2.43) 2.33 (1.91, 2.85)  
 Model 1 HR  
(95% CI) c 
1 1.76 (1.20, 2.58) 1.76 (1.20, 2.59) 1.89 (1.28, 2.78) 0.001 
 Model 2 HR  
(95% CI) d 
1 1.77 (1.19, 2.64) 1.77 (1.19, 2.65) 1.84 (1.23, 2.77) 0.003 
CI, confidence interval; HR, hazard ratio 
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a Higher level of the Beta Index indicates less carotid artery distensibility; 
b Incidence rate per 1000 person-years. 
c Model 1: Adjusted for age, sex, race, and ARIC center 
d Model 2: Adjusted for age, sex, race, ARIC center, height, smoking status, pack-years of smoking, total cholesterol, 
high-density lipoprotein cholesterol, lipid medications, systolic blood pressure, use of antihypertensive medications, and 




Table 3.33 Risk of clinical abdominal aortic aneurysm in relation to quartiles of carotid intima-media thickness 
(cIMT) and quartiles of Beta Index, ARIC, 1987 - 2011   
Exposure 
variable  
 HR (95%CI) a,b P for 




Not adjusted for Beta Index 1 1.11 (0.80, 1.54) 1.15 (0.84, 1.59) 1.55 (1.13, 2.11) 0.006 
Adjusted for Beta Index 
quartile 
1 1.10 (0.73, 1.67) 1.38 (0.93, 2.04) 1.46 (1.00, 2.14) 0.05 
Beta Index  
 
 
Not adjusted for cIMT 1 1.61 (1.12, 2.31) 1.62 (1.12, 2.33) 1.68 (1.16, 2.43) 0.006 
Adjusted for cIMT quartile 1 1.62 (1.12, 2.33) 1.58 (1.09, 2.30) 1.64 (1.12, 2.39) 0.01 
HR: hazard ratio. 
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a For cIMT as the exposure variable, the model also adjusted for age, sex, race, ARIC center, height, smoking status, 
pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic blood 
pressure, use of antihypertensive medications, and diabetes at ARIC Visit 1; 
b For Beta Index as the exposure variable, the model also adjusted for age, sex, race, ARIC center, height, smoking 
status, pack-years of smoking, total cholesterol, high-density lipoprotein cholesterol, use of lipid medications, systolic 

















cIMT= (α+ β+ γ on the right 
carotid plus the left carotid)/6
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Figure 3.2 Restricted cubic spline for the natural and log scaled hazard ratio (95% CI) of incident clinical 

















Figure 3.5 Kaplan Meier curves for abdominal aortic aneurysm (AAA) free probability by quartiles of carotid 
intima-media thickness (cIMT) in ARIC. The data for cIMT were based on the follow-up during 1987 - 2011. The 
number at risk by the exposure quartile and follow-up year (in 5-year interval) is shown below the graphs. 
Kaplan Meier curves for AAA free probability by quartile of cIMT















Figure 3.6 Restricted cubic spline for the natural and log scaled hazard ratio (95% CI) of incident clinical 










Figure 3.8 Kaplan Meier curves for abdominal aortic aneurysm (AAA) free probability by quartiles of Beta Index in 
ARIC. The data for Beta Index were based on the follow-up during 1990 - 2011. The number at risk by the 
exposure quartile and follow-up year (in 5-year interval) is shown below the graphs. 
 
Kaplan Meier curves for AAA free probability by quartile of Beta Index















Chapter 4. Manuscript 2: Correlates of infrarenal aortic diameter in a 
population sample without aneurysms: The Atherosclerosis Risk in 
Communities (ARIC) Study 
4.1 Introduction 
An abdominal aortic aneurysm (AAA) is defined using a threshold of aortic 
diameter. Although there is no consensus for defining AAA,16,27 some 
organizations, such as The Society for Vascular Surgery and the International 
Society for Cardiovascular Surgery, have recommended that AAA be defined as 
an infrarenal aortic diameter (IAD) 50% greater than the population means 
reported in the literature.43 Most experts advocate the use of IAD ≥ 3 cm,16,28-36,82 
a cutpoint more than two standard deviations above the average maximum IAD 
in the general population.38 Although a 3 cm cutpoint has been useful for clinical 
management of AAAs, the biological and pathological evidence for this being the 
optimal cutpoint is limited.16,27 For example, autopsy studies have demonstrated 
ruptures in patients with IAD < 3 cm.41,42 Furthermore, prospective cohort studies 
conducted in the US, Europe, and Australia have shown that, compared to an 
IAD of 2.1-2.3 cm, IADs of 2.4-2.6 cm, and 2.7-2.9 cm were associated with 2.4 
and 4.2 fold risk of future AAA, 1.2 and 1.3 fold risk of all-cause mortality, 1.2 and 
1.8 fold risk of cardiovascular disease mortality.36,44-46 The findings from these 
studies suggest that an IAD above 2.1-2.3 may indicate a pre-AAA stage carrying 
increased risk for AAA and other life-threatening cardiovascular diseases.  
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Advanced age, male sex, white race, greater height, obesity, smoking, 
hypertension, dyslipidemia and absence of diabetes are risk factors for clinically-
defined AAA.48,49,52,149 Of these, male sex, white race, greater height, obesity, 
smoking, and dyslipidemia are also risk factors for asymptomatic AAA detected 
by ultrasound exam.47,50,52,149 If any of these risk factors are associated with an 
elevated IAD among persons without an AAA, such evidence may help to 
improve risk stratification and to refine AAA primary prevention strategies. 
However, the associations of risk factors with an increased, non-aneurysmal IAD 
have not been extensively examined in population-based studies.82 Thus, we 
explored the association between antecedent AAA risk factors and increased 
non-aneurysmal IAD in a population-based sample.  
4.2 Methods 
4.2.1 Study population 
The Atherosclerosis Risk in Communities (ARIC) Study is a community-
based, cohort study conducted in four communities in the US: Washington 
County, Maryland; Forsyth County, North Carolina; Jackson, Mississippi; and 
selected suburbs of Minneapolis, Minnesota.115 ARIC recruited 15,792 
participants 45 - 64 years of age in 1987-89 (Visit 1, baseline); conducted follow-
up visits in 1990-92 (Visit 2); 1993-95 (Visit 3); 1996-98 (Visit 4); 2011-13 (Visit 5); 
and 2016-17 (Visit 6). A seventh visit is underway. Institutional review boards at 
each study site approved the study, and written informed consent was obtained 
from all ARIC participants at each study visit.  
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There were 5,913 participants who had an abdominal ultrasound 
screening in ARIC Visit 5. We excluded participants whose race was not white or 
African American (N = 38); those with an asymptomatic AAA detected by the 
ultrasound exam (maximum IAD ≥ 3 cm, N = 75); unusable IAD in the ultrasound 
exam (N = 85); uncertain status of AAA (N = 3); and those with clinical AAA 
identified by hospital discharge codes, death codes, and Medicare outpatient 
claims prior to the Visit 5 exam (N = 92).25 After these exclusions, data from 
5,620 participants were included in the analysis.  
4.2.2 Measurement of abdominal aortic size by ultrasound exam 
Details on the abdominal ultrasound scanning in ARIC Visit 5 have been 
reported elsewhere.51,52 Briefly, certified cardiac ultrasonographers obtained 
images with a Philips iE33 high-resolution duplex scanner using a Philips C5-1 
transducer in each ARIC field center. Transverse images of anterior-posterior 
and transverse diameters were recorded at the proximal aorta just below the 
superior mesenteric artery, the proximal infrarenal aorta 2 cm below the renal 
arteries, and the distal infrarenal aorta 1 cm above the bifurcation. The 
ultrasonographers recorded maximal IAD if the maximal diameters could be 
determined based on the above three measures; otherwise they obtained and 
used an additional transverse image at the point of maximal IAD. To ensure 
quality of ultrasound scanning, physicians experienced in reading ultrasound 
images over-read all images that the sonographers judged had IAD > 2.8 cm or 
probable pathology, and a 5% random sample of the normal images. We defined 
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an ultrasound-detected AAA based on maximum IAD measurement ≥ 3 cm,23 
and excluded them from this analysis. Since the physician over-read values were 
more accurate, we used over-read diameters when available in the analysis. In 
participants without an AAA, the correlation coefficient for the readings of 
maximum IADs made between the physicians and sonographers was 0.86 (P < 
0.001), and the concordance between the readings by physicians and 
sonographers in classifying an elevated IAD (ranked into the highest IAD quartile) 
was 91.5%. 
4.2.3 Measurement of risk factors 
The present study included risk factors collected through ARIC Visit 5. 
ARIC obtained information on demographic variables, medical history, and 
traditional cardiovascular risk factors at each visit.115 Standardized 
anthropometric measurements of weight, height, and waist circumference were 
obtained on all participants. Weight was measured to the nearest pound with the 
participants wearing a scrub suit and no shoes. Height was measured to the 
nearest centimeter with the participants wearing a scrub suit and no shoes. Body 
mass index was defined as body weight in kilograms divided by height in meters 
squared. Waist circumference was measured to the nearest centimeter (cm) at 
the waist (umbilical level). Participants reported smoking status, the length of 
smoking history, and the number of cigarettes smoked, and we calculated pack-
years of smoking by multiplying the number of years smoked by the mean 
number of cigarettes per day divided by 20.126 ARIC collected information on use 
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of medications from the medication bottles brought to each visit, and measured 
systolic and diastolic blood pressure three times each in Visits 1 - 3, and twice 
each in Visits 4 - 5 using random zero sphygmomanometers on the right arm of 
seated participants after a 5-minute rest period. We used the mean of the last 
two measurements in Visits 1 - 3 and mean of the two measurements in Visits 4 - 
5, in the analysis. Prevalent hypertension was defined as mean systolic pressure 
≥ 140 mm Hg or diastolic pressure ≥ 90 mm Hg or use of antihypertensive 
medications. Using stored blood specimens from each visit, the ARIC laboratory 
measured plasma total cholesterol and triglycerides by enzymatic methods, HDL 
cholesterol after dextran-magnesium precipitation,134 and calculated LDL 
cholesterol for those with plasma triglyceride levels ≤ 400 mg/dL by Friedewald 
methods.132 Serum or plasma glucose was assessed by the hexokinase method 
or glucose-6-phosphate dehydrogenase method, depending on the visit.144 We 
defined prevalent diabetes mellitus as a fasting glucose ≥ 126 mg/dL, a 
nonfasting glucose ≥ 200 mg/dL, and/or self-reported physician diagnosis of or 
treatment for diabetes. 
4.2.4 Statistical Analysis  
Since most cardiovascular risk variables (except for race and sex) 
changed over time, we applied the following strategies to assess long-term 
exposures from middle age (baseline in 1987-89) to the latest visit available for a 
participant (maximum: Visit 5 in 2013). For waist circumference, body mass index, 
total cholesterol, HDL cholesterol, and LDL cholesterol, we calculated the 
128 
 
cumulative risk factor as the weighted average across Visit 1- Visit 5, weighted 
by the number of years between each examination.159 For example, the 
cumulative HDL value was calculated by summing the product of the average 
HDL concentration from two consecutive examinations and the corresponding 
time interval (in years) between the two examinations, divided by the time interval 
(in years) between Visit 1 and Visit 5. We coded the use of lipid-lowering 
medication as ‘ever positive/yes’ in our analysis if it was categorized as 
positive/yes in at least one visit; otherwise it was coded as ‘never positive.’ 
Diabetes and hypertension were categorized as never, short-term (incident cases 
occurring 1998 to 2011-13), intermediate-term (incident cases occurring 1987-89 
to 1996-98), and long-term (prevalent cases at 1987-89). We used age and pack-
years of smoking at Visit 5 directly because these two variables reflect 
cumulative values. Height at Visit 1 was used in the analysis. For both 
continuous and categorical variables, we imputed a missing value at a given visit 
using the value in the previous examination. The proportions of the sample with 
imputed values varied from 9.2% to 25.2%, depending on the variable. 
We defined the outcome of this study, an elevated IAD, as being in the 
highest quartile of the IAD distribution (i.e., IAD ≥ 2.2 cm) without an AAA. 
Participants whose IAD was under 2.2 cm were analyzed as the reference group. 
Although AAA risk has not been shown to be absent at an IAD as low as 1.8 cm, 
AAA risk increases exponentially as IAD increases beyond 2.2 cm.45 Thus, 2.2 
cm was chosen a priori as the cutpoint for the present analysis as it indicates 
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clearly elevated risk of clinical AAA. As previously described, we used inverse 
probability weighting to account for attrition due to loss to follow-up and death 
prior to the 2011-13 ARIC Visit 5.148 The weights were calculated based on the 
product of the probability of being alive in 2011-13 and the probability of having 
an abdominal ultrasound, conditional on being alive.25 Odds ratios (ORs) and 95% 
confidence intervals (CIs) of elevated IAD were obtained for each cumulative risk 
factor estimate from inverse probability of attrition weighted general estimating 
equation models. For each continuous risk factor, we calculated an OR for each 
quintile of the variable, with the lowest quintile as the reference group. For 
diabetes and hypertension, we calculate an OR associated with each category of 
the variable, with the “never” group as the reference group. We tested trends in 
ORs across quantiles by analyzing the quantile value as an ordinal variable. The 
basic models adjusted for baseline age, sex, race, and field center. The fully-
adjusted model additionally and simultaneously adjusted for all potential risk 
factors including height, waist circumference, total cholesterol, HDL cholesterol, 
smoking pack-year, diabetes, and hypertension. Models of LDL cholesterol did 
not adjust for total cholesterol. We included the use of lipid-lowering medications 
as a covariate in the multivariate adjustment model because use of lipid-lowering 
medications altered lipid profiles160 and might be associated with reduced AAA 
risk.112 A sensitivity analysis was conducted by replacing height by body mass 
index in the fully-adjusted model. Since body size differs remarkably by sex, we 
examined the association of body size (height and waist circumference) with 
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elevated IAD stratified on sex in a secondary data analysis. All analyses were 
performed using SAS (Version 9.4, SAS Institute Inc., Cary, NC, USA) 
4.3 Results 
4.3.1 Sample characteristics 
The final sample included 2,268 (40.4%) men and 3,352 (59.6%) women, 
and 4,374 (77.8%) whites and 1,246 (22.2%) blacks. The mean age was 51.7 
years (SD 5.0) at baseline and 75.4 (SD 5.1) at Visit 5 when the ultrasound exam 
was performed. On average, participants in the highest quartile of IAD compared 
to the rest were more often male and blacks, were taller, had greater body mass 
index and larger waist circumference, more pack-years of smoking, and lower 
concentrations of total cholesterol, and HDL cholesterol (P for difference < 0.001 
for all; Table 4.1).  
4.3.2 Associations of elevated IADs with AAA risk factors 
Table 4.2 shows data on associations of elevated IADs with AAA risk 
factors. In the basic models (adjusted for age, sex, race, and field center), male 
sex, height, waist circumference, and  smoking pack-years were positively 
associated with elevated IADs while HDL cholesterol, diabetes, and hypertension 
were inversely associated with an elevated IAD (P < 0.05). Participants in the 
highest quintiles of height, waist circumference, cigarette pack-years, and HDL 
cholesterol had 2.34 (95% CI: 1.65, 3.32) fold higher, 1.61 (95% CI: 1.23, 2.09) 
fold higher, 1.65 (95% CI: 1.29, 2.11) fold higher, and 0.74 (95% CI: 0.56, 0.98) 
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fold odds of having an elevated IAD, respectively, compared to those in the 
lowest quintiles. Men had 4.15 (95% CI: 3.56, 4.84; P<0.001) fold higher odds of 
having elevated IAD than women. Participants with long-term diabetes and 
hypertension had 0.70 (95% CI: 0.52, 0.93) and 0.81 (95% CI: 0.68, 0.98) lower 
odds of having an elevated IAD, respectively. Age, race, total cholesterol, and 
LDL cholesterol were not significantly associated with IAD. 
With mutual adjustment for all covariates plus lipid-lowering medications in 
the fully-adjusted model, all of the significant associations observed in the basic 
adjustment models remained, except that HDL cholesterol and hypertension 
were no longer associated with elevated IADs. Height, waist circumstance and 
smoking pack-years were positively associated with elevated IADs [ORs (95% CI) 
for the highest vs. lowest quintiles of the risk factor: 1.93 (1.36, 2.75), 1.67 (1.28, 
2.19) and 1.62 (1.26, 2.08), respectively; P for trend: <0.001 for all). The dose-
response associations of height, waist circumstance and smoking pack-years 
with elevated IAD are further depicted in Figures 4.1 A- 4.1 C. Men had 2.50 (95% 
CI: 1.90, 3.28; P for difference < 0.001) times higher odds of having elevated 
IADs than females. Participants with long-term diabetes had 0.52 (95% CI: 0.35, 
0.77; P for trend: 0.004) times lower odds of having an elevated IAD than 
participants without diabetes. 
The sensitivity analysis replacing height by body mass index in the fully-
adjusted model showed results similar to the primary analysis. The association 
between waist circumference and elevated IADs was attenuated, but in the same 
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direction as in the primary analysis (Table 4.3). BMI was positively associated 
with greater IAD in the basic model, but the positive association was no longer 
significant in the fully-adjusted model (Table 4.3). 
There was no significant interaction for waist circumference and height by 
sex in the association with elevated IAD either in the basic model or in the fully-
adjusted model (P for interaction > 0.20 for all). The secondary analyses 
conducted in each sex group showed height and waist circumference positively 
associated with IAD both in men and women (Table 4.4). 
4.4 Discussion 
In this population-based prospective study, male sex, greater height, 
greater pack-years cigarette smoking, and larger waist circumference were 
independently associated with elevated IAD in persons without an AAA (i.e. 
maximum IAD ≥ 3.0 cm). Previous studies have demonstrated that an elevated 
IAD (2.3 - 3.0 cm) within the normal range was positively associated with the risk 
of AAA and cardiovascular morbidity and mortality.36,44-46 Our study provides data 
to improve the understanding of AAA etiology by extending risk factor information 
to the pre-AAA stage. The identification of overlapping risk factors between AAA 
and less elevated IAD suggests that the pathophysiological mechanisms that 
lead to AAA development likely start or become activated during the pre-AAA 
stage. Thus, primary prevention efforts that focus on these risk factors at the pre-
AAA stage may be an effective strategy in reducing AAA occurrence, progression, 
and cardiovascular mortality, a hypothesis that could be tested in clinical trials. 
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Our results regarding height, measures of adiposity, male sex, and 
smoking were consistent with most previous cross-sectional studies conducted in 
clinical settings.77-80 Among population-based studies, Lederle and colleagues 
found that male sex, greater height, and larger waist circumference were 
associated with greater IAD in a cross-sectional survey among men and women 
aged 55-70 years who had no AAA history and IAD < 3 cm.82 Similar results 
regarding waist circumference and IAD were observed in a cross-sectional 
analysis in the Framingham Heart Study.81 Another non-concurrent cross-
sectional analysis using data from Tromso, Norway (mean age: 59 years) 
showed that male sex and cigarette smoking were positively associated with IAD 
measured 5.4-7.2 years later.55 However, both the Framingham Heart and the 
Tromso studies did not conduct a separate analysis among subjects without 
AAA.55,81 In comparison, our sample consists of community-dwelling black and 
white participants free of AAA, and information on AAA risk factors was 
cumulated over multiple visits during a follow-up of more than 20 years. 
Therefore, our study provides information in addition to what has already been 
reported. Our observation along with previous findings suggests a role of male 
sex, greater height, greater adiposity, and smoking in the early stages of AAA 
development.   
Given the strong correlation between male sex and IAD, the role of sex 
hormones in the development of AAA is of interest. However, there is no clear 
evidence that male sex hormones are positively associated with AAA nor female 
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hormones inversely related to AAA. Yet, data from animal studies suggested that 
male sex hormones promote AAA,161,162 and a cross-sectional study of older men 
showed that circulating free testosterone was inversely associated with AAA.163 
In a prospective cohort study of women, hormone replacement therapy of > 5 
years was associated with decreased risk of AAA (OR (95% CI) = 0.52 (0.34, 
0.78)),48 but this association was not observed in another cohort study conducted 
in an integrated health-care delivery system.49 On the other hand, hormone 
replacement therapy may trigger adverse thrombotic and proinflammatory 
outcomes.164 To our knowledge, there is no human study examining the role of 
endogenous estrogen in AAA. Men had larger IAD than women after accounting 
for body size (height and waist circumference) in the fully-adjusted model, 
indicating that the excess risk of men over women is not attributable to 
differences in body size. Further studies are required to clarify why men have 
higher IADs. 
The pathophysiological mechanisms underlying the associations of 
greater height, larger waist circumference, and smoking with elevated IAD are 
not well understood. The positive associations of height and waist circumference 
with elevated IAD are unlikely to be confounded by sex because we adjusted for 
sex in both basic and fully-adjusted models. Also, our sex-specific sensitivity 
analysis suggested height and waist circumference were positively associated 
with elevated IAD in both men and women. Animal studies have shown that 
smoking is involved in early stages of aneurysmal dilation of the aorta, including 
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accelerated elastin degradation,165,166 and this might be mediated through altered 
peripheral blood leukocyte response to aortic injury, activation of matrix 
metalloproteinases and inflammation, and apoptosis of smooth muscle cells.167-
169  
Regarding the negative association between diabetes and elevated IAD, 
both an age- and sex-adjusted analysis from the Tromso study55 and a clinical-
based study that included AAAs and non-AAAs78 reported the same direction of 
association between prevalent diabetes and IAD. In contrast, another clinical-
based study did not report any relation between newly-diagnosed diabetes and 
IAD.77 Evidence indicates that long-term diabetes rather than short-term diabetes 
may matter in relation to IAD, which is in line with our results. The diabetes- IAD 
relationship might be confounded by indication, because some diabetic 
medications such as metformin170,171 and thiazolidinediones,172 including 
rosiglitazone,173,174 may inhibit the development of AAA. However, we were 
unable to examine the effects of diabetes medication use. Alternatively, the 
negative association between diabetes and IAD might be attributed to 
hyperglycemia and the advanced glycation products associated with diabetes. 
Hyperglycemia has been associated with a reduction in proteolysis of matrix in 
the arterial wall,175 decreased aortic wall stress,103,104 and increased collagen 
synthesis.173,176,177 The advanced glycation products associated with diabetes 
may increase smooth muscle cell proliferation and induce cross-linking of 
collagen lattices in the media of the aorta, thereby reducing dilation.178,179 More 
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evidence is needed to clarify the causal relationship between diabetes and 
reduced IAD.   
In the Framingham Heart Study, HDL cholesterol was inversely correlated 
with IAD as well as other measures of aortic diameters in sex-specific, age-
adjusted univariate analysis.81 Our result in the basic model, that HDL cholesterol 
was inversely associated with elevated IAD, was consistent with the Framingham 
results.81 However, our fully-adjusted model suggested the relationship no longer 
existed. This suggests that the effects of HDL on elevated IAD may be 
confounded by other factors included in the fully-adjusted model such as body 
size, hypertension, diabetes, and smoking.   
There is a perception that IAD increases with age.82 However, our study 
showed no significant association between age and elevated IAD after 
adjustment for potential confounding variables. Advanced age was associated 
with elevated IADs in previous studies; however, these studies either were 
conducted in clinical settings77,78 or in populations younger than ours (mean age 
59 years vs 75 years at ultrasound measurement).55,82 In comparison, several 
population-based studies not excluding AAA showed that median IAD remained 
stable after 55 years of age (mean ages range from 61.1 to 72.5 years).46,83-85 
Thus, the age-IAD relation is unclear and further studies are warranted to 
address this issue.  
The strengths of our study include high quality measurements of risk 
factors and outcomes, a large sample size, and our use of cumulative long-term 
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exposure for the AAA risk factors. Nonetheless, this study is subject to some 
limitations. As in other observational studies, residual confounding cannot be 
eliminated. Measurement errors may have occurred in the aortic diameter data. 
However, we observed a high correlation between the readings made by the 
ultrasonographers and physicians; we also used a binary outcome (the highest 
quartile of IAD vs. the rest) to minimize the impact of outliers and measurement 
error. Finally, the use of a carry forward method for imputing missing values may 
misclassify risk factor levels across multiple time points for some participants.  
In summary, we identified that male sex, greater pack-years of smoking, 
greater height, larger waist circumference, and absence of diabetes were 
associated with elevated IADs in persons without an AAA in this large population-
based sample. Our findings enhance understanding of the risk factor profile for 
the pre-AAA stage and have the potential to improve risk stratification and the 




4.5 Tables  
Table 4.1 Baseline characteristics (mean (SD) or N (%)) according to maximal infrarenal aortic diameter (IAD) in 
ARIC participants without abdominal aortic aneurysms (N = 5620) 
Characteristic Maximum IAD P value b 
Lower three quartiles (< 2.2 cm) Highest quartile (≥ 2.2 cm) 
Age at V1, years 51.7 (5.0) 51.9 (5.1) 0.33 
Age at V5, years 75.4 (5.1) 75.5 (5.1) 0.96 
Male (%) 29.2 64.5 <0.001 
White (%) 80.0 73.1 <0.001 
Height at V1, cm 166.4 (8.5) 172.8 (9.1) <0.001 
Waist circumference, cm 98.1 (12.5) 101.5 (12.1) <0.001 
Body mass index, kg/m2 28.0 (5.0) 28.8 (4.8) <0.001 
Smoking, pack-years c 23.9 (20.6) 27.0 (22.9) <0.001 
Diabetes (%) 28.7 29.6 0.51 
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Hypertension (%) 75.9 74.4 0.20 
Total cholesterol, mg/dL 198.8 (28.6) 192.8 (29.8) <0.001 
LDL cholesterol, mg/dL 119.5 (25.0) 118.6 (26.2) 0.25 
HDL cholesterol, mg/dL 53.7 (14.6) 48.9 (13.6) <0.001 
Use of lipid lowering medication (%) 57.9 56.8 0.46 
HDL, high-density lipoprotein; LDL, low-density lipoprotein  
a Values of continuous risk factors (except for age and height which were from Visit 1) were cumulative averages among 
five visits, and values of categorical risk factors were ever/never across five visits. 
b P value from Student’s t test or chi-square test. 







Table 4.2 Adjusted odds ratios and confidence intervals for the associations between risk factors and greater 
infrarenal aortic diameter (≥ 2.2 cm). 
 
N at risk N events c Model 1 d  Model 2 e 
Age at V5, year  
    Q1 (66, 71) 1543 469 1 1 
Q2 (72, 73) 829 273 1.29 (1.03, 1.62) 1.33 (1.06, 1.67) 
Q3 (74, 76) 1072 334 1.15 (0.94, 1.42) 1.16 (0.94, 1.43) 
Q4 (77, 80) 1145 368 1.19 (0.93, 1.51) 1.27 (1.01, 1.59) 
Q5 (81, 90) 1031 330 1.08 (0.84. 1.37) 1.22 (0.96, 1.55) 




    No 3352 630 1 1 
Yes 2268 1144 4.15 (3.56, 4.84) 2.50 (1.90, 3.28) 






    No 1246 477 1 1 
Yes 4374 1,297 0.84 (0.47, 1.47) 0.82 (0.48, 1.43) 
P for difference 
  
0.54 0.37 
Height at V1, cm 
   
 Q1 (144, 160) 1191 182 1 1 
Q2 (161, 165) 1181 233 1.03 (0.80, 1.32) 0.96 (0.74, 1.23) 
Q3 (166, 170) 1065 299 1.50 (1.12, 2.03) 1.35 (1.01, 1.80) 
Q4 (171, 177) 1134 467 1.48 (1.07, 2.05) 1.36 (0.98, 1.88) 
Q5 (178, 199) 1047 591 2.34 (1.65, 3.32) 1.93 (1.36, 2.75) 
P for trend  
  
<0.001 <0.001 
Waist circumference, cm a 
    Q1 (63.4, 88.8) 1128 230 1 1 
Q2 (88.9, 95.4) 1121 328 0.97 (0.75, 1.24) 1.04 (0.81, 1.33) 
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Q3 (95.5, 101.6) 1123 352 0.95 (0.73, 1.23) 0.98 (0.75, 1.29) 
Q4 (101.7, 109.0) 1126 437 1.40 (1.09, 1.79) 1.45 (1.11, 1.88) 
Q5 (109.1, 149.7) 1119 424 1.61 (1.23, 2.09) 1.67 (1.28, 2.19) 
P for trend  
  
<0.001 <0.001 
Total cholesterol, mg/dL a 
    Q1 (96, 172) 1122 448 1 1 
Q2 (173, 188) 1129 405 0.97 (0.77, 1.21) 0.95 (0.76, 1.19) 
Q3 (189, 202) 1117 324 0.91 (0.70, 1.17) 0.93 (0.73, 1.19) 
Q4 (203, 220) 1123 297 0.77 (0.61, 0.98) 0.80 (0.63, 1.02) 
Q5 (221, 378) 1121 298 0.86 (0.67, 1.10) 0.92 (0.71, 1.18) 
P for trend  
  
0.07 0.25 
LDL cholesterol, mg/dL a 
    Q1 (17.6, 39.7) 1118 380 1 1 
Q2 (39.8, 46.5) 1119 365 0.90 (0.72, 1.13) 0.87 (0.70, 1.10) 
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Q3 (46.6, 53.6) 1119 334 0.88 (0.70, 1.12) 0.86 (0.67, 1.09) 
Q4 (53.7, 63.5) 1119 349 1.02 (0.80, 1.31) 0.97 (0.77, 1.23) 
Q5 (63.6, 118.4) 1118 333 0.91 (0.72, 1.16) 0.90 (0.71, 1.15) 
P for trend  
  
0.95 0.76 
HDL cholesterol, mg/dL a 
    Q1 (27.6, 99.0) 1122 471 1 1 
Q2 (99.1, 112.2) 1123 435 1.02 (0.81, 1.29) 1.05 (0.83, 1.32) 
Q3 (112.3, 124.1) 1122 339 0.82 (0.63, 1.07) 0.89 (0.69, 1.15) 
Q4 (124.2, 139.1) 1123 281 0.74 (0.58, 0.96) 0.84 (0.64, 1.09) 
Q5 (139.2, 291.0) 1122 246 0.74 (0.56, 0.98) 0.89 (0.66, 1.19) 
P for trend  
  
0.007 0.24 
Pack-years of smoking a 
    Q1 (0, 0) 2946 744 1 1 
Q2 (0.1, 8.5) 654 223 1.30 (1.05, 1.62) 1.32 (1.07, 1.63) 
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Q3 (8.6, 19.5) 651 238 1.29 (1.05, 1.59) 1.24 (1.01, 1.53) 
Q4 (19.6, 36.2) 651 240 1.53 (1.15, 2.03) 1.61 (1.25, 2.08) 
Q5 (36.3, 186.0) 652 275 1.65 (1.29, 2.11) 1.62 (1.26, 2.08) 




    Never 3990 1249 1 1 
Short-term 904 299 1.07 (0.91, 1.26) 1.02 (0.84, 1.25) 
Intermediate-term 435 147 0.92 (0.72, 1.19) 0.95 (0.67, 1.34) 
Long-term 291 79 0.70 (0.52, 0.93) 0.52 (0.35, 0.77) 




    Never 1381 455 1 1 
Short-term 1787 569 0.90 (0.77, 1.06) 0.91 (0.75, 1.10) 
Intermediate-term 1143 334 0.80 (0.66, 0.97) 0.73 (0.57, 0.93) 
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Long-term 1309 416 0.81 (0.68, 0.98) 0.81 (0.65, 1.01) 
P for trend  
  
0.01 0.06 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Q, quintile 
a Values were cumulative averages among five visits, weighted by time interval between the visits.   
b Disease status was classified as were never, short-term (since 2011 - 13), moderate (since 1990 - 92), and long-term 
(since 1987 - 89 and earlier).  
c Events were defined as being in the highest quartile of infrarenal aortic diameters distribution (≥ 2.2 cm). 
d Adjusted for age, sex, race, and field center.  
e Adjusted for age at V5, sex, race, field center, height, waist circumference, total cholesterol, HDL cholesterol, lipid-






Table 4.3 Adjusted odds ratios and confidence intervals for the associations between risk factors and greater 
infrarenal aortic diameter (≥ 2.2 cm) in the sensitivity analysis.  
 N at risk N Event c Model 1 d Model 2 e 
Age at V5, year      
Q1 (66, 71) 1543 469 1 1 
Q2 (72, 73) 829 273 1.29 (1.03, 1.62) 1.32 (1.05, 1.66) 
Q3 (74, 76) 1072 334 1.15 (0.94, 1.42) 1.15 (0.93, 1.42) 
Q4 (77, 80) 1145 368 1.19 (0.93, 1.51) 1.26 (1.01, 1.58) 
Q5 (81, 90) 1031 330 1.08 (0.84. 1.37) 1.18 (0.93, 1.51) 
P for trend  
  
0.55 0.31 
Male      
No 3352 630 1 1 
Yes 2268 1144 4.15 (3.56, 4.84) 3.68 (3.05, 4.45) 
P for difference   <0.001 <0.001 
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White race     
No 1246 477 1 1 
Yes 4374 1297 0.84 (0.47, 1.47) 0.86 (0.50, 1.49) 
P for difference   0.54 0.52 
Body mass index, kg/m2     
Q1 (15.7, 24.1) 1123 263 1 1 
Q2 (24.2, 26.4) 1124 349 0.91 (0.71, 1.16) 0.95 (0.72, 1.25) 
Q3 (26.5, 28.7) 1124 369 0.97 (0.76, 1.24) 0.92 (0.68, 1.26) 
Q4 (28.8, 31.8) 1124 385 1.14 (0.89, 1.45) 0.98 (0.69, 1.41) 
Q5 (31.9, 56.5) 1123 406 1.62 (1.25, 2.12) 1.31 (0.86, 2.01) 
P for trend    <0.001 0.20 
Waist circumference, cm a     
Q1 (63.4, 88.8) 1128 230 1 1 
Q2 (88.9, 95.4) 1121 328 0.97 (0.75, 1.24) 1.08 (0.82, 1.43) 
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Q3 (95.5, 101.6) 1123 352 0.95 (0.73, 1.23) 1.05 (0.76, 1.45) 
Q4 (101.7, 109.0) 1126 437 1.40 (1.09, 1.79) 1.48 (1.04, 2.11) 
Q5 (109.1, 149.7) 1119 424 1.61 (1.23, 2.09) 1.49 (0.98, 2.25) 
P for trend    <0.001 0.07 
Total cholesterol, mg/dL a     
Q1 (96, 172) 1122 448 1 1 
Q2 (173, 188) 1129 405 0.97 (0.77, 1.21) 0.96 (0.76, 1.20) 
Q3 (189, 202) 1117 324 0.91 (0.70, 1.17) 0.95 (0.74, 1.21) 
Q4 (203, 220) 1123 297 0.77 (0.61, 0.98) 0.81 (0.64, 1.02) 
Q5 (221, 378) 1121 298 0.86 (0.67, 1.10) 0.92 (0.72, 1.18) 
P for trend    0.07 0.20 
LDL cholesterol, mg/dL a     
Q1 (17.6, 39.7) 1118 380 1 1 
Q2 (39.8, 46.5) 1119 365 0.90 (0.72, 1.13) 0.90 (0.71, 1.13) 
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Q3 (46.6, 53.6) 1119 334 0.88 (0.70, 1.12) 0.87 (0.68, 1.10) 
Q4 (53.7, 63.5) 1119 349 1.02 (0.80, 1.31) 0.99 (0.78, 1.25) 
Q5 (63.6, 118.4) 1118 333 0.91 (0.72, 1.16) 0.92 (0.73, 1.17) 
P for trend    0.95 0.75 
HDL cholesterol, mg/dL a     
Q1 (27.6, 99.0) 1122 471 1 1 
Q2 (99.1, 112.2) 1123 435 1.02 (0.81, 1.29) 1.05 (0.83, 1.33) 
Q3 (112.3, 124.1) 1122 339 0.82 (0.63, 1.07) 0.90 (0.69, 1.17) 
Q4 (124.2, 139.1) 1123 281 0.74 (0.58, 0.96) 0.85 (0.65, 1.11) 
Q5 (139.2, 291.0) 1122 246 0.74 (0.56, 0.98) 0.91 (0.68, 1.23) 
P for trend    0.007 0.37 
Pack-years of smoking a     
Q1 (0, 0) 2946 744 1 1 
Q2 (0.1, 8.5) 654 223 1.30 (1.05, 1.62) 1.34 (1.08, 1.65) 
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Q3 (8.6, 19.5) 651 238 1.29 (1.05, 1.59) 1.26 (1.02, 1.55) 
Q4 (19.6, 36.2) 651 240 1.53 (1.15, 2.03) 1.60 (1.23, 2.08) 
Q5 (36.3, 186.0) 652 275 1.65 (1.29, 2.11) 1.65 (1.29, 2.12) 
P for trend    <0.001 <0.001 
Diabetes b     
Never 3990 1249 1 1 
Short-term 904 299 1.07 (0.91, 1.26) 1.01 (0.82, 1.23) 
Intermediate-term 435 147 0.92 (0.72, 1.19) 0.93 (0.65, 1.32) 
Long-term 291 79 0.70 (0.52, 0.93) 0.51 (0.34, 0.76) 
P for trend    0.06 0.003 
Hypertension b     
Never 1381 455 1 1 
Short-term 1787 569 0.90 (0.77, 1.06) 0.89 (0.74, 1.08) 
Intermediate-term 1143 334 0.80 (0.66, 0.97) 0.70 (0.55, 0.90) 
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Long-term 1309 416 0.81 (0.68, 0.98) 0.79 (0.64, 0.99) 
P for trend    0.01 0.04 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Q, quintile. 
a Values were cumulative averages among five visits, weighted by time interval between the visits.   
b Disease status was classified as were never, short-term (since 2011 - 13), moderate (since 1990 - 92), and long-term. 
(since 1987 - 89 and earlier).  
c Events were defined as being in the highest quartile of infrarenal aortic diameters distribution (≥ 2.2 cm). 
d Adjusted for age, sex, race, and field center.  
e Adjusted for age at V5, sex, race, field center, body mass index, waist circumference, total cholesterol, HDL cholesterol, 
lipid-lowering medication use, pack-years of smoking, diabetes, and hypertension; models of LDL cholesterol did not 




Table 4.4 Adjusted odds ratios and confidence intervals for the associations between risk factors and greater 
infrarenal aortic diameter (≥ 2.2 cm) by sex. 
 
N at risk N events b Model 1 c   Model 2 d 
Male  
Height at V1, cm 
   
 Q1 (157, 171) 491 206 1 1 
Q2 (172, 175) 455 208 1.18 (0.86, 1.63) 1.15 (0.84, 1.58) 
Q3 (176, 178) 417 199 1.15 (0.83, 1.61) 1.08 (0.78, 1.50) 
Q4 (179, 182) 471 268 1.90 (1.39, 2.61) 1.64 (1.20, 2.24) 
Q5 (183, 199) 402 246 2.03 (1.47, 2.81) 1.84 (1.32, 2.55) 
P for trend  
  
<0.001 <0.001 
Waist circumference, cm a 
    Q1 (71.6, 93.3) 446 206 1 1 
Q2 (93.4, 98.3) 451 209 0.94 (0.68, 1.29) 0.97 (0.71, 1.34) 
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Q3 (98.4, 103.2) 449 214 0.98 (0.72, 1.33) 1.03 (0.75, 1.41) 
Q4 (103.3, 109.5) 443 241 1.48 (1.09, 2.00) 1.44 (1.04, 1.99) 
Q5 (109.6, 149.7) 447 256 1.52 (1.09, 2.10) 1.68 (1.18, 2.38) 




Height at V1, cm     
Q1 (144, 158) 798 101 1 1 
Q2 (159, 161) 585 108 1.53 (1.07, 2.18) 1.48 (1.04, 2.12) 
Q3 (162, 164) 672 124 1.47 (1.06, 2.03) 1.42 (1.02, 1.99) 
Q4 (165, 168) 724 163 2.03 (1.45, 2.82) 1.84 (1.32, 2.57) 
Q5 (169, 188) 538 127 2.08 (1.39, 3.10) 1.90 (1.31, 2.75) 
P for trend    <0.001 <0.001 
Waist circumference, cm a     
Q1 (63.4, 85.5) 666 119 1 1 
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Q2 (85.6, 92.8) 659 96 0.71 (0.49, 1.03) 0.72 (0.50, 1.04) 
Q3 (92.9, 99.8) 659 112 0.78 (0.55, 1.12) 0.79 (0.55, 1.14) 
Q4 (99.9, 108.6) 661 139 1.04 (0.73, 1.49) 1.14 (0.79, 1.64) 
Q5 (108.7, 149.3) 662 157 1.34 (0.93, 1.94) 1.37 (0.96, 1.96) 
P for trend    0.02 0.01 
Q: quintile.  
a Values were cumulative averages among five visits, weighted by time interval between the visits.   
b Events were defined as being in the highest quartile of infrarenal aortic diameters distribution (≥ 2.2 cm). 
c Adjusted for age, race, and field center.  
d Adjusted for age, race, field center, height, waist circumference, smoking pack years, total cholesterol, low-density 







Figure 4.1 Adjusted restricted cubic splines a for the association between greater infrarenal aortic diameter (IAD) 
and (A) height, (B) waist circumference, and (C) smoking pack-year.  a Adjusted for age, sex, race, and field center. 
The dotted lines indicate 95% confidence bands. Five knots were used, located at the 5th, 25th, 50th, 75th and 
95th percentiles of risk factors except for smoking pack-year (45th, 55th, 70th, 85th and 95th percentiles due to a 















Chapter 5. Manuscript 3: Diabetes and Risk of Abdominal Aortic Aneurysm: 
A Meta-Analysis of Epidemiologic Studies 
5.1 Introduction 
Studies of the relationship between diabetes and abdominal aortic 
aneurysm (AAA) have been inconsistent. A negative association between 
diabetes and AAA prevalence, initially observed in a few large screening studies, 
was considered counterintuitive in the context of diabetes being a risk factor for 
various cardiovascular diseases.37,180 Recent large case-control studies and 
prospective cohort studies have reported inconsistent associations between 
diabetes and AAA in various populations; most studies showed an inverse 
relationship,48,52,57-61 while others did not show an association.38,49,62-68 
Meta-analysis increases the power of inferences.181 Although two meta-
analyses have been conducted on the association between diabetes and AAA, 
they are subject to potential limitations.56,69 For example, the one published in 
2004 included only cross-sectional studies and thus may be subject to reverse 
causality;56 the other study, published in 2015, pooling six cohort studies and two 
case-control studies was unable to examine the association by subgroups, such 
as population-based vs. clinical-based groups.69 Several new studies on this 
topic have been published since the 2015 meta-analysis was conducted.52,60,61,66-
68 Thus, we conducted this systematic review and meta-analysis to rigorously 
quantify the association between diabetes (type 1 or 2) and the risk of AAA. We 




This meta-analysis pooled results from observational studies (case-control 
and prospective cohort studies) available through a literature search, following 
standard reporting guidelines set by the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA).182 
5.2.1 Data searches and study selection 
 Investigator LY and an experienced librarian (DR) independently 
searched the literature and selected studies based on the same search and 
eligibility criteria. Disagreements were resolved by consensus in discussion with 
a senior investigator (WT). We used the MEDLINE online database (from 1966), 
EMBASE, and Web of Science until February 2018 to identify studies that 
examined the association between diabetes and incidence of AAA. The following 
key words were used: aortic aneurysm, diabetes, diabetes mellitus, hemoglobin 
A1c, glycated hemoglobin, glucose, case-control, prospective, and cohort. The 
search was limited to studies in English. In addition, we conducted a manual 
search of the references from selected original research and review articles.   
To be eligible for inclusion in this meta-analysis, the study needed to be 
an original research publication with a case-control design (including incident 
based, nested case-control, and case-cohort) or a prospective cohort design and 
be conducted in adults to examine diabetes in relation to later risk of AAA. 
Studies were excluded if participants were < 18 years of age; neither type 1 nor 
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type 2 diabetes was included as the exposure variable; incident AAA risk was not 
reported by diabetes status; or the association estimates and measures of 
variance were not reported or could not be computed. When the results of a 
population were published more than once, only the most recent article or article 
including the most appropriate data (e.g., most complete adjustments for 
potential confounding) was included in the meta-analysis. LY reviewed all 
potentially relevant publications and made decisions on inclusion according to 
the aforementioned eligibility criteria. Another reviewer (WT) reviewed LY’s 
literature search results and resolved disagreement by consensus. 
5.2.2 Data extraction and quality assessment 
 Data was abstracted using a standardized data collection form. The 
following data were collected: article title, first and last author’s names, year and 
source of publication, study design (case-control, cohort), setting (clinical, 
population), follow-up time in cohort studies, AAA ascertainment (methods, 
number of AAA events), diabetes definition (self-report diagnosis or treatment for 
diabetes, clinical records, self-report plus clinically measured diabetes, others), 
diabetes type (type 1, type 2, unclear), diabetes prevalence at baseline, 
characteristics of the study population (age, sex, race, anthropometric and 
lifestyle risk factors, prior disease status (including hypertension, cardiovascular 
disease, etc), and sample size), covariates in the fully adjustment models, 
relative risk of AAA, and measures of variance for association estimates. We 
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abstracted association estimates from the model with the most complete 
adjustments for potential confounders in each study.  
5.2.3 Data synthesis and analysis 
In the meta-analysis, we extracted data on mean (SD) or median 
(Interquartile range) levels of basic descriptive characteristics when appropriate 
for each study. An odds ratio, hazard ratio, and relative risk were treated equally 
in meta-analysis.183 In the primary analysis, the pooled relative risk and its 95% 
confidence interval (CI) was calculated using DerSimonian and Laird random-
effects models.184 The DerSimonian and Laird random-effects model is the most 
widely used model in meta-analyses, as it provides conservative estimates and 
accounts for between-study heterogeneity.185 The presence of heterogeneity was 
assessed with the Cochran’s Q test and the extent of heterogeneity was 
quantified with the I-square index.186 The Cochran’s Q test is a statistical test to 
assess whether there is true heterogeneity among studies in a meta-analysis.181 
We interpreted an I-square value of < 50%, 50 - 75%, and ≥ 75% as low, 
moderate, and high heterogeneity, respectively.187 If low heterogeneity between 
studies existed, we still used random-effects models as our primary analysis. The 
reason is that inherent heterogeneity did almost always exist in population 
characteristics, AAA ascertainment, adjustment factors, and duration of follow-up 
among studies included in the meta-analysis.  
The potential for publication and reporting bias was assessed through the 
use of funnel plots, as the asymmetry of the funnel plot indicates possible 
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publication bias.188 To examine the asymmetry of the funnel plot, we conducted 
Begg’s rank correlation test and Egger’s regression test.188,189 Begg’s rank test 
examines the correlation between association estimate and its variance, and a 
significant correlation (P value for correlation < 0.1) indicates significant 
asymmetry at the 0.1 level.188 Egger’s weighted linear regression test examines 
the association between the mean association estimate and its variance, and a 
significant association (P value for association < 0.05) rejects the hypothesis that 
symmetry exists in the studies included in the meta-analysis at the 0.05 level.189  
Additionally, we conducted the following sensitivity analyses to test the 
robustness of the results: 1) excluding each study in turn; 2) removing studies 
with no clear exclusion of type-1 diabetes; 3) removing one cohort study with only 
1 year of follow-up for AAA occurrence (among cohort studies only); 4) removing 
studies that did not use clinical records for AAA ascertainment; 5) removing 
studies in which association estimates were not adjusted for age, sex, race and 
smoking as the minimal adjustment unless the population involved primarily one 
sex or one race group, which was defined as a study population with ≥80% of a 
single sex or race group; and 6) by excluding studies with poor and fair overall 
quality based on the Newcastle-Ottawa Scale (≤ 5 points), a standard approach 
of quality scoring for observational studies.190,191 
Finally, we conducted subgroup analyses in men and women, for a cohort 
design vs. case-control design, and for clinical settings vs. population settings to 
explore the possible relationship between diabetes and AAA in these pre-
164 
 
specified subgroups. All analyses were conducted in STATA version 12 (College 
Station, Texas). 
5.3 Results 
From a total of 504 potentially relevant references, we kept 323 records 
after exclusion of duplicates between databases. Among the 323 records, we 
eliminated 291 articles after reviewing titles and abstracts, and then excluded 16 
additional articles after reviewing full text articles. A total of 16 studies met all the 
eligibility criteria and were included in the meta-analysis (Figure 5.1). 
Table 5.1 presents a study description and population characteristics of 
the 16 included studies, of which 12 were prospective cohort studies and 4 were 
case-control studies. Most of the prospective cohort studies (11 / 12 = 91%) were 
population-based, whereas most of the case-control studies (3 / 4 = 75%) were 
hospital or clinical-based. Follow-up time ranged from 1 to 30 years (median 10 
years) across the 12 cohort studies. Diabetes was defined by clinical records in 
four studies, by self-reported diagnosis in ten studies, and by both self-report and 
clinical measurements in two studies. Measurement of AAAs also varied across 
studies, but most studies (12 / 16 = 75%) ascertained AAA by clinical records 
(hospitalization records, death certificates and/or Medicare records), three relied 
on imagining detecting AAA, and one study used both methods. Notably, of the 
12 studies that ascertained AAAs by clinical records, five did not provide details 
on International Classification of Diseases (ICD) codes, five used ICD-CM codes 
only, and two used both ICD-CM codes and procedure codes. In addition, one 
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defined an AAA as an ultrasound-scanned maximum infrarenal aortic diameter 
(IAD) ≥ 3 cm, the second one defined an AAA as any ultrasound-scanned 
definite focal widening, and another defined an AAA based on both ultrasound 
and computed tomography scans (both used maximum IAD ≥ 3 cm as the 
cutpoint). Finally, one study used clinical records based on ICD-CM codes and 
then validated the ICD codes by ultrasound scan with a maximum IAD ≥ 3 cm. 
Overall, the studies included data on 2,665,121 participants with 11,410 AAAs 
from 12 cohort studies and 1,065 AAAs from 4 case-control studies of 12,074 
participants.  
Table 5.2 shows baseline characteristics of study participants in the 
included studies. The mean age ranged from 43.9 to 71.4 years (median 60.1 
years). Seven studies were conducted in men and four were conducted in 
women only. All studies included predominantly white participants (overall 
approximately 88%) with the exception being one study where white participants 
constituted 40% of the population. One study was conducted in patients with 
clinical cardiovascular disease or people at high risk of cardiovascular disease. In 
that study, 81.8% participants had prevalent hypertension and 44.0% had 
prevalent diabetes at baseline.   
Figure 5.2 presents study-specific and the pooled relative risk of AAA in 
relation to diabetes by the random-effects model. Comparing those with diabetes 
to those without, the pooled relative risk (95% CI) for AAA from the 16 studies 
was 0.56 (0.50, 0.63). Heterogeneity in the relative risk estimates among studies 
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was low as I2 (18.7%), and the test of heterogeneity was not statistically 
significant (P = 0.24).  
There was no evidence of publication bias using either Begg’s rank 
correlation (P = 0.37) or Egger’s linear regression tests (P = 0.28). The funnel 
plot with pseudo 95% CI is presented in Figure 5.3.  
In sensitivity analyses, the exclusion of any one study from the analysis 
did not significantly alter the pooled relative risk (Figure 5.4). Also, the inverse 
association between diabetes and AAA became slightly stronger when only 
studies of type-2 diabetes were included [studies remaining in the meta-analysis: 
N = 2; 0.45 (0.36, 0.56)] (Figures 5.5 - 5.6).  Results were similar by excluding 
studies in which AAAs were not ascertained using clinical records [N = 10; 0.56 
(0.50, 0.64)], by removing one cohort study with 1-year follow-up [N = 11; 0.57 
(0.48, 0.68)], or by removing studies which reported unadjusted estimates or 
estimates without adjustment for age, sex, race, and smoking [N = 9; 0.55 (0.47, 
0.64)] (Figures 5.7 - 5.9). Overall study quality scores are presented in Tables 
5.3 and 5.4 for cohort studies and case-control studies, respectively. The inverse 
association between diabetes and AAA remained consistent [N = 12; 0.54 (0.47, 
0.61)] after removing studies with low or moderate overall study quality 
(Newcastle-Ottawa score ≤ 5) (Figure 5.10).  
Results of subgroup analyses by sex, study design, and setting are 
presented in Table 5.5. As in the primary analysis, an inverse association 
between diabetes and incident AAA was observed within each subgroup. The 
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pooled relative risk (95% CI) was 0.58 (0.51, 0.66) in cohort studies, 0.42 (0.29, 
0.60) in case-control studies, 0.53 (0.42, 0.66) in studies conducted in clinical 
settings, and 0.57 (0.48, 0.68) in studies conducted in population settings. Similar 
associations were seen in men [0.58 (0.46, 0.74)] and women [0.67 (0.32, 1.43)], 
although the pooled relative risk in women was not statistically significant (N of 
studies = 4) (Figures 5.11 - 5.14).  
5.4 Discussion 
This meta-analysis of case-control and prospective cohort studies 
suggested that diabetes is inversely related to the risk of incident AAA in both 
general and patient populations. We observed low between-study heterogeneity 
and no evidence of publication bias.  
Our findings contradict the 2004 meta-analysis of cross-sectional studies 
which did not find a significant association between diabetes and prevalent 
AAA.56 Since the 2004 meta-analysis only included cross-sectional studies, it 
was subject to potential limitations such as survival bias. A 2015 meta-analysis 
pooled data from case-control studies (114 AAAs and 195 non-AAAs) and 
prospective cohort studies (6,403 AAAs and 643,896 non-AAAs). That meta-
analysis reported a negative association between diabetes and AAA.69 However, 
the 2015 meta-analysis included only two case-control studies and six cohort 
studies, with three of the cohort studies not adjusting for potential confounding 
variables, including age, sex, race, and smoking. Moreover, the 2015 meta-
analysis had insufficient data to explore whether the diabetes-AAA relation 
168 
 
differed by other factors such as study design and setting. In contrast, our meta-
analysis included 4-times as many subjects than the 2015 meta-analysis was 
able to examine associations by subgroups. Our meta-analysis was also able to 
examine the association among studies that did minimal adjustment (eg, 
adjusting for age, sex, race, and smoking). Our study confirmed an inverse 
association between diabetes and AAA, which remained in subgroups of cohort 
vs. case-control studies, a population setting vs. clinical setting, and males vs. 
females.  
There are several possible mechanisms that might mediate the negative 
association between diabetes and AAA. First, hyperglycemia reduces proteolysis 
of matrix in the arterial wall. Hyperglycemia reduces concentrations of MMP-2 
and MMP-9, both of which degrade extracellular matrix and promote the 
development of AAAs through their proteolytic effects.175 Hyperglycemia is 
associated with lower aortic wall stress,103,104 which prevents AAA 
development.192 Hyperglycemia might also decelerate arterial matrix loss by 
increasing collagen synthesis.173,176,177 The advanced glycation products 
associated with diabetes have been shown to resist proteolysis, inhibit secretion 
of MMPs, and increase matrix proteins by increasing smooth muscle cell 
proliferation and inducing cross-linking of collagen lattices in the aortic 
media.178,179 Diabetes may also suppress elevated plasmin193 and increased cell 
division autoantigen 1, both of which are key factors of extracellular matrix 
degradation and initiation of fibrinolysis.194,195 All of the above mechanisms due 
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to hyperglycemia are consistent with population-based studies in which 
continuous levels of fasting glucose and hemoglobin A1c are inversely 
associated with AAA risk.196,197 It is unclear whether insulin resistance is related 
to AAA. In a cohort study, fasting insulin was not associated with AAA risk.45  
Our findings contradict the results from a Mendelian Randomization study 
conducted in Dutch descent.70 That Mendelian Randomization study did not 
show an association between AAA and the instrumental variable defined by the 
genotypes of 65 single-nucleotide polymorphisms associated with type-2 
diabetes, suggesting that type-2 diabetes was not associated with AAA.70 
However, Mendelian randomization study results should be interpreted with 
caution because of possible limitations related to the assumptions of Mendelian 
randomization analysis, such as potential pleiotropic effects, weak instruments, 
etc.75 Nevertheless, the following two aspects should also be concerned when 
interpreting our results. First, it is possible that the inverse relation between 
diabetes and AAA observed in our study is confounded. For example, the 
negative association of diabetes with AAA may be attributable to the use of some 
diabetic medications. Metformin has been suggested to improve aortic wall 
elasticity, and decrease mural macrophages, smooth muscle cell proliferation 
and neovessel density in the aortic wall.170,171 Rosiglitazone and pioglitazone 
may decrease expression of matrix metalloproteinases in the aortic wall.173,174 
Anti-inflammatory effects of thiazolidinediones have been reported in animal 
models.172 Nonetheless, existing observational studies are unable to disentangle 
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the effects of medication use on the diabetes-AAA relation. Therefore, more 
evidence is needed to establish or refute a causal, inverse relationship between 
diabetes and AAA.   
The present study has some limitations. First, information on some 
potential confounders was missing in the included studies. Since individual data 
were not available, we had to use association estimates after adjustment for local 
confounders at the study level and then pool them across studies. However, 
results were similar after removing studies that reported unadjusted or 
insufficiently adjusted association estimates. Nonetheless, residual confounding 
cannot be eliminated, as in other observational studies. An individual-level meta-
analysis using complete data would be more desirable. Second, we were not 
able to examine the type of diabetes in relation to AAA risk due to lack of detailed 
information in many of the included studies. Although only two studies had a 
clear statement that they included type-2 diabetes only, type-2 diabetes was 
likely analyzed in most studies because the vast majority of diabetes cases in 
adult population are type-2.198 Nonetheless, a sensitivity analysis among the two 
studies including type-2 diabetes explicitly showed consistent results. On the 
other hand, there are several strengths in the present study. We conducted this 
meta-analysis following a stringent protocol.182 This meta-analysis has a large 
sample size and a number of high-quality studies,191 which provided sufficient 
power to detect statistically significant association estimates, assess publication 
bias, and conduct subgroup analysis.   
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In conclusion, this meta-analysis of case-control and prospective cohort 
studies suggests that diabetes is strongly and inversely associated with the risk 
of AAA. The findings are contrary to the fact that diabetes is a risk factor for most 
other cardiovascular diseases. Since the underlying pathophysiological pathways 
are intricate and uncertain, future studies are warranted to further investigate the 





5.5 Tables  
Table 5.1 Characteristics of included studies 




N case DM definition AAA 
ascertainment 
AAA definition Covariates 
Baumgartner 2008 clinical cohort 1 68236 1752 DM treatment record clinical records Not provided age, sex, race, smoking, 
HTN, and dyslipidemia 
Blanchard 2000 clinical case-
control 
N/A 200 98 FG ≥7 mmol/L or self-
reported DM 
diagnosis or DM 
treatment 
ultrasound scan Any definite focal 
widening classified 
as AAA, 92% ≥3 cm 
age, sex, smoking, and 
family history 
Franks 1996 clinical case-
control 
N/A 288 44 self-reported DM 
diagnosis 
clinical records Not provided age and sex matched 
Iribarren 2007 population cohort 13 104813 605 self-reported DM 
diagnosis 
clinical records ICD-9:441.3, 441.4 age, sex, race, 
education, height, 
weight, smoking, 
alcohol, white blood cell 
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counts, chronic kidney 
disease, HTN, CVD, 
and hormone use. 
Jahangir 2015 population cohort 4.9 18782 281 self-reported DM 
diagnosis 
clinical records ICD-9:441.3, 441.4 sex, race, education, 
BMI, smoking, CVD, 
and HTN 
Lederle 2008 population cohort 7.8 161808 184 self-reported DM 
diagnosis 
clinical records Not provided age, sex, race, height, 
weight, smoking, 
alcohol, CVD, HTN, 
COPD, hormone use, 
and lipid meds 
Ohrlander 2012 population cohort 13 246957 3335 DM treatment record clinical records ICD-10: I71.3, I71.4 age, income, HTN, CVD 
and COPD 
Robin 2003 population cohort 30 19274 418 self-reported DM 
diagnosis 
clinical records ICD-9: 441.3, 441.4 
ICD-10: 71.3, 71. 
N/A 
Shah 2015 population cohort 5.5 1921260 3051 DM treatment record clinical records Not provided age, sex, deprivation, 
BMI, smoking, lipids and 
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lipid meds, BP and BP 
meds 
Smelser 2014 clinical case-
control 
N/A 11411 888 type-2 diabetes 






ICD-9: 441.3, 441.4 
Max IAD ≥3 cm 
age and sex matched 
Tang 2016 population Cohort 22.5 15703 588 FG ≥7 mmol/L or Non-




clinical records ICD-9: 441.3, 441.4 
ICD-10: 71.3, 71.4 
Procedure code 
38.44, 39.71 
age, sex, race, height, 
smoking, alcohol, lipids, 
HTN and PAD 
Tornwall 2001 population cohort 5.8 29133 181 self-reported DM 
diagnosis 





age, education, BMI, 
smoking, physical 
activity, BP, lipids, and 
trial group 
Wanhainen 2005 population case- N/A 175 35 self-reported DM ultrasound and Mean max IAD by N/A 
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control diagnosis computed 
tomography 
scan 
the two methods ≥3 
cm 
Wong 2007 population cohort 4 39352 376 self-reported DM 
diagnosis 
clinical records Not provided age, smoking, BMI, 
physical activity, HTN 
and dyslipidemia, 





Max IAD ≥3 cm education, smoking, 
BMI, WC, diet, physical 
activity, alcohol intake, 
HTN, CVD, and 
dyslipidemias 





ICD-9: 441.3, 441.4 age, race, trial 
assignment, BMI, 
smoking status, alcohol 
use, physical activity, 




AAA, abdominal aortic aneurysm; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; COPD, 
chronic obstructive pulmonary disease; DM, diabetes; FG, fasting glucose; IAD, infrarenal aortic diameter; HTN, 
hypertension; NDI, National Death Index; PAD, peripheral artery disease 
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Table 5.2 Baseline characteristics of study populations 
Author Mean age (SD), 
year 




HTN Diabetes Comorbidities 
Baumgartner 68.6 (10.1) 63.0% 67.2% N/A 14.8% 81.8% 44.0% With established CVD, 
or with ≥3 
atherothrombotic risk 
factors 
Blanchard 69.0 51.0% 100.0% N/A 26.9% 38.4% 14.5% Not indicated 
Franks 70.4 (10.5) 83.0% 100.0% 172 100.0% 20.7% 6.3% Not indicated 
Iribarren 43.9 (14.1) 44.8% 82.0% 167 37.3% 36.5% 3.2% Not indicated 
Jahangir 64.4 (5.6) 63.9% 40.0% 168 21.2% 71.3% 30.0% Not indicated 
Lederle 63.2 (7.2) 0.0% 82.5% 162 6.9% 38.9% 5.9% Not indicated 
Ohrlander 71.4 43.4% 100% N/A N/A N/A 2.4% Not indicated 
Robin 50.5 (6.6) 54.9% 94.9% 169 38.0% 59.1% 3.4% Not indicated 
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Shah 46.9 (14) 49.4% 90.0% N/A 20.5% N/A 1.8% b Not indicated 
Smelser N/A 42.2% 100.0% N/A N/A N/A N/A b Not indicated 
Tang 54.2 (5.8) 44.8% 72.9% 169 26.1% 35.0% 11.9% Not indicated 
Tornwall 57 (53-61) a 100.0% 100.0% N/A 100.0% N/A 4.0% a Not indicated 
Wanhainen N/A 83.0% 100.0% N/A 12.0% 43.2% 11.4% Not indicated 
Wong 53.3 100.0% N/A N/A 9.6% 19.3% 2.0% Not indicated 
Stackelberg 55.3 (4.2) 100% 100% N/A 22.3% 17.9% 4.6% Not indicated 
Wang 65.5 (8.3) 100% 90.50% N/A 3.8% 45.9% 7.6% Not indicated 
CVD, cardiovascular disease; HTN, hypertension 
a Median value (Interquartile range). 





Table 5.3 Newcastle-Ottawa Scale assessments for cohort studies (a study can be awarded a point for each of the 
nine items) 





























Tornwall (2001) 0 1 0 0 1 1 1 1 1 6 
Robin (2003) 0 1 0 0 0 1 1 1 1 5 
Iribarren (2007) 1 1 0 0 1 1 1 1 1 7 
Wong (2007) 1 1 0 0 0 1 1 1 1 6 
Baumgartner (2008) 0 1 1 1 1 1 1 0 1 7 
Lederle (2008) 1 1 0 0 1 1 1 1 1 7 
Ohrlander (2012) 0 1 1 1 0 1 1 1 1 7 
Jahangir (2015) 0 1 0 0 0 1 1 1 1 5 
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Shah (2015) 1 1 1 0 1 1 1 1 1 8 
Tang (2016) 1 1 1 0 1 1 1 1 0 7 
Stackelberg (2017) 0 1 0 0 0 1 1 1 1 5 
Wang (2017) 1 1 0 0 1 1 1 1 1 7 
a Within the Selection category. External validity: the exposed cohort is truly or somewhat representative of the average 
demographics in the community (1 point); Selection of the non-exposed cohort: drawn from the same community as the 
exposed cohort (1 point); Ascertainment of exposure to implants: secure record (eg surgical records) or structured 
interview (1 point); No outcome present at baseline: demonstration that outcome of interest was not present at start of 
study: yes (1 point);  
b Within the Comparability category. Comparability of cohorts on the basis of the design or analysis: study controls for the 
most important factor (1 point); study controls for any additional factor (1 point; this criteria could be modified to indicate 
specific control for a second important factor);  
c Within the Outcome category. Outcome assessment: independent blind assessment or record linkage (1 point); Follow 
up long enough: was follow-up long enough for outcomes to occur: yes (1 point; select an adequate follow up period for 
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outcome of interest); Adequacy of follow up: complete follow up, or small number lost to follow up, or description provided 






Table 5.4 Newcastle-Ottawa Scale assessments for case-control studies (a study can be awarded a point for each 
of the nine items) 





















Same method of 
ascertainment 





Franks (1996) 1 0 1 0 1 0 0 1 0 4 
Blanchard (2000) 0 1 1 1 1 0 1 1 1 7 
Wanhainen (2005) 0 1 1 1 0 0 0 1 1 6 
Smelser (2014) 1 1 1 1 0 0 1 1 1 7 
a Within the Selection category. Adequate case definition: is the case definition adequate: Yes with independent validation 
(1 point); Case representativeness: consecutive or obviously representative series of cases (1 point); Control selection: 
community controls (1 point); Control definition: no history of endpoint (1 point);  
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b Within the Comparability category. Comparability of cases and controls on the basis of the design or analysis: study 
controls for the most important factor (1 point); Study controls for any additional factor (1 point; this criteria could be 
modified to indicate specific control for a second important factor);  
c Within the Exposure category. Exposure ascertainment: secure record (e.g. surgical records) or structured interview 
where blind to case/control status (1 point); Same method of ascertainment for cases and controls: yes (1 point); Non-





Table 5.5 Subgroup analyses by sex, design, and setting  
 
No. study Fixed-effects model Random-effects model  
Overall  16 0.57 (0.53, 0.62) 0.56 (0.50, 0.63) 
By sex    
Men  7 0.60 (0.49, 0.73) 0.58 (0.46, 0.74) 
Women  4 0.68 (0.48, 0.97) 0.67 (0.32, 1.43) 
By design    
Cohort 12 0.58 (0.53, 0.64) 0.58 (0.51, 0.66) 
Case control 4 0.42 (0.29, 0.60) 0.42 (0.29, 0.60) 
By setting    
Clinical setting 4 0.57 (0.51, 0.64) 0.53 (0.42, 0.66) 









Figure 5.2. Pooled relative risk (95% confidence interval, CI) of abdominal 





Figure 5.3 Funnel plot with pseudo 95% confidence limits to test potential 





Figure 5.4 Sensitivity analysis using random-effects model by excluding 




Figure 5.5 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a random-effects model by 






Figure 5.6 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a random-effects model by 






Figure 5.7 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm (AAA) in relation to diabetes (yes, no) using a random-effects 
model by removing studies where AAA was not ascertained using clinical 
records (n studies = 14) 
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Figure 5.8 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm (AAA) in relation to diabetes (yes, no) using a random-effects 





Figure 5.9 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a random-effects model by 
removing studies with inadequate adjustment (age, sex, race, and smoking; 






Figure 5.10 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a random-effects model by 
removing studies with low and moderate overall study quality (Newcastle-





Figure 5.11 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) (n = 16 studies) using a 





Figure 5.12 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) (n = 16 studies) using a 





Figure 5.13 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) using a random-effects 




Figure 5.14 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) using a random-effects 





Figure 5.15 Pooled relative risk (95% confidence interval) of abdominal 






Figure 5.16 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a fixed-effects model by 




Figure 5.17 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a fixed-effects model by 






Figure 5.18 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a fixed-effects model by 






Figure 5.19 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm (AAA) in relation to diabetes (yes, no) using a fixed-effects 
model by removing studies where AAA was not ascertained using clinical 





Figure 5.20 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm (AAA) in relation to diabetes (yes, no) using a fixed-effects 





Figure 5.21 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a fixed-effects model by 
removing studies with inadequate adjustment (age, sex, race, and smoking; 





Figure 5.22 Relative risk (95% confidence interval) of abdominal aortic 
aneurysm in relation to diabetes (yes, no) using a fixed-effects model by 
removing studies with low and moderate overall study quality (Newcastle-




Figure 5.23 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) (n = 16 studies) using a 





Figure 5.24 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) (n = 16 studies) using a 





Figure 5.25 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) using a fixed-effects model 





Figure 5.26 Pooled relative risk (95% confidence interval) of abdominal 
aortic aneurysm in relation to diabetes (yes, no) using a fixed-effects model 





Chapter 6. Summary   
AAA is an important public health problem. The etiology of AAAs is not 
fully understood. Several risk factors for AAA, except for being free of diabetes, 
are well-known risk factors for atherosclerosis and atherosclerotic cardiovascular 
disease, but the relation between AAA and atherosclerosis is unclear. Previous 
findings also warrant us to further investigate the possible relation between 
diabetes and AAA.  
In addition, an AAA is usually defined as an IAD ≥ 3 cm, but this is not a 
uniform definition, and an increased IAD from 2.3 to 3.0 cm has also been related 
to higher risk of being an AAA as well as other cardiovascular events. Thus, 
examining the determinants of IAD even among individuals whose IAD is smaller 
than 3 cm is potentially important to the prevention of AAAs. However, data on 
risk factors for an elevated IAD (≥ 2.2 cm) is limited. 
The overall objectives of this dissertation were to fill a gap of literature and 
further assess AAA etiology by completing the following specific aims 1) examine 
the association of carotid atherosclerosis and stiffness with AAA occurrence, 2) 
explore the risk factors for elevated IAD among persons without an AAA, and 3) 
perform a systematic review and meta-analysis to quantify the association 
between diabetes mellitus and AAA. The ultimate goal is to improve the 
prevention, particularly early prevention, of AAAs at the population level. Findings 
from my dissertation studies may have potential to clinically identify high risk 
individuals. The summary of each manuscript is below. 
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6.1 Manuscript 1 Summary 
Individuals with generalized atherosclerosis and arterial stiffness often 
have increased abdominal aortic diameters, but prospective evidence linking 
them to the risk of AAA is limited. In Manuscript 1, we prospectively examined 
the relationship of carotid atherosclerosis and stiffness with future risk of AAA in 
ARIC. At Visits 1 (1987-89) or 2 (1990-92), we assessed carotid atherosclerosis 
(represented by greater cIMT or presence of atherosclerotic plaque) and lower 
carotid distensibility (reflected by a higher carotid Beta Index). We identified 
incident, clinical AAAs during follow-up through 2011 using hospital discharge 
codes, Medicare outpatient diagnoses, or death certificates. Participants' mean 
age at baseline was 54.2 years (SD 5.8), 45% were male and 73% white. During 
a median of 22.5 years of follow-up, 542 clinical AAAs were ascertained. After 
multivariable adjustment, the presence of carotid atherosclerotic plaque at 
baseline was associated with 1.31 (95% CI: 1.10 - 1.57; P = 0.003) times higher 
risk of clinical AAA. Greater cIMT and Beta Index were also associated with 
clinical AAA with a dose-response across quartiles (P trend for both: 0.006; 
hazard ratios [95% CI] for the highest vs. lowest quartiles: 1.55 [1.13 - 2.11] and 
1.68 [1.16 - 2.43], respectively). The associations of cIMT and Beta Index with 
AAA were independent of each other. Despite limitations summarized in Chapter 
3.4, this prospective population-based study found that indices of greater carotid 
atherosclerosis and lower carotid distensibility are markers of increased AAA risk. 
In addition to a contribution to understanding AAA etiology, this study also has 
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clinical implications. For example, our study indicates that persons who have 
carotid atherosclerosis or who have ‘stiff’ carotid arteries may be high-risk for 
AAAs. 
6.2 Manuscript 2 Summary 
Although most of studies defined an AAA as an IAD ≥ 3 cm, an increased 
IAD over 2.3 - 3.0 cm has been associated with higher risk of AAA as well as 
other cardiovascular events. Data regarding the correlates of elevated IAD in the 
absence of AAA are sparse. In Manuscript 2, we examined the relationship 
between AAA risk factors and elevated IAD among ARIC participants who 
attended an abdominal ultrasound screening in 2011 - 13, after excluding those 
with prior AAAs by clinical records or the ultrasound exam. Weighted general 
estimating equation models were used to examine the relationships between the 
cumulative risk factors (across 1987 - 2013) and the odds of elevated IAD, 
defined as being in the highest quartile of the IAD distribution (2.2 cm ≤ IAD < 3.0 
cm). Of 5,620 participants included in the analysis, 40.4% were men and 77.8% 
were whites. In the model with adjustment for AAA risk factors, men (vs. women) 
had 2.50 (95% CI: 1.90, 3.28) times higher odds, and participants with long-term 
diabetes (vs. non-diabetics) had 0.52 (95% CI: 0.35, 0.77) times lower odds of 
having an elevated IAD. Height, waist circumference and smoking pack-years 
were positively associated with elevated IADs [ORs (95% CI) for the highest vs. 
lowest quintiles of each risk factor: 1.93 (1.36, 2.75), 1.67 (1.28, 2.19) and 1.62 
(1.26, 2.08), respectively). Other factors were not associated with elevated IAD. 
214 
 
In summary, male sex, smoking, greater height, larger waist circumference and 
diabetes were associated with elevated IAD among persons without an AAA. 
Despite limitations described in the limitation section of Chapter 4.4, the findings 
highlight the potential for primary prevention of AAA through control of these 
factors. 
6.3 Manuscript 3 Summary 
Literature regarding the relationship between diabetes and AAA are 
inconsistent across studies: some studies showed an inverse relationship while 
others did not show an association. We conducted a meta-analysis to examine 
the association between diabetes and AAA based on published data from case-
control and prospective cohort studies. We searched literature in English from 
online databases, including MEDLINE (1966 - ), EMBASE, and Web of Science 
as of Febuary 2018. In addition, we did a manual examination of references in 
selected articles. The eligibility criteria included: (1) a case-control or prospective 
cohort study conducted in adults; (2) diabetes was the exposure variable and 
AAA was the outcome variable; and (3) association estimates (hazard ratios, 
odds ratios, or relative risks) and measurement of variance (P value, confidence 
interval, or standard error) were available. A DerSimonian and Laird random 
effects model was used to pool association estimates and their 95% confidence 
intervals from studies. We included a total of 12 cohort studies with 11,410 AAAs 
in 2,665,121 participants and 4 case-control studies with 1,065 AAAs and 12,074 
controls that met the pre-determined eligibility criteria in the meta-analyses. The 
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study populations were predominantly white (88%). Diabetes was inversely 
associated with the risk of AAA (pooled relative risk: 0.56; 95% confidence 
interval: 0.50 - 0.63). Results were similar in the subgroup analyses by sex 
(male/female), setting (population/clinical), and study design (cohort/case-
control). In summary, in contrast with diabetes being a risk factor for most 
cardiovascular diseases, diabetes appears to be strongly and inversely 
associated with the risk of AAA.  Future studies are warranted to investigate the 
potential mechanisms. 
6.4 Overall Conclusions 
This dissertation reports the relation between carotid atherosclerosis/ 
stiffness and diabetes with AAA occurrence, and the association between AAA 
risk factors and elevated IAD among persons without AAA. Future studies are 
needed to investigate the potential mechanisms mediating these associations. It 
is noteworthy that the dissertation research may be insufficient to establish 
causal relationship because these are all observational studies or a meta-
analysis of observational studies. Nonetheless, we believe this information 
contributed to understanding of AAA etiology, and may be useful in formulating 







1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, 
Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley 
JC, Taylor LM,Jr, White CJ, White J, White RA, Antman EM, Smith SC,Jr, Adams 
CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, 
Nishimura R, Ornato JP, Page RL, Riegel B, American Association for Vascular 
Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography 
and Interventions, Society for Vascular Medicine and Biology, Society of 
Interventional Radiology, ACC/AHA Task Force on Practice Guidelines Writing 
Committee to Develop Guidelines for the Management of Patients With 
Peripheral Arterial Disease, American Association of Cardiovascular and 
Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for 
Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease 
Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients 
with peripheral arterial disease (lower extremity, renal, mesenteric, and 
abdominal aortic): a collaborative report from the American Association for 
Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular 
Angiography and Interventions, Society for Vascular Medicine and Biology, 
Society of Interventional Radiology, and the ACC/AHA Task Force on Practice 
Guidelines (Writing Committee to Develop Guidelines for the Management of 
Patients With Peripheral Arterial Disease): endorsed by the American 
Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, 
217 
 
Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-
Society Consensus; and Vascular Disease Foundation. Circulation. 2006; 113: 
e463-654.  
2. Arrington S, Ogata T, Davis PM,Jr, Sam AD,2nd, Hollier LH, Tromp G, 
Kuivaniemi H. Aneurysm Outreach Inc., a nonprofit organization, offers 
community-based, ultrasonography screening for abdominal aortic aneurysms. 
Ann N Y Acad Sci. 2006; 1085: 291-293.  
3. Badger SA, O'Donnell ME, Sharif MA, Boyd CS, Hannon RJ, Lau LL, Lee B, 
Soong CV. Risk factors for abdominal aortic aneurysm and the influence of social 
deprivation. Angiology. 2008; 59: 559-566.  
4. Badger SA, O'Donnell ME, Sharif MA, Boyd CS, Soong CV. Advantages and 
pitfalls of abdominal aortic aneurysm screening in high-risk patients. Vascular. 
2008; 16: 201-206.  
5. Bailey MA, Dunne JA, Griffin KJ, Coughlin PA, Scott DJ. Systematic review 
and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms 
(Br J Surg 2011; 98: 362-353). Br J Surg. 2011; 98: 744-5.  
6. Ballard DJ, Filardo G, Fowkes G, Powell JT. Surgery for small asymptomatic 
abdominal aortic aneurysms. Cochrane Database Syst Rev. 2008; 
(4):CD001835. doi: CD001835.  
218 
 
7. Bartoli MA, Thevenin B, Sarlon G, Giorgi R, Albertini JN, Lerussi G, 
Branchereau A, Magnan PE. Secondary procedures after infrarenal abdominal 
aortic aneurysms endovascular repair with second-generation endografts. Ann 
Vasc Surg. 2012; 26: 166-174.  
8. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW,Jr, Kent KC, 
Upchurch GR,Jr, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson 
RW. Prolonged administration of doxycycline in patients with small asymptomatic 
abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. 
J Vasc Surg. 2002; 36: 1-12.  
9. Bengtsson H, Bergqvist D, Ekberg O, Janzon L. A population based screening 
of abdominal aortic aneurysms (AAA). Eur J Vasc Surg. 1991; 5: 53-57.  
10. Bergqvist D. Pharmacological interventions to attenuate the expansion of 
abdominal aortic aneurysm (AAA) - a systematic review. Eur J Vasc Endovasc 
Surg. 2011; 41: 663-667.  
11. Li X, Zhao G, Zhang J, Duan Z, Xin S. Prevalence and trends of the 
abdominal aortic aneurysms epidemic in general population--a meta-analysis. 
PLoS One. 2013; 8: e81260.  
12. Sampson UK, Norman PE, Fowkes FG, Aboyans V, Song Y, Harrell FE,Jr, 
Forouzanfar MH, Naghavi M, Denenberg JO, McDermott MM, Criqui MH, 
Mensah GA, Ezzati M, Murray C. Estimation of global and regional incidence and 
219 
 
prevalence of abdominal aortic aneurysms 1990 to 2010. Glob Heart. 2014; 9: 
159-170.  
13. VascularWeb®. Abdominal Aortic Aneurysm. Chicago: Society for Vascular 
Surgery; 2011. Available at: 
http://www.vascularweb.org/vascularhealth/Pages/abdominal-aortic-
aneurysm.aspx?PF=1. Accessed Nov/11, 2015.  
14. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, 
Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, 
Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland 
DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, 
McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, 
Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner 
MB, American Heart Association Statistics Committee and Stroke Statistics 
Subcommittee. Heart disease and stroke statistics--2013 update: a report from 
the American Heart Association. Circulation. 2013; 127: e6-e245.  
15. LeFevre ML, U.S. Preventive Services Task Force. Screening for abdominal 
aortic aneurysm: U.S. Preventive Services Task Force recommendation 
statement. Ann Intern Med. 2014; 161: 281-290.  
16. Guirguis-Blake JM, Beil TL, Senger CA, Whitlock EP. Ultrasonography 
screening for abdominal aortic aneurysms: a systematic evidence review for the 
U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160: 321-329.  
220 
 
17. Reimerink JJ, van der Laan MJ, Koelemay MJ, Balm R, Legemate DA. 
Systematic review and meta-analysis of population-based mortality from ruptured 
abdominal aortic aneurysm. Br J Surg. 2013; 100: 1405-1413.  
18. Lederle FA. The rise and fall of abdominal aortic aneurysm. Circulation. 2011; 
124: 1097-1099.  
19. Sidloff D, Stather P, Dattani N, Bown M, Thompson J, Sayers R, Choke E. 
Aneurysm global epidemiology study: public health measures can further reduce 
abdominal aortic aneurysm mortality. Circulation. 2014; 129: 747-753.  
20. Hirose Y, Hamada S, Takamiya M, Imakita S, Naito H, Nishimura T. Aortic 
aneurysms: growth rates measured with CT. Radiology. 1992; 185: 249-252.  
21. Sweeting MJ, Thompson SG, Brown LC, Powell JT, RESCAN collaborators. 
Meta-analysis of individual patient data to examine factors affecting growth and 
rupture of small abdominal aortic aneurysms. Br J Surg. 2012; 99: 655-665.  
22. Delin A, Ohlsen H, Swedenborg J. Growth rate of abdominal aortic 
aneurysms as measured by computed tomography. Br J Surg. 1985; 72: 530-
532.  
23. RESCAN Collaborators, Bown MJ, Sweeting MJ, Brown LC, Powell JT, 
Thompson SG. Surveillance intervals for small abdominal aortic aneurysms: a 
meta-analysis. JAMA. 2013; 309: 806-813.  
221 
 
24. Best VA, Price JF, Fowkes FG. Persistent increase in the incidence of 
abdominal aortic aneurysm in Scotland, 1981-2000. Br J Surg. 2003; 90: 1510-
1515.  
25. Melton LJ,3rd, Bickerstaff LK, Hollier LH, Van Peenen HJ, Lie JT, Pairolero 
PC, Cherry KJ, O'Fallon WM. Changing incidence of abdominal aortic 
aneurysms: a population-based study. Am J Epidemiol. 1984; 120: 379-386.  
26. Fowkes FG, Macintyre CC, Ruckley CV. Increasing incidence of aortic 
aneurysms in England and Wales. BMJ. 1989; 298: 33-35.  
27. Smith SC,Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy 
SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, 
Pfeffer MA, Taubert KA, AHA/ACC, National Heart, Lung, and Blood Institute. 
AHA/ACC guidelines for secondary prevention for patients with coronary and 
other atherosclerotic vascular disease: 2006 update: endorsed by the National 
Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372.  
28. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard GA, 
Timaran CH, Upchurch GR,Jr, Veith FJ. SVS practice guidelines for the care of 
patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg. 
2009; 50: 880-896.  
29. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson 
SG, Walker NM, Multicentre Aneurysm Screening Study Group. The Multicentre 
222 
 
Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm 
screening on mortality in men: a randomised controlled trial. Lancet. 2002; 360: 
1531-1539.  
30. Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the 
incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized 
controlled study. Br J Surg. 1995; 82: 1066-1070.  
31. Smith FC, Grimshaw GM, Paterson IS, Shearman CP, Hamer JD. 
Ultrasonographic screening for abdominal aortic aneurysm in an urban 
community. Br J Surg. 1993; 80: 1406-1409.  
32. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy 
RJ, Parsons RW, Dickinson JA. Population based randomised controlled trial on 
impact of screening on mortality from abdominal aortic aneurysm. BMJ. 2004; 
329: 1259.  
33. Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal 
aortic aneurysms: single centre randomised controlled trial. BMJ. 2005; 330: 750.  
34. Boll AP, Verbeek AL, van de Lisdonk EH, van der Vliet JA. High prevalence 
of abdominal aortic aneurysm in a primary care screening programme. Br J Surg. 
1998; 85: 1090-1094.  
35. McGregor JC, Pollock JG, Anton HC. The value of ultrasonography in the 
diagnosis of abdominal aortic aneurysm. Scott Med J. 1975; 20: 133-137.  
223 
 
36. Freiberg MS, Arnold AM, Newman AB, Edwards MS, Kraemer KL, Kuller LH. 
Abdominal aortic aneurysms, increasing infrarenal aortic diameter, and risk of 
total mortality and incident cardiovascular disease events: 10-year follow-up data 
from the Cardiovascular Health Study. Circulation. 2008; 117: 1010-1017.  
37. Lederle FA, Johnson GR, Wilson SE, Chute EP, Littooy FN, Bandyk D, 
Krupski WC, Barone GW, Acher CW, Ballard DJ. Prevalence and associations of 
abdominal aortic aneurysm detected through screening. Aneurysm Detection and 
Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern 
Med. 1997; 126: 441-449.  
38. Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegard J, Bjorck M. Risk 
factors associated with abdominal aortic aneurysm: a population-based study 
with historical and current data. J Vasc Surg. 2005; 41: 390-396.  
39. Wanhainen A. How to define an abdominal aortic aneurysm--influence on 
epidemiology and clinical practice. Scand J Surg. 2008; 97: 105-9.  
40. Wanhainen A, Svensjo S, Mani K. Screening for abdominal aortic aneurysm--
areas where information is still inadequate. Scand J Surg. 2008; 97: 131-135.  
41. Choksy SA, Wilmink AB, Quick CR. Ruptured abdominal aortic aneurysm in 




42. Hall AJ, Busse EF, McCarville DJ, Burgess JJ. Aortic wall tension as a 
predictive factor for abdominal aortic aneurysm rupture: improving the selection 
of patients for abdominal aortic aneurysm repair. Ann Vasc Surg. 2000; 14: 152-
157.  
43. Johnston KW, Rutherford RB, Tilson MD, Shah DM, Hollier L, Stanley JC. 
Suggested standards for reporting on arterial aneurysms. Subcommittee on 
Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting 
Standards, Society for Vascular Surgery and North American Chapter, 
International Society for Cardiovascular Surgery. J Vasc Surg. 1991; 13: 452-
458.  
44. Forsdahl SH, Solberg S, Singh K, Jacobsen BK. Abdominal aortic 
aneurysms, or a relatively large diameter of non-aneurysmal aortas, increase 
total and cardiovascular mortality: the Tromso study. Int J Epidemiol. 2010; 39: 
225-232.  
45. Solberg S, Forsdahl SH, Singh K, Jacobsen BK. Diameter of the infrarenal 
aorta as a risk factor for abdominal aortic aneurysm: the Tromso Study, 1994-
2001. Eur J Vasc Endovasc Surg. 2010; 39: 280-284.  
46. Norman P, Le M, Pearce C, Jamrozik K. Infrarenal aortic diameter predicts 
all-cause mortality. Arterioscler Thromb Vasc Biol. 2004; 24: 1278-1282.  
225 
 
47. Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal 
aortic aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. 
Circulation. 2009; 119: 2202-2208.  
48. Lederle FA, Larson JC, Margolis KL, Allison MA, Freiberg MS, Cochrane BB, 
Graettinger WF, Curb JD, Women's Health Initiative Cohort Study. Abdominal 
aortic aneurysm events in the women's health initiative: cohort study. BMJ. 2008; 
337: a1724.  
49. Iribarren C, Darbinian JA, Go AS, Fireman BH, Lee CD, Grey DP. Traditional 
and novel risk factors for clinically diagnosed abdominal aortic aneurysm: the 
Kaiser multiphasic health checkup cohort study. Ann Epidemiol. 2007; 17: 669-
678.  
50. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, 
Gelijns AC, Greco G. Analysis of risk factors for abdominal aortic aneurysm in a 
cohort of more than 3 million individuals. J Vasc Surg. 2010; 52: 539-548.  
51. Folsom AR, Yao L, Alonso A, Lutsey PL, Missov E, Lederle FA, Ballantyne 
CM, Tang W. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: 
The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015; 132: 
578-585.  
52. Tang W, Yao L, Roetker NS, Alonso A, Lutsey PL, Steenson CC, Lederle FA, 
Hunter DW, Bengtson LG, Guan W, Missov E, Folsom AR. Lifetime Risk and 
226 
 
Risk Factors for Abdominal Aortic Aneurysm in a 24-Year Prospective Study: The 
ARIC Study (Atherosclerosis Risk in Communities). Arterioscler Thromb Vasc 
Biol. 2016; 36: 2468-2477.  
53. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: 
cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010; 
30: 1075-1077.  
54. Greco G, Egorova NN, Gelijns AC, Moskowitz AJ, Manganaro AJ, Zwolak 
RM, Riles TS, Kent KC. Development of a novel scoring tool for the identification 
of large >/=5 cm abdominal aortic aneurysms. Ann Surg. 2010; 252: 675-682.  
55. Johnsen SH, Forsdahl SH, Solberg S, Singh K, Jacobsen BK. Carotid 
atherosclerosis and relation to growth of infrarenal aortic diameter and follow-up 
diameter: the Tromso Study. Eur J Vasc Endovasc Surg. 2013; 45: 135-140.  
56. Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for 
asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis 
of population-based screening studies. Eur J Public Health. 2004; 14: 343-349.  
57. Baumgartner I, Hirsch AT, Abola MT, Cacoub PP, Poldermans D, Steg PG, 
Creager MA, Bhatt DL, REACH Registry investigators. Cardiovascular risk profile 
and outcome of patients with abdominal aortic aneurysm in out-patients with 
atherothrombosis: data from the Reduction of Atherothrombosis for Continued 
Health (REACH) Registry. J Vasc Surg. 2008; 48: 808-814.  
227 
 
58. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic 
aneurysm: results of a case-control study. Am J Epidemiol. 2000; 151: 575-583.  
59. Ohrlander T, Merlo J, Ohlsson H, Sonesson B, Acosta S. Socioeconomic 
position, comorbidity, and mortality in aortic aneurysms: a 13-year prospective 
cohort study. Ann Vasc Surg. 2012; 26: 312-321.  
60. Smelser DT, Tromp G, Elmore JR, Kuivaniemi H, Franklin DP, Kirchner HL, 
Carey DJ. Population risk factor estimates for abdominal aortic aneurysm from 
electronic medical records: a case control study. BMC Cardiovasc Disord. 2014; 
14: 174-2261-14-174.  
61. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, 
Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and 
incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet 
Diabetes Endocrinol. 2015; 3: 105-113.  
62. Rodin MB, Daviglus ML, Wong GC, Liu K, Garside DB, Greenland P, Stamler 
J. Middle age cardiovascular risk factors and abdominal aortic aneurysm in older 
age. Hypertension. 2003; 42: 61-68.  
63. Tornwall ME, Virtamo J, Haukka JK, Albanes D, Huttunen JK. Life-style 
factors and risk for abdominal aortic aneurysm in a cohort of Finnish male 
smokers. Epidemiology. 2001; 12: 94-100.  
228 
 
64. Wong DR, Willett WC, Rimm EB. Smoking, hypertension, alcohol 
consumption, and risk of abdominal aortic aneurysm in men. Am J Epidemiol. 
2007; 165: 838-845.  
65. Franks PJ, Edwards RJ, Greenhalgh RM, Powell JT. Risk factors for 
abdominal aortic aneurysms in smokers. Eur J Vasc Endovasc Surg. 1996; 11: 
487-492.  
66. Wang L, Djousse L, Song Y, Akinkuolie AO, Matsumoto C, Manson JE, 
Gaziano JM, Sesso HD. Associations of Diabetes and Obesity with Risk of 
Abdominal Aortic Aneurysm in Men. J Obes. 2017; 2017: 3521649.  
67. Stackelberg O, Wolk A, Eliasson K, Hellberg A, Bersztel A, Larsson SC, 
Orsini N, Wanhainen A, Bjorck M. Lifestyle and Risk of Screening-Detected 
Abdominal Aortic Aneurysm in Men. J Am Heart Assoc. 2017; 6: 
10.1161/JAHA.116.004725.  
68. Jahangir E, Lipworth L, Edwards TL, Kabagambe EK, Mumma MT, Mensah 
GA, Fazio S, Blot WJ, Sampson UK. Smoking, sex, risk factors and abdominal 
aortic aneurysms: a prospective study of 18 782 persons aged above 65 years in 
the Southern Community Cohort Study. J Epidemiol Community Health. 2015; 
69: 481-488.  
69. Takagi H, Umemoto T. A contemporary meta-analysis of the association of 
diabetes with abdominal aortic aneurysm. Int Angiol. 2015; 34: 375-382.  
229 
 
70. van 't Hof FN, Vaucher J, Holmes MV, de Wilde A, Baas AF, Blankensteijn 
JD, Hofman A, Kiemeney LA, Rivadeneira F, Uitterlinden AG, Vermeulen SH, 
Rinkel GJ, de Bakker PI, Ruigrok YM. Genetic variants associated with type 2 
diabetes and adiposity and risk of intracranial and abdominal aortic aneurysms. 
Eur J Hum Genet. 2017; 25: 758-762.  
71. Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic 
upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation 
analysis. Lancet Diabetes Endocrinol. 2015; 3: 243-253.  
72. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-
Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes 
mellitus. N Engl J Med. 2007; 356: 1517-1526.  
73. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. 
Treatment with Anakinra improves disposition index but not insulin sensitivity in 
nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, 
placebo-controlled study. J Clin Endocrinol Metab. 2011; 96: 2119-2126.  
74. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, 
Greenbaum CJ, Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett 
DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Canakinumab 
Study Group, Pickersgill L, de Koning E, Ziegler AG, Boehm B, Badenhoop K, 
Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, 
Lervang HH, Perrild H, Mandrup-Poulsen T, AIDA Study Group. Interleukin-1 
230 
 
antagonism in type 1 diabetes of recent onset: two multicentre, randomised, 
double-blind, placebo-controlled trials. Lancet. 2013; 381: 1905-1915.  
75. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian 
randomization: using genes as instruments for making causal inferences in 
epidemiology. Stat Med. 2008; 27: 1133-1163.  
76. Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas AF, 
Gretarsdottir S, Badger SA, Bradley DT, Burnand K, Child AH, Clough RE, 
Cockerill G, Hafez H, Scott DJ, Futers S, Johnson A, Sohrabi S, Smith A, 
Thompson MM, van Bockxmeer FM, Waltham M, Matthiasson SE, Thorleifsson 
G, Thorsteinsdottir U, Blankensteijn JD, Teijink JA, Wijmenga C, de Graaf J, 
Kiemeney LA, Assimes TL, McPherson R, CARDIoGRAM Consortium, Global 
BPgen Consortium, DIAGRAM Consortium, VRCNZ Consortium, Folkersen L, 
Franco-Cereceda A, Palmen J, Smith AJ, Sylvius N, Wild JB, Refstrup M, Edkins 
S, Gwilliam R, Hunt SE, Potter S, Lindholt JS, Frikke-Schmidt R, Tybjaerg-
Hansen A, Hughes AE, Golledge J, Norman PE, van Rij A, Powell JT, Eriksson 
P, Stefansson K, Thompson JR, Humphries SE, Sayers RD, Deloukas P, Samani 
NJ. Abdominal aortic aneurysm is associated with a variant in low-density 
lipoprotein receptor-related protein 1. Am J Hum Genet. 2011; 89: 619-627.  
77. Glauser F, Mazzolai L, Darioli R, Depairon M. Interaction between widening 
of diameter of abdominal aorta and cardiovascular risk factors and 
atherosclerosis burden. Intern Emerg Med. 2014; 9: 411-417.  
231 
 
78. Allison MA, Kwan K, DiTomasso D, Wright CM, Criqui MH. The epidemiology 
of abdominal aortic diameter. J Vasc Surg. 2008; 48: 121-127.  
79. Sonesson B, Lanne T, Hansen F, Sandgren T. Infrarenal aortic diameter in 
the healthy person. Eur J Vasc Surg. 1994; 8: 89-95.  
80. Taimour S, Zarrouk M, Holst J, Rosengren AH, Groop L, Nilsson PM, 
Gottsater A. Aortic diameter at age 65 in men with newly diagnosed type 2 
diabetes. Scand Cardiovasc J. 2017; 51: 202-206.  
81. Rogers IS, Massaro JM, Truong QA, Mahabadi AA, Kriegel MF, Fox CS, 
Thanassoulis G, Isselbacher EM, Hoffmann U, O'Donnell CJ. Distribution, 
determinants, and normal reference values of thoracic and abdominal aortic 
diameters by computed tomography (from the Framingham Heart Study). Am J 
Cardiol. 2013; 111: 1510-1516.  
82. Lederle FA, Johnson GR, Wilson SE, Gordon IL, Chute EP, Littooy FN, 
Krupski WC, Bandyk D, Barone GW, Graham LM, Hye RJ, Reinke DB. 
Relationship of age, gender, race, and body size to infrarenal aortic diameter. 
The Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative 
Study Investigators. J Vasc Surg. 1997; 26: 595-601.  
83. Singh K, Bonaa KH, Jacobsen BK, Bjork L, Solberg S. Prevalence of and risk 
factors for abdominal aortic aneurysms in a population-based study : The Tromso 
Study. Am J Epidemiol. 2001; 154: 236-244.  
232 
 
84. Grimshaw GM, Thompson JM. Changes in diameter of the abdominal aorta 
with age: an epidemiological study. J Clin Ultrasound. 1997; 25: 7-13.  
85. Wilmink AB, Pleumeekers HJ, Hoes AW, Hubbard CS, Grobbee DE, Quick 
CR. The infrarenal aortic diameter in relation to age: only part of the population in 
older age groups shows an increase. Eur J Vasc Endovasc Surg. 1998; 16: 431-
437.  
86. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of 
abdominal aortic aneurysm presence and progression. Circulation. 2008; 118: 
2382-2392.  
87. Beveridge LA, Witham MD. Vitamin D and the cardiovascular system. 
Osteoporos Int. 2013; 24: 2167-2180.  
88. Norman PE, Powell JT. Vitamin D, shedding light on the development of 
disease in peripheral arteries. Arterioscler Thromb Vasc Biol. 2005; 25: 39-46.  
89. Kudo K, Hasegawa S, Suzuki Y, Hirano R, Wakiguchi H, Kittaka S, Ichiyama 
T. 1alpha,25-Dihydroxyvitamin D(3) inhibits vascular cellular adhesion molecule-
1 expression and interleukin-8 production in human coronary arterial endothelial 
cells. J Steroid Biochem Mol Biol. 2012; 132: 290-294.  
90. Norman PE, Wysocki SJ, Lamawansa MD. The role of vitamin D3 in the 
aetiology of abdominal aortic aneurysms. Med Hypotheses. 1995; 45: 17-20.  
233 
 
91. Norman PE, Curci JA. Understanding the effects of tobacco smoke on the 
pathogenesis of aortic aneurysm. Arterioscler Thromb Vasc Biol. 2013; 33: 1473-
1477.  
92. Blanchard JF, Armenian HK, Peeling R, Friesen PP, Shen C, Brunham RC. 
The relation between Chlamydia pneumoniae infection and abdominal aortic 
aneurysm: case-control study. Clin Infect Dis. 2000; 30: 946-947.  
93. Pasterkamp G, Schoneveld AH, van Wolferen W, Hillen B, Clarijs RJ, 
Haudenschild CC, Borst C. The impact of atherosclerotic arterial remodeling on 
percentage of luminal stenosis varies widely within the arterial system. A 
postmortem study. Arterioscler Thromb Vasc Biol. 1997; 17: 3057-3063.  
94. Pasterkamp G, Wensing PJ, Post MJ, Hillen B, Mali WP, Borst C. 
Paradoxical arterial wall shrinkage may contribute to luminal narrowing of human 
atherosclerotic femoral arteries. Circulation. 1995; 91: 1444-1449.  
95. Golledge J, Clancy P, Yeap BB, Hankey GJ, Norman PE. Increased serum 
angiopoietin-2 is associated with abdominal aortic aneurysm prevalence and 
cardiovascular mortality in older men. Int J Cardiol. 2013; 167: 1159-1163.  
96. Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwala M, Bujak-Gizycka B, Filip 
G, Grudzien G, Kapelak B, Zmudka K, Mrowiecki T, Sadowski J, Korbut R, Guzik 
TJ. Mechanisms of oxidative stress in human aortic aneurysms - Association with 
234 
 
clinical risk factors for atherosclerosis and disease severity. Int J Cardiol. 
2013;168(3): 2389-96.  
97. Li MW, Mian MO, Barhoumi T, Rehman A, Mann K, Paradis P, Schiffrin EL. 
Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic 
aneurysms in apolipoprotein e knockout mice. Arterioscler Thromb Vasc Biol. 
2013; 33: 2306-2315.  
98. Zarins CK, Glagov S, Vesselinovitch D, Wissler RW. Aneurysm formation in 
experimental atherosclerosis: relationship to plaque evolution. J Vasc Surg. 
1990; 12: 246-256.  
99. Benvenuti LA, Onishi RY, Gutierrez PS, de Lourdes Higuchi M. Different 
patterns of atherosclerotic remodeling in the thoracic and abdominal aorta. 
Clinics (Sao Paulo). 2005; 60: 355-360.  
100. Sakalihasan N, Heyeres A, Nusgens BV, Limet R, Lapiere CM. 
Modifications of the extracellular matrix of aneurysmal abdominal aortas as a 
function of their size. Eur J Vasc Surg. 1993; 7: 633-637.  
101. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. 
Inflammation and matrix metalloproteinases in the enlarging abdominal aortic 
aneurysm. Arterioscler Thromb Vasc Biol. 1995; 15: 1145-1151.  
102. Mauer SM. Structural-functional correlations of diabetic nephropathy. 
Kidney Int. 1994; 45: 612-622.  
235 
 
103. Astrand H, Ryden-Ahlgren A, Sundkvist G, Sandgren T, Lanne T. Reduced 
aortic wall stress in diabetes mellitus. Eur J Vasc Endovasc Surg. 2007; 33: 592-
598.  
104. Sonesson B, Hansen F, Stale H, Lanne T. Compliance and diameter in the 
human abdominal aorta--the influence of age and sex. Eur J Vasc Surg. 1993; 7: 
690-697.  
105. Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, 
Heine RJ, Bouter LM, Westerhof N, Stehouwer CD. Increased central artery 
stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. 
Hypertension. 2004; 43: 176-181.  
106. Fukui D, Miyagawa S, Soeda J, Tanaka K, Urayama H, Kawasaki S. 
Overexpression of transforming growth factor beta1 in smooth muscle cells of 
human abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2003; 25: 540-
545.  
107. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-
induced inhibition of mesangial matrix degradation. Diabetes. 1999; 48: 2066-
2073.  
108. Shibamura H, Olson JM, van Vlijmen-Van Keulen C, Buxbaum SG, Dudek 
DM, Tromp G, Ogata T, Skunca M, Sakalihasan N, Pals G, Limet R, MacKean 
GL, Defawe O, Verloes A, Arthur C, Lossing AG, Burnett M, Sueda T, Kuivaniemi 
236 
 
H. Genome scan for familial abdominal aortic aneurysm using sex and family 
history as covariates suggests genetic heterogeneity and identifies linkage to 
chromosome 19q13. Circulation. 2004; 109: 2103-2108.  
109. Morris DR, Biros E, Cronin O, Kuivaniemi H, Golledge J. The association of 
genetic variants of matrix metalloproteinases with abdominal aortic aneurysm: a 
systematic review and meta-analysis. Heart. 2014; 100: 295-302.  
110. Wang SM, Zhao G, Peng L, Yang W. Exome sequencing reveals new 
insights into the progression of abdominal aortic aneurysm. Eur Rev Med 
Pharmacol Sci. 2013; 17: 2401-2409.  
111. Alcorn HG, Wolfson SK,Jr, Sutton-Tyrrell K, Kuller LH, O'Leary D. Risk 
factors for abdominal aortic aneurysms in older adults enrolled in The 
Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1996; 16: 963-970.  
112. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T, ALICE (All-Literature 
Investigation of Cardiovascular Evidence) Group. Effects of statin therapy on 
abdominal aortic aneurysm growth: a meta-analysis and meta-regression of 
observational comparative studies. Eur J Vasc Endovasc Surg. 2012; 44: 287-
292.  
113. Johnsen SH, Forsdahl SH, Singh K, Jacobsen BK. Atherosclerosis in 
abdominal aortic aneurysms: a causal event or a process running in parallel? 
The Tromso study. Arterioscler Thromb Vasc Biol. 2010; 30: 1263-1268.  
237 
 
114. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and 
epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011; 8: 92-102.  
115. The Atherosclerosis Risk in Communities (ARIC) Study: design and 
objectives. The ARIC investigators. Am J Epidemiol. 1989; 129: 687-702.  
116. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, van 
Herwaarden JA, Holt PJ, van Keulen JW, Rantner B, Schlosser FJ, Setacci F, 
Ricco JB, European Society for Vascular Surgery. Management of abdominal 
aortic aneurysms clinical practice guidelines of the European society for vascular 
surgery. Eur J Vasc Endovasc Surg. 2011; 41 Suppl 1: S1-S58.  
117. Lederle FA, Walker JM, Reinke DB. Selective screening for abdominal 
aortic aneurysms with physical examination and ultrasound. Arch Intern Med. 
1988; 148: 1753-1756.  
118. Lindholt JS, Vammen S, Juul S, Henneberg EW, Fasting H. The validity of 
ultrasonographic scanning as screening method for abdominal aortic aneurysm. 
Eur J Vasc Endovasc Surg. 1999; 17: 472-475.  
119. Costantino TG, Bruno EC, Handly N, Dean AJ. Accuracy of emergency 
medicine ultrasound in the evaluation of abdominal aortic aneurysm. J Emerg 
Med. 2005; 29: 455-460.  
120. Chaikof EL, Brewster DC, Dalman RL, Makaroun MS, Illig KA, Sicard GA, 
Timaran CH, Upchurch GR,Jr, Veith FJ, Society for Vascular Surgery. The care 
238 
 
of patients with an abdominal aortic aneurysm: the Society for Vascular Surgery 
practice guidelines. J Vasc Surg. 2009; 50: S2-49.  
121. Tayal VS, Graf CD, Gibbs MA. Prospective study of accuracy and outcome 
of emergency ultrasound for abdominal aortic aneurysm over two years. Acad 
Emerg Med. 2003; 10: 867-871.  
122. Zarnke MD, Gould HR, Goldman MH. Computed tomography in the 
evaluation of the patient with symptomatic abdominal aortic aneurysm. Surgery. 
1988; 103: 638-642.  
123. High-resolution B-mode ultrasound reading methods in the Atherosclerosis 
Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging. 
1991; 1: 168-172.  
124. Riley WA, Barnes RW, Evans GW, Burke GL. Ultrasonic measurement of 
the elastic modulus of the common carotid artery. The Atherosclerosis Risk in 
Communities (ARIC) Study. Stroke. 1992; 23: 952-956.  
125. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M, Heiss G. 
Arterial stiffness and the development of hypertension. The ARIC study. 
Hypertension. 1999; 34: 201-206.  
126. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, 
McGovern P, Nieto FJ, Tell GS. Cigarette smoking and progression of 
239 
 
atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. JAMA. 
1998; 279: 119-124.  
127. Folsom AR, Arnett DK, Hutchinson RG, Liao F, Clegg LX, Cooper LS. 
Physical activity and incidence of coronary heart disease in middle-aged women 
and men. Med Sci Sports Exerc. 1997; 29: 901-909.  
128. Florido R, Kwak L, Lazo M, Nambi V, Ahmed HM, Hegde SM, Gerstenblith 
G, Blumenthal RS, Ballantyne CM, Selvin E, Folsom AR, Coresh J, Ndumele CE. 
Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: 
ARIC Study. Circulation. 2018; 137: 2142-2151.  
129. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability 
in clinical chemistry test results. Experience from the Atherosclerosis Risk in 
Communities Study. Arch Pathol Lab Med. 1994; 118: 496-500.  
130. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, 
England J, Bucksa J, Nowicki M. Hemoglobin A1c measurements over nearly 
two decades: sustaining comparable values throughout the Diabetes Control and 
Complications Trial and the Epidemiology of Diabetes Interventions and 
Complications study. Clin Chem. 2005; 51: 753-758.  
131. Selvin E, Coresh J, Zhu H, Folsom A, Steffes MW. Measurement of HbA1c 
from stored whole blood samples in the Atherosclerosis Risk in Communities 
study. J Diabetes. 2010; 2: 118-124.  
240 
 
132. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the 
enzymatic determination of serum total cholesterol with improved lipolytic 
efficiency. Clin Chem. 1983; 29: 1075-1080.  
133. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of 
low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem. 1972; 18: 499-502.  
134. Patsch JR, Sailer S, Kostner G, Sandhofer F, Holasek A, Braunsteiner H. 
Separation of the main lipoprotein density classes from human plasma by rate-
zonal ultracentrifugation. J Lipid Res. 1974; 15: 356-366.  
135. Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G, Shen YL. 
Short-term intraindividual variability in lipoprotein measurements: the 
Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1992; 136: 
1069-1081.  
136. Clauss A. Rapid physiological coagulation method in determination of 
fibrinogen. Acta Haematol. 1957; 17: 237-246.  
137. Chambless LE, McMahon R, Wu K, Folsom A, Finch A, Shen YL. Short-
term intraindividual variability in hemostasis factors. The ARIC Study. 
Atherosclerosis Risk in Communities Intraindividual Variability Study. Ann 
Epidemiol. 1992; 2: 723-733.  
241 
 
138. Schermerhorn M, Zwolak R, Velazquez O, Makaroun M, Fairman R, 
Cronenwett J. Ultrasound screening for abdominal aortic aneurysm in medicare 
beneficiaries. Ann Vasc Surg. 2008; 22: 16-24.  
139. Centers for Disease Control and Prevention. CDC Wide-ranging ONline 
Data for Epidemiologic Research: Compressed Mortality, 1999-2015. Access 
April 2017.  
140. Walsh R, Fang J, Fuster V, O'Rourke R. Hurst's the Heart Manual of 
Cardiology. In: 13th ed. Cleveland, OH: McGraw Hill Professional; 2012: 630-
639.  
141. Sonesson B, Hansen F, Lanne T. Abdominal aortic aneurysm: a general 
defect in the vasculature with focal manifestations in the abdominal aorta? J 
Vasc Surg. 1997; 26: 247-254.  
142. Dijk JM, van der Graaf Y, Grobbee DE, Banga JD, Bots ML, SMART Study 
Group. Increased arterial stiffness is independently related to cerebrovascular 
disease and aneurysms of the abdominal aorta: the Second Manifestations of 
Arterial Disease (SMART) Study. Stroke. 2004; 35: 1642-1646.  
143. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, 
Clegg LX. Association of coronary heart disease incidence with carotid arterial 
wall thickness and major risk factors: the Atherosclerosis Risk in Communities 
(ARIC) Study, 1987-1993. Am J Epidemiol. 1997; 146: 483-494.  
242 
 
144. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, 
Cram KB, Hutchinson RG. Relation of carotid artery wall thickness to diabetes 
mellitus, fasting glucose and insulin, body size, and physical activity. 
Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994; 
25: 66-73.  
145. Desquilbet L, Mariotti F. Dose-response analyses using restricted cubic 
spline functions in public health research. Stat Med. 2010; 29: 1037-1057.  
146. Greenland S. Dose-response and trend analysis in epidemiology: 
alternatives to categorical analysis. Epidemiology. 1995; 6: 356-365.  
147. Steenland K, Deddens JA. A practical guide to dose-response analyses and 
risk assessment in occupational epidemiology. Epidemiology. 2004; 15: 63-70.  
148. Gottesman RF, Rawlings AM, Sharrett AR, Albert M, Alonso A, Bandeen-
Roche K, Coker LH, Coresh J, Couper DJ, Griswold ME, Heiss G, Knopman DS, 
Patel MD, Penman AD, Power MC, Selnes OA, Schneider AL, Wagenknecht LE, 
Windham BG, Wruck LM, Mosley TH. Impact of differential attrition on the 
association of education with cognitive change over 20 years of follow-up: the 
ARIC neurocognitive study. Am J Epidemiol. 2014; 179: 956-966.  
149. Cronin O, Walker PJ, Golledge J. The association of obesity with abdominal 
aortic aneurysm presence and growth. Atherosclerosis. 2013; 226: 321-327.  
243 
 
150. Desai CS, Ning H, Kang J, Folsom AR, Polak JF, Sibley CT, Tracy R, Lloyd-
Jones DM. Competing cardiovascular outcomes associated with subclinical 
atherosclerosis (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 
2013; 111: 1541-1546.  
151. Ferket BS, van Kempen BJ, Wieberdink RG, Steyerberg EW, Koudstaal PJ, 
Hofman A, Shahar E, Gottesman RF, Rosamond W, Kizer JR, Kronmal RA, 
Psaty BM, Longstreth WT,Jr, Mosley T, Folsom AR, Hunink MG, Ikram MA. 
Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology. 
2014; 82: 1804-1812.  
152. Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007; 
26: 1360-1367.  
153. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models 
with competing risks: methods and application to coronary risk prediction. 
Epidemiology. 2009; 20: 555-561.  
154. Lanne T, Sonesson B, Bergqvist D, Bengtsson H, Gustafsson D. Diameter 
and compliance in the male human abdominal aorta: influence of age and aortic 
aneurysm. Eur J Vasc Surg. 1992; 6: 178-184.  
155. MacSweeney ST, Young G, Greenhalgh RM, Powell JT. Mechanical 
properties of the aneurysmal aorta. Br J Surg. 1992; 79: 1281-1284.  
244 
 
156. Baxter BT, Davis VA, Minion DJ, Wang YP, Lynch TG, McManus BM. 
Abdominal aortic aneurysms are associated with altered matrix proteins of the 
nonaneurysmal aortic segments. J Vasc Surg. 1994; 19: 797-802; discussion 
803.  
157. Fantin F, Bulpitt CJ, Bonapace S, Cameron JD, Rajkumar C. Is vascular 
stiffness associated with the diameter of the abdominal aorta? Age Ageing. 2009; 
38: 466-469.  
158. Wilson KA, Lee AJ, Lee AJ, Hoskins PR, Fowkes FG, Ruckley CV, 
Bradbury AW. The relationship between aortic wall distensibility and rupture of 
infrarenal abdominal aortic aneurysm. J Vasc Surg. 2003; 37: 112-117.  
159. Liu K, Colangelo LA, Daviglus ML, Goff DC, Pletcher M, Schreiner PJ, 
Sibley CT, Burke GL, Post WS, Michos ED, Lloyd-Jones DM. Can 
Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal 
Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) 
Study and the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Heart Assoc. 
2015; 4: e002275.  
160. Wu J, Province MA, Coon H, Hunt SC, Eckfeldt JH, Arnett DK, Heiss G, 
Lewis CE, Ellison RC, Rao DC, Rice T, Kraja AT. An investigation of the effects 
of lipid-lowering medications: genome-wide linkage analysis of lipids in the 
HyperGEN study. BMC Genet. 2007; 8: 60-2156-8-60.  
245 
 
161. Ailawadi G, Eliason JL, Roelofs KJ, Sinha I, Hannawa KK, Kaldjian EP, Lu 
G, Henke PK, Stanley JC, Weiss SJ, Thompson RW, Upchurch GR,Jr. Gender 
differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc 
Biol. 2004; 24: 2116-2122.  
162. Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen 
increases AT1a receptor expression in abdominal aortas to promote angiotensin 
II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc 
Biol. 2008; 28: 1251-1256.  
163. Yeap BB, Hyde Z, Norman PE, Chubb SA, Golledge J. Associations of total 
testosterone, sex hormone-binding globulin, calculated free testosterone, and 
luteinizing hormone with prevalence of abdominal aortic aneurysm in older men. 
J Clin Endocrinol Metab. 2010; 95: 1123-1130.  
164. Vitale C, Fini M, Speziale G, Chierchia S. Gender differences in the 
cardiovascular effects of sex hormones. Fundam Clin Pharmacol. 2010; 24: 675-
685.  
165. Bergoeing MP, Arif B, Hackmann AE, Ennis TL, Thompson RW, Curci JA. 
Cigarette smoking increases aortic dilatation without affecting matrix 
metalloproteinase-9 and -12 expression in a modified mouse model of aneurysm 
formation. J Vasc Surg. 2007; 45: 1217-1227.  
246 
 
166. Buckley C, Wyble CW, Borhani M, Ennis TL, Kobayashi DK, Curci JA, 
Shapiro SD, Thompson RW. Accelerated enlargement of experimental 
abdominal aortic aneurysms in a mouse model of chronic cigarette smoke 
exposure. J Am Coll Surg. 2004; 199: 896-903.  
167. Jin J, Arif B, Garcia-Fernandez F, Ennis TL, Davis EC, Thompson RW, 
Curci JA. Novel mechanism of aortic aneurysm development in mice associated 
with smoking and leukocytes. Arterioscler Thromb Vasc Biol. 2012; 32: 2901-
2909.  
168. Li ZZ, Dai QY. Pathogenesis of abdominal aortic aneurysms: role of nicotine 
and nicotinic acetylcholine receptors. Mediators Inflamm. 2012; 2012: 103120.  
169. Peshkova IO, Schaefer G, Koltsova EK. Atherosclerosis and aortic 
aneurysm - is inflammation a common denominator? FEBS J. 2016; 283: 1636-
1652.  
170. Kaya MG, Calapkorur B, Karaca Z, Yildirim S, Celik A, Akpek M, Unluhizarci 
K, Kelestimur F. The effects of treatment with drospirenone/ethinyl oestradiol 
alone or in combination with metformin on elastic properties of aorta in women 
with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012; 77: 885-892.  
171. Fujimura N, Xiong J, Kettler EB, Xuan H, Glover KJ, Mell MW, Xu B, 
Dalman RL. Metformin treatment status and abdominal aortic aneurysm disease 
progression. J Vasc Surg. 2016; 64: 46-54.e8.  
247 
 
172. Torsney E, Pirianov G, Cockerill GW. Diabetes as a negative risk factor for 
abdominal aortic aneurysm - does the disease aetiology or the treatment provide 
the mechanism of protection? Curr Vasc Pharmacol. 2013; 11: 293-298.  
173. Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, 
Nasr H, Loftus IM, Thompson MM, Cockerill GW. Rosiglitazone reduces the 
development and rupture of experimental aortic aneurysms. Circulation. 2009; 
119: 3125-3132.  
174. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, Daugherty A, 
Campbell JH, Norman PE. Peroxisome proliferator-activated receptor ligands 
reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 
2010; 210: 51-56.  
175. Sakalihasan N, Delvenne P, Nusgens BV, Limet R, Lapiere CM. Activated 
forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg. 1996; 
24: 127-133.  
176. Jones SC, Saunders HJ, Pollock CA. High glucose increases growth and 
collagen synthesis in cultured human tubulointerstitial cells. Diabet Med. 1999; 
16: 932-938.  
177. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 
2005; 365: 1577-1589.  
248 
 
178. Golledge J, Karan M, Moran CS, Muller J, Clancy P, Dear AE, Norman PE. 
Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes 
may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008; 29: 
665-672.  
179. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end 
products on the proliferation and fibronectin production of smooth muscle cells. J 
Atheroscler Thromb. 2000; 7: 169-176.  
180. LaMorte WW, Scott TE, Menzoian JO. Racial differences in the incidence of 
femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: 
relationship to cardiovascular risk factors. J Vasc Surg. 1995; 21: 422-431.  
181. Egger M, Smith GD, Altman D. Systematic Reviews in Health Care: Meta-
Analysis in Context. . In: London: BMJ Publishing Group, ed. 2nd ed. ; 2001.  
182. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA 
statement. Ann Intern Med. 2009; 151: 264-9, W64.  
183. Greenland S. Quantitative methods in the review of epidemiologic literature. 
Epidemiol Rev. 1987; 9: 1-30.  
184. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 
1986; 7: 177-188.  
249 
 
185. Kelley GA, Kelley KS. Statistical models for meta-analysis: A brief tutorial. 
World J Methodol. 2012; 2: 27-32.  
186. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency 
in meta-analyses. BMJ. 2003; 327: 557-560.  
187. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. 
Stat Med. 2002; 21: 1539-1558.  
188. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test 
for publication bias. Biometrics. 1994; 50: 1088-1101.  
189. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis 
detected by a simple, graphical test. BMJ. 1997; 315: 629-634.  
190. Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to 
authors' assessments. BMC Med Res Methodol. 2014; 14: 45-2288-14-45.  
191. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell PT. 
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised 
studies in meta-analyses. 
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. 2013; .  
192. Vorp DA. Biomechanics of abdominal aortic aneurysm. J Biomech. 2007; 
40: 1887-1902.  
250 
 
193. Dua MM, Miyama N, Azuma J, Schultz GM, Sho M, Morser J, Dalman RL. 
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic 
diameter in experimental aortic aneurysm disease. Surgery. 2010; 148: 429-435.  
194. Li J, Huynh P, Dai A, Wu T, Tu Y, Chow B, Kiriazis H, Du XJ, Bach LA, 
Wilkinson-Berka JL, Biros E, Walker P, Nataatmadja M, West M, Golledge J, 
Allen TJ, Cooper ME, Chai Z. Diabetes Reduces Severity of Aortic Aneurysms 
Depending on the Presence of Cell Division Autoantigen 1 (CDA1). Diabetes. 
2018; 67: 755-768.  
195. De Rango P, Farchioni L, Fiorucci B, Lenti M. Diabetes and abdominal 
aortic aneurysms. Eur J Vasc Endovasc Surg. 2014; 47: 243-261.  
196. Kubota Y, Folsom AR, Pankow JS, Wagenknecht LE, Tang W. Diabetes-
related factors and abdominal aortic aneurysm events: the Atherosclerotic Risk in 
Communities Study. Ann Epidemiol. 2018; 28: 102-106.e1.  
197. Kristensen KL, Dahl M, Rasmussen LM, Lindholt JS. Glycated Hemoglobin 
Is Associated With the Growth Rate of Abdominal Aortic Aneurysms: A Substudy 
From the VIVA (Viborg Vascular) Randomized Screening Trial. Arterioscler 
Thromb Vasc Biol. 2017; 37: 730-736.  
198. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 
diabetes mellitus and its complications. Nat Rev Endocrinol. 2018; 14: 88-98.  
 
